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ABSTRACT 
 
Viruses are the most widespread and abundant entity on this planet, further constituting the 
largest part of the genosphere. The majority of these infectious agents are miniature, 
having been described as being smaller than the smallest bacteria. Even though they 
encode a limited number of viral proteins, they still obtain the bulk of the material they 
require for their replication and propagation from the infected host cell.  
 
Recently, this traditional concept of viruses has been shaken up by the breakthrough 
finding of a new group of viruses, the Giant Viruses. They have been assigned this 
definition due to their amazingly and surprisingly large genomic size. The vast majority 
have their own replication machinery. They have been discovered in the sea, where they 
prefer to infect amoebas and other marine microorganisms. For the purpose of this study, 
we focused on three of these giant viruses; Mimivirus, Marseillevirus, and Cafeteria 
roenbergensis virus (CroV).  
 
The aim of the study was to comprehend how these giant viruses replicate and propagate 
their genetic material through the generations, to have reached a point where their genome 
size is comparable to normal-sized bacteria. For this reason, an extensive biochemical 
analysis on the molecular biology of giant viruses’ DNA replication machinery was 
performed, hoping to obtain new insights into the evolution and lifestyle of these unique 
viruses. We specifically focused on what we considered to be two of the most important 
DNA replication proteins; the Proliferating Cell Nuclear Antigen (PCNA) and Flap 
structure-specific Endonuclease 1 (FEN1). Our goal was to determine their properties. 
[6] 
 
The protocols performed were a series of protein expression procedures, during which the 
particular synthetic genes were cloned in a selection of expression vectors and were then 
expressed in bacteria (i.e. E.coli host expression strains). Depending on the protein 
expression efficiencies, some trial protein purification procedures followed.  
 
For the first few months of the project, however, it was impossible to obtain any 
conclusive results concerning the expression of the proteins. The synthetic genes were 
proving to be extremely difficult to express in vectors containing an expression tag. Only 
when we switched to un-tagged expression vectors, much later on in the project, did we 
start getting better and more promising results. This was a particularly useful outcome in 
itself, as it revealed that enhanced expression of the PCNA and FEN1 proteins 
preferentially occurs when no expression tags are present. Towards the end of the project, 
some protein purification trials were performed, but unfortunately they only resulted in an 
incredibly low protein purity level.  
 
The discovery of these distinctive viruses has not only incited scientists to maybe rethink 
and change their view about the general nature of viruses, but it has also begun to alter and 
question the outlook regarding the history of life as a whole. As the investigation is still in 
its very early stages, there are many aspects concerning the giant viruses still to be 
discovered. This in the end could essentially teach us a great deal more than we ever hoped 
to expect, and therefore it is of great significance and importance to continue with this 
research. 
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-CHAPTER ONE-  
 
Introduction 
 
1.1 Viruses 
Viruses were first discovered and differentiated from bacteria in the late 1800s when it was 
observed that they could not be isolated by filtration protocols due to their exceptionally 
minute sizes (Minor PD, 2007; Van Etten JL, 2011). A typical virus can be seen in Figure 1.1. 
 
Figure 1.1: Example of a common virus structure and the parts it comprises of [Minor PD, 
2007]. 
 
According to the traditional perception of viruses; these are tiny infectious cells forming a 
large and distinct group, defined by their ability to cause disease. They are obligate 
intracellular parasites that infect all kinds of organisms and by doing so they depend on 
these organisms’ raw material, cell machinery and metabolism for their own replication. 
[23] 
 
Nevertheless, they do contain some of their own genetic material necessary for the 
production of progeny, some of which may or may not have been acquired from their 
hosts’ during their evolution. [McKenna R & Faulkner L, 2001; Minor PD, 2007]. The process 
that viruses make use of for increasing their genetic diversity is known as horizontal gene 
transfer (HGT), during which they can basically incorporate host genes into their own 
genome; this method is of spectacular importance during their evolutionary reproduction, 
because by performing this procedure viruses can essentially select and only pick up the 
relevant host material required for their subsequent replication, thus providing them with a 
way by which they can productively evolve (Domingo E, 2007; Koonin EV & Yutin N, 2010). 
 
Viruses distinctively replicate by forcing their infected host organism to manufacture more 
of the same complex viral components. They do this by inserting their own genetic 
information, which has been specifically packaged for this purpose, into the host cells. This 
process will cause the host system to divert its replication mechanism and biosynthesis 
machinery in a way that the virus requires, so instead of producing cellular proteins it will 
produce more viruses. Viruses pass their packaged genetic information into the hosts’ cells 
by an accurate delivery system that ensures that the suitable cells and cell compartments 
are reached for the virus to multiply successfully. For this purpose, the parasitised cell 
must also be able to recognise and decode the viral genetic information, a fact that the 
virus itself has ensured to occur properly once inside the host cells. By using their host as a 
template for viral replication, which will take place in a shielded environment, and 
hijacking their normal cellular processes, viruses can also take advantage of the host cells’ 
biology. This ensures that the viral material produced is assembled in an appropriate way 
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and emerges from the cell in the correct packaged form so as to infect other cells. These 
newly manufactured viruses will then escape the host and infect passively another one, 
hence continuing their replication cycle passing on their viral genome to subsequent 
generations, whilst at the same time they constantly mutate and acquire new genetic 
material. This whole process is done in a very profound, precise, but at the same time, 
subtle way. [Cann AJ, 2001; Minor PD, 2007; Harper DR, 2012]. A diagrammatical 
representation of the viral life cycle is illustrated in Figure 1.2. 
[25] 
 
 
Figure 1.2: The life cycle of a virus [Minor PD, 2007]. 
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In general, viruses are as diverse as the number of species that exist; this is the case due to 
genetic variation and evolution. Viruses differ significantly both in their magnitude and 
their genetic complexity, while they are also capable of using an incredible diversity of 
strategies so as to reproduce in the host cells. Therefore, they are commonly classified 
depending on their replication pathways, and the fact that there is a huge variety of such 
procedures suggests that viruses have an amazing evolutionary divergence having evolved 
through multiple origins during the course of history. [McKenna R & Faulkner L, 2001; Iyer 
LM et al, 2006; Domingo E, 2007]. 
 
The origin of viruses is a subject extensively questioned and greatly debated upon amongst 
experts (Minor PD, 2007; Wessner DR, 2010). Several models concerning this type of origin 
have been proposed over the years. Three main hypothesis have especially been circulated; 
1. The progressive, or escape; 2. The regressive, or reduction; and 3. The predatory or co-
evolutionary hypothesis.  First of all, the progressive theory asserts that viruses arose from 
primitive genetic elements or forms of cells, which gained the ability to shift between other 
types of cells hence gradually acquiring genetic material from their host organisms. 
Secondly, the regressive theory assumes that viruses broke loose from the original complex 
cells, which they now infect. This suggests that viruses are actually remnants of the 
modern complex cellular organisms that gradually degenerated, losing their ability to 
synthesise important genetic material thus rendering themselves dependent on the host 
cells. [Iyer LM et al, 2006; Moreira D & Brochier-Armanet C, 2008; Claverie JM & Abergel C, 
2010]. Lastly, the predatory or co-evolutionary theory simply states that viruses predate or 
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co-evolved simultaneously with their current cellular hosts, both of which had common 
replication origins promoting lateral gene transfer. This refers to an independent co-
evolution of viruses and complex cell organisms, both of which exploited cells that 
developed concurrently. [Domingo E, 2007; Filee J et al, 2008; Flugel RM, 2010; Sinkovics JG; 
2011]. Co-existence, nevertheless, of these two entities surely suggests that viruses have 
also evolved mechanisms to counteract the hosts’ defensive responses (Forterre P, 2010).  
 
Over the years, scientists all over the world have been struggling with the challenge of 
deriving a single phylogenetic tree that would relate all known viruses (Domingo E, 2007; 
Minor PD, 2007). However, their great diversity and abundance has designated them as 
polyphyletic, even though different categories of viruses appear to have significant 
similarities in their structure, organisation of their genome and replication strategies 
(Moreira D & Brochier-Armanet C, 2008). 
 
An exciting new aspect is the fairly recent knowledge of the existence of viral ‘hallmark 
genes’, meaning the genes found within viral genomes to be central for virus replication 
that are in fact absent from cells (Koonin EV & Yutin N, 2010). This information has now led 
to the suggestion of an ancient ‘virus world’. This proposal would further suggest that 
during evolution viruses have had a major part in the formation of all the other types of 
organisms, i.e. archaea, bacteria and eukarya. [Domingo E, 2007; Van Etten JL, 2011]. This is 
a topic of immense discussion.  
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A question that has arisen quite recently, specifically after the discovery of some members 
of the giant viruses group, is whether or not viruses should be included in the tree of life, 
together with archaea, bacteria and eukarya. Should viruses be considered as living 
organisms or not? This is another issue that has caused tremendous discussions over recent 
periods of time. [Minor PD, 2007; Raoult D & Forterre P, 2008; Claverie JM & Abergel C, 
2010; Ruiz-Saenz J & Rodas JP, 2010; Van Etten JL, 2011]. The conventional definition of a 
‘living organism’ is in simple terms an organism that can move, grow, reproduce and 
evolve, carrying out metabolic process and responding to external stimuli. But do viruses 
comply with these characteristics? The answer is not as straight forward as expected; they 
do and they do not. Even though we are aware that they reproduce, transfer between cells 
and evolve over time, they do not, however, perform metabolic processes. A living 
organism requires the generation of adenosine triphosphate (ATP), as well as the presence 
of ribosomes and other translational machinery, for the purpose of forming proteins. Thus, 
going by the textbook definition, viruses cannot independently form proteins from mRNA; 
they require a living host cell for their replication, thus leaving them completely bound up 
with the cellular processes of the cell. [Moreira D & Brochier-Armanet C, 2008; Wessner DR, 
2010].  
 
The discovery of the giant viruses is now here to stir up this conservative concept and give 
reason to argue that viruses may indeed be living organisms, which have their own right to 
be included in the tree of life (Moreira D & Brochier-Armanet C, 2008; Yutin N & Koonin EV, 
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2009; Yutin N et al, 2009; Boyer M et al, 2010; Colson P et al, 2011). Nonetheless, will it ever 
be entirely possible to tell where all the diverse species of viruses truly originate from?  
 
1.2 Giant Viruses 
Around the turn of the decade, a completely new group of viruses unexpectedly began to 
be discovered in aquatic habitats. The only reason that these viruses were not discovered 
until recently is that up till now researchers have focused all their time and energy on 
viruses that infect humans, animals and plants, as it has been crucial to understand all 
aspects of their replication strategies and hence pathogenicity (Boyer M et al, 2009). At the 
same time, because viruses have always been considered the smallest entities on earth, no 
scientist could even come close to imaging the existence of significantly bigger ones. This 
conservative notion changed with the breakthrough finding of novel viruses that were 
assigned into a separate group, namely the giant viruses group (often referred to as 
“giruses”), relating to their unique properties and remarkably unanticipated large size (i.e. 
some of them being as big as a normal-sized bacterium cell, thus possibly making their 
isolation by filtration protocols more plausible). [Claverie JM & Abergel C, 2010; Fischer MG 
et al, 2010; Raoult D & Boyer M, 2010; Van Etten JL et al, 2010; Van Etten JL, 2011].  
 
These giant viruses were notably located in marine microorganisms, such as amoebas and 
microzooplankton. These microorganisms, which are thought of as wild phagocytes 
consuming everything that comes their way (from phytoplankton to heterotrophic bacteria 
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and viruses), can ingest quite large-sized particles rendering them a highly potential source 
of giant viruses, besides making them the perfect environment from which diverse forms of 
viruses may have emerged from throughout evolution. [Boyer M et al, 2009; Fischer MG et 
al, 2010; Moliner C et al, 2010; Van Etten JL et al, 2010; Van Etten JL, 2011]. A number of the 
amoebae discovered have currently the largest genome size estimated on Earth (Raoult D & 
Boyer M, 2010). New viruses belonging to the giant viruses group are being explored with 
increasing frequency ever since.  
 
The giant viruses found in the aqueous microenvironments display a remarkable degree of 
‘biological sophistication’, when compared to simpler cellular life forms. Even the viruses 
that are classified as being in the same sub-family can have divergent lifestyles, 
morphologies, and of course, they may differ vastly in their genetic complement. 
Specifically, having risen from various origins, they have an extremely complex repertoire 
of genetic material. [Ogata H & Claverie JM, 2007; Van Etten JL et al, 2010; Van Etten JL, 
2011]. Nevertheless, both giant viruses and cellular life forms appear to have evolved by 
analogous mechanisms, including HGT and gene duplication events (Suhre K, 2005; Monier 
A et al, 2007; Moreira D & Brochier-Armanet C, 2008; Boyer M et al, 2009; Filee J & Chandler 
M, 2010).  
 
It has been determined that amoebas play a major role in this diverse genomic repertoire, 
due to the fact that they allow themselves to be parasitised at the same time by various 
other organisms ─from bacteria, archaea and eukarya to viruses─ and, as such, they act as 
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the perfect environment in which intracellular bacteria and viruses can live and experience 
a sympatric lifestyle (Figure 1.3) (Colson P & Raoult D, 2010; Moliner C et al, 2010; Raoult D, 
2010; Raoult D & Boyer M, 2010). This further accounts for the lateral gene transfer and gene 
exchange between the host and the parasites, but also between the different parasites 
themselves.  
[32] 
 
Figure 1.3: Intra-amoebal 
lifestyle as a source of 
complex chimeric gene 
contents. Colored boxes 
containing a G indicate 
genes from various origins 
(bacteria, viruses, 
eukaryotes) [Colson P and 
Raoult D, 2010]. 
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The biology and evolutionary origin of giant viruses has, without a doubt, provoked ardent 
debate over time (Forterre P, 2010; Van Etten JL, 2011); with some scientists arguing that 
these viruses are simply “gene robbers”, acquiring their genetic material from their 
parasitised hosts through the HGT pathway (Moreira D & Brochier-Armanet C, 2008; Filee J 
& Chandler M, 2010; Fischer MG et al, 2010), whereas others support the hypothesis that 
these viruses date back to the original emergence of eukaryotic cells and hence their 
genetic material is viral in origin (Monier A et al, 2007; Mrazek J & Karlin S, 2007; Flugel RM, 
2010). 
 
In recent years, and especially since the discovery of giant viruses, it has become apparent 
that protozoans possibly host the largest and most complex viruses, while the remaining 
giant viruses are most likely prevalent in the oceans (Fischer MG et al, 2010; Raoult D & 
Boyer M, 2010; Van Etten JL et al, 2010; Van Etten JL, 2011). However, so far only the giant 
viruses infecting the Acanthoamoeba spp. and the Cafeteria spp. have been to some extent 
characterised, even though it has become quite evident that some of the giant viruses are 
most likely pathogens of phytoplankton (Claverie JM et al, 2009-a/b). Therefore, maybe it is 
about time that scientists turned their attention to other forms of life present in our oceans; 
they may be in for more surprises.  
 
Nowadays, a gradual rising number of giant viruses have been uncovered from diverse 
aquatic environments, implying that they may possibly comprise an ubiquitous and 
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quantitatively important part of marine viruses (Moliner C et al, 2010; Van Etten JL et al, 
2010; Van Etten JL, 2011). As a consequence, it is worthy to note that marine giant viruses 
may have a considerable impact on the ocean ecosystems as a whole. Thus, understanding 
the biology behind these viruses may potentially be very significant for the management of 
future ecosystems.  
 
1.2.1 Mimivirus (APMV) 
Mimivirus (or Acanthoamoeba polyphaga mimivirus; Mimivirus is short for “mimicking 
microbe”) was discovered in 2003 within the freshwater Acanthoamoeba polyphaga spp., 
from which it took its name. When it was first discovered it had been mistaken for a 
bacterial cell due to its unusually big size. [Raoult D et al, 2004; Renesto P et al, 2006; 
Claverie JM & Abergel C, 2009; Fischer MG et al, 2010; Raoult D & Boyer M, 2010; Van Etten 
JL, 2011]. It is the first member of the Mimiviridae family of viruses and it belongs to the 
nucleocytoplasmic large DNA viruses (NCLDV) group, which is a monophyletic group of 
double-stranded DNA viruses containing a conserved core set of replication proteins 
(viruses belonging to this group may have a common ancestor). These viruses have been 
named as such because, apart from having a typical stage during their replication cycle that 
takes place in the nucleus of the host, they also have a stage that occurs within the 
cytoplasm, hence separating their replication and expression activities from the host 
genome, whilst at the same time they contain within their own genome the appropriate 
genes to help them do so. [Yutin N & Koonin EV, 2009; Colson P and Raoult D, 2010; Filee J & 
Chandler M, 2010; Koonin EV & Yutin N, 2010; Mutsafi Y et al, 2010; Colson P et al, 2011].  
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Mimivirus is the second largest virus in size, but has the largest and rather complex 
genome, explaining why it was originally characterised as being a bacterial cell. It has a 
1.2 Mb genome (more than double the size of any previously sequenced viral genome), 
which specifically possesses an estimated 981 protein coding genes, as determined by 
multiple sequencing analysis studies. [Raoult D et al, 2004; Suhre K, 2005; Kuznetsov YG et al, 
2010; Legendre M et al, 2011]. From these protein coding genes, 21 of them encode 
homologs to proteins that are found to be highly conserved in the majority of NCLDVs, 
while some of its genes are unique amongst viruses (some of these are expressed in living 
organisms). Nonetheless, the majority of its genes have no cellular homologs and are thus 
presumed to be very ancient. [Renesto P et al, 2006; Claverie JM & Abergel C, 2009; Yutin N & 
Koonin EV, 2009; Colson P and Raoult D, 2010; Colson P et al, 2011]. A second group of the 
Mimivirus’ genes is predicted to have arisen by gene duplication events, while the third 
group consists of genes that were horizontally transferred into the Mimivirus genome from 
eukaryotic and bacteria hosts (Filee J et al, 2006; Moreira D & Brochier-Armanet C, 2008; 
Colson P and Raoult D, 2010; Filee J & Chandler M, 2010; Fischer MG et al, 2010; Raoult D & 
Boyer M, 2010). Mimivirus is the first giant viruses described to contain genes involved in 
replication, transcription and translation, bringing it somewhat closer to the description of a 
typical living cell (Claverie JM et al, 2006).  A summarised representation of the gene 
content of the Mimivirus genome can be seen in Figure 1.4. Not much is known about its 
replication cycle. 
[36] 
 
 
Figure 1.4: Schematic representation of the Mimivirus gene content. Abbreviations for the COG functional classes: E = amino acid transport and 
metabolism; F = nucleotide transport and metabolism; G = carbohydrate transport and metabolism; I = lipid transport and metabolism; J = translation; K = 
transcription; L = replication, recombination and repair; M = cell wall/membrane biogenesis; O = post-translational modification, protein turnover, chaperones; Q = 
secondary metabolite biosynthesis, transport and catabolism; R = general function prediction only; S = function unknown; T = signal transduction mechanisms; U = 
intracellular trafficking and secretion [Colson P and Raoult D, 2010]. 
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Different phylogenetic studies conducted on this virus have suggested that it may possibly 
be one of the very early divergents of the NCLDV group that evolved through extensive 
integration of genes between widely diverse genomes, while other studies have 
hypothesised that it may be related to a type of DNA virus that emerged even before 
cellular organisms did, and therefore, played a key role in the development of all life on 
Earth (Claverie JM et al, 2006; Iyer LM et al, 2006; Koonin EV & Yutin N, 2010; Colson P et al, 
2011).
 
An alternative hypothesis, however, is that originally three distinct types of DNA 
viruses existed that were involved in generating the three known domains of life (Filee J et 
al, 2008; Filee J and Chandler M, 2010; Van Etten JL, 2011). Whatever the actual origin of this 
virus is, its remarkably large size definitely helps it establish a bridge between the viral and 
cellular worlds. The origin of viruses, or rather giant viruses, is a topic that requires 
immense investigation.  
 
A number of recent studies, nevertheless, have provided exceptionally strong arguments in 
favour of a fourth domain of life containing the NCLDV group of viruses (Claverie JM, 
2006; Raoult D & Forterre P, 2008; Ruiz-Saenz J & Rodas JP, 2010; Nasir A et al, 2012). This 
theory has basically been supported by various bioinformatic and phylogenetic analyses 
based on a variety of common sets of proteins involved in information storage and 
processing, including genome replication (Colson P et al, 2011). The proteins under 
investigation were found to be conserved in all three domains of life, as we know them 
today (i.e. Archaea, Bacteria and Eukarya), while at the same time they were discovered to 
be conserved also in viruses. Additionally, more detailed analysis of the phylogenetic trees, 
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presented in some of these investigations (e.g. paper published by Boyer M et al, 2010), 
revealed distinct Archaea, Bacteria, Eukarya and NCLDV monophylies, and so led the 
researchers to the conclusion of “the existence of a viral clade with ancestral DNA 
replication machinery branching separately from Archaea, Bacteria and Eukarya”. On the 
contrary, other explorations (i.e. research conducted by Williams TA et al, 2011) argue 
against this proposition; they particularly state that information gene phylogenies do not in 
fact support a fourth domain of life containing the NCLDVs (Moreira D & Brochier-Armanet 
C, 2008). A third group of studies argues that the answer to this question is much more 
complex, and as such, cannot be solved by conducting only computation analysis of the 
giant viruses (Yutin N & Koonin EV, 2009; Yutin N et al, 2009). The question is where does the 
truth lie in reality, and the answer is that no one truly knows as yet.  
 
As a final point, Mimivirus may be a causative agent of some forms of pneumonia. This 
matter arose from a single reported case when a laboratory technician, who had previously 
dealt with a living Mimivirus particle, unfortunately died (Raoult D et al, 2006). There is no 
evidence to prove, however, that this incident was directly linked to the Mimivirus particle, 
and no more cases have been accounted for in the following years. Nowadays, however, 
hospitalised pneumonia patients are screened for the presence of Mimivirus particles in 
their respiratory tracts (La Scola B et al, 2005; Dare RK et al, 2008). 
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1.2.2 Marseillevirus  (MAR) 
Marseillevirus was first isolated in 2009 from Acanthoamoeba polyphaga spp. It is the 
only member so far of a new family of viruses termed Marseilleviridae (closely related to 
the Iridoviridae and Ascoviridae sub-families), but it is a prototype of the NCLDV group 
of viruses. It has the fifth largest viral genome sequenced to date, encoding for a minimum 
of 49 proteins, as well as some mRNAs encompassing a 368 kb genome. The genetic 
material included within the core of this virus is rather varied compared to other viruses. 
Even though it contains typical NCLDV genes (some also found within the Mimivirus), 
nonetheless it also contains other genes that have apparently been obtained from some of 
its eukaryotic hosts, as well as their parasites or symbionts, these being viral, bacterial 
and/or archaeal, perhaps through the HGT mechanism (Figure 1.5). [Boyer M et al, 2009; 
Raoult D & Boyer M, 2010; Deresinski S, 2010]. As with all other giant viruses characterised, 
gene duplication events must have also occurred sometime during the Marseillevirus 
evolutionary history (Colson P and Raoult D, 2010; Filee J & Chandler M, 2010; Van Etten JL, 
2011). Not much more is known about this giant virus or its replication cycle, but, similarly 
to Mimivirus, it is considered to contain genes involved in its replication, transcription and 
translation processes.  
[40] 
 
Figure 1.5: Map of the Marseillevirus chromosome, depicting the different variety of sources from which it has obtained its 
genetic material [Boyer M et al, 2009]. 
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1.2.3 Cafeteria roenbergensis virus (CroV) 
CroV was only quite recently isolated (2010), when it was discovered to infect the 
Cafeteria roenbergensis microorganism, a widespread marine microflagellate zooplankton 
grazer that is one of the oceans major and abundant predators. CroV is itself parasitised by 
a virophage named Mavirus. The microzooplankton Cafeteria roenbergensis is 
phylogenetically relatively distant from the amoeba hosts of the Mimivirus and the 
Marseillevirus. The CroV virus, however, is for some reason very closely related to the 
Mimivirus, although there is a huge phylogenetic distance and difference between their 
hosts and also less than a third of the CroV genes have been found to have homologs in the 
Mimivirus. Both these viruses have recently been classified within a new sub-family, the 
Megaviridae, belonging to the NCLDV group of viruses. It has the second largest genome, 
encompassing a 730 kb double-stranded DNA genome (618 kb represent the total protein 
coding genome) that includes 544 protein coding genes, many of which encode putative 
functions that are exceptionally unusual for a virus, maybe revealing the presence of a 
diverse coding potential (Figure 1.6). Nevertheless, it is the largest genome of any known 
marine virus and the most extraordinarily complex genome studied so far. As with most 
other giant viruses, the same is the case for CroV; a group of its genetic material has arisen 
due to gene duplication events, while another group is the result of HGT. [Filee J & 
Chandler M, 2010; Fischer MG et al, 2010; Colson P et al, 2011; Van Etten JL, 2011]. This giant 
virus is at its early stages of investigation, thus not much is known about its replication 
cycle.  
[42] 
 
Figure 1.6: Genomic diagram of CroV [Fischer MG et al, 
2010]. 
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Some of the component factors included in the diverse coding potential of the CroV are 
DNA repair enzymes, DNA replication and promoter motifs, in addition to translation/ 
transcription factors. Furthermore, a 38 kb genomic region has been detected and has been 
characterised as being of ‘a putative bacterial origin’. This coding sequence encoded 
several enzymes that were predicted to be involved in the carbohydrate metabolising 
pathway. This discovery is exceptionally interesting as nutrient recycling and carbon 
transfer, both in freshwater and marine environments, is majorly achieved by protistan 
gracers’ predation (Van Etten JL, 2011). What is more, a significant number of genes have 
been shown to be expressed during CroV infection. All these facts indicate that CroV has a 
highly autonomous reproduction and propagation strategy during infection (Fischer MG et 
al, 2010).  
 
1.3 Replication                                                                                                              
DNA replication is regarded as the most fundamental process for all entities, as survival 
requires that replication of genomic material occurs in an extremely precise but also 
efficient way. For this purposes, it is a highly coordinated procedure engaging many 
proteins that work cooperatively towards correct DNA replication and hence accurate 
transmission of genetic information. All three known domains of life, Archaea, Bacteria 
and Eukarya, seem to replicate their genome in a similar way; in basic terms, they copy 
their genetic material and divide it into the next generation cells. [Alberts BM, 1987; 
DePamphilis ML, 1993; Vas A & Leatherwood J, 2000; Bell SP & Dutta A, 2002; Mechali M, 
2010; Kazlauskas D & Venclovas C, 2011]. The textbook definition is: DNA replication is a 
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process during which the particular DNA molecule is duplicated in a semi-conservative 
way further resulting in the production of two identical DNA molecules that are eventually 
divided, hence forming new and identical progeny or daughter cells synthesised from that 
original cell (Karp G, 2009). As a result, each progeny cell contains an identical DNA 
molecule to that of the parental cell from where it came from. Consequently, Archaea, 
Bacteria and Eukarya grow and divide, whereas viruses do not follow this kind of process 
(Cann AJ, 2003). 
 
1.3.1 Eukaryotic Replication 
As previously mentioned, DNA replication is the accurate and timely duplication of the 
eukaryotic genome. For this process to be completed in a precise and successful way the 
cooperation of multiple factors and enzymes is required. These will further ensure that the 
genetic information will be maintained and stably passed down to the progeny cells each 
time the parental cells divide. This process is detrimental for the fate of the newly 
generated daughter cells. [Bell SP & Dutta A, 2002; Kelly TJ & Spillman B, 2006] 
 
More specifically, in eukaryotes DNA synthesis is initiated by the orderly binding of 
initiator proteins in a series of steps to the origins of replication, found at multiple 
chromosomal sites (Bell SP & Dutta A, 2002). A multi-subunit protein called the origin 
recognition complex (ORC) initially recognises and binds specifically to autonomously 
replicating sequences (ARS) found within conserved replication initiation sites (origins) 
[45] 
 
(Bell SP& Stillman B, 1992; Bryant JA et al, 2001; Shen Z & Prasanth SG, 2012). This ORC 
complex particularly consists of six proteins, Orc1p-Orc6p, which are all essential for 
initiation and viability of DNA replication (Stillman B, 1996; Kelly TJ & Spillman B, 2006; 
Bochman ML & Schwacha A, 2009 (Refer to Figure 1.7)). In eukaryotes, the ORC complex 
forms the core of the origin complex to which other components are loaded onto the DNA 
replication fork in a step-wise manner (Wang TA & Li JJ, 1995). 
 
The first step in the initiation of eukaryotic DNA replication is the assembly of the pre-
replication complex (pre-RC), a multi-protein complex that controls where and when 
replication will initiate. The assembly of this complex specifically begins with ORC 
marking the origins of replication, loading onto them and thus recruiting two other factors, 
namely Cdc6 and Cdt1.  The binding of both Cdc6 and Cdt1 proteins to the ORC complex 
is essential for the next step in DNA synthesis initiation, which is loading of the 
minichromosome maintenance (MCM) proteins (i.e. MCM2-7) onto chromatin (Bryant JA 
et al, 2001). As a result, the protein complex comprising of ORC, Cdc6/Cdt1 and MCMs 
forms the complete pre-RC, and this is established at the end of mitosis of the previous cell 
cycle after separation of sister chromatids (Kelly TJ & Spillman B, 2006; Bochman ML & 
Schwacha A, 2009 (Refer to Figure 1.7); Shen Z & Prasanth SG, 2012).  
 
At the onset of S-phase, the pre-RC has to be converted into a pre-initiation complex (pre-
IC) that leads to initiation of DNA synthesis by causing the initial denaturation of the 
double-helix and thus the formation of a replication ‘bubble’. This activation of pre-RC is 
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accomplished by the action of S-phase specific cyclin-dependent kinases (CDKs) and 
Dbf4-dependent kinases (DDKs), which activate the firing of the replication origins 
allowing access and hence assembly of further replication factors (i.e. Dbp11, Sld3/Sld2, 
Mcm10, GINS complex, Cdc45, DNA polymerases etc.) to the exposed DNA template 
(Gerbi S et al, 2002; Kelly TJ & Spillman B, 2006; Bochman ML & Schwacha A, 2009 (Refer to 
Figure 1.7); Shen Z & Prasanth SG, 2012). The DNA double strand is specifically unwound 
by the action of a DNA helicase complex known as CMG (Cdc45-MCMs-GINS) complex 
(Remus D & Diffley JFX, 2009; Zegerman P, 2013), while this unwound DNA state is 
maintained by replication protein A (RPA) that binds single-stranded DNA and prevents it 
from winding back or forming other secondary structures (Bambara RA et al, 1997; Hickey 
RJ et al, 2003; Chilkova O et al, 2007).  
[47] 
 
 
Figure 1.7: Initiation and early stages of eukaryotic DNA replication. “(A) During G1 phase, Cdc6 
and Cdt1 recruit and load the MCMs complex (Mcm2-7) to origins of replication (marked by the binding 
of Orc1-6) to form a stable and inactive complex called the pre-RC. (B) In late G1/early S phase, the pre-
RC is activated for DNA unwinding by the CDKs and DDKs, and is now named the pre-IC complex. This 
facilitates the loading of additional replication factors (e.g. Cdc45, Mcm10, GINS, polymerase α/primase 
and DNA polymerases δ and ε) and unwinding of the DNA at the origin. (C) During S phase, 
bidirectional DNA replication ensues.” [Bochman ML & Schwacha A, 2009] 
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Once the parental DNA strands have been separated by the DNA helicase complex, as well 
as with the help of topoisomerases (Topoisomerase I) that remove DNA supercoils ahead 
of the replication fork, and the replication ‘bubble’ has been formed, then DNA synthesis 
can commence. However, only one of the original DNA strands is synthesised 
continuously, and this is termed the leading strand, while the other strand is produced in 
short discontinuous segments in the opposite orientation of the fork movement, and this is 
termed the lagging strand. In the latter case, the fragments generated are known as Okazaki 
fragments and these are specifically synthesised from a series of short RNA primers, which 
are eventually removed and the several DNA fragments produced are finally joined by 
DNA ligases (DNA ligase I) to complete lagging strand synthesis. In particular, lagging 
strand synthesis is initiated by multiple RNA primers that are generated by the intrinsic 
primase subunits of DNA polymerase α, while the polymerase subunit of the polymerase 
then adds a stretch of deoxyribonucleotides to the primer (Bambara RA et al, 1997 (Refer to 
Figure 1.8); Takisawa H et al 2000; Kelly TJ & Spillman B, 2006). The DNA polymerase α is 
also responsible for causing an initial priming event on the leading strand (Mossi R et al, 
2000; Hickey RJ et al, 2003; Chilkova O et al, 2007).  
 
Next step in eukaryotic DNA synthesis, for both the leading and the lagging strand, is the 
binding of the replication factor C (RFC) that will initiate polymerase switching in an 
ATP-dependent manner. This has two effects; first it causes the displacement of the DNA 
polymerase α-primase complex, and secondly it allows the assembly of the proliferating 
cell nuclear antigen (PCNA) that will form a sliding clamp structure and encircle the DNA 
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strand. The DNA polymerase δ (and ε) then comes along and interacts with the PCNA, 
ensuring the PCNA remains tightly bound to the DNA for processive synthesis (Bambara 
RA et al, 1997 (Refer to Figure 1.7); Takisawa H et al 2000; Hickey RJ et al, 2003; Kelly TJ & 
Spillman B, 2006). Experiments have shown that DNA polymerase δ is responsible for 
lagging strand synthesis, while DNA polymerase ε participates in leading strand synthesis 
(Chilkova O et al, 2007; Pavlov YI & Shcherbakova PV, 2010). This polymerase switching 
event occurs only once for the leading strand just after it has been primed, while for the 
lagging strand it happens during the synthesis of every Okazaki fragment (Mossi R et al, 
2000).  
 
In the final stages of the replication process, the initiator RNA primers are removed from 
the DNA strands by nucleases, commonly RNase H1 that has an endonucleolytic activity, 
while any remaining 5’-ribonucleotides are removed by the FEN1/RTH1 complex, 
containing both an endonucleolytic and exonucleolytic activity. The numerous single-
stranded short DNA fragments generated from the lagging strand are finally ligated 
together to create a uniform DNA strand. The resulting daughter DNA strands intertwine to 
form a complete newly replicated double-helix (Bambara RA et al, 1997 (Refer to Figure 
1.8); Hickey RJ et al, 2003; Kelly TJ & Spillman B, 2006). 
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In general, DNA replication is a very tightly controlled process for the reason that it should 
only occur once per cell-cycle, and therefore ensures that DNA is not re-replicated within 
* 
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one cycle (Wang TA & Li JJ, 1995; Bryant JA et al, 2001; Shen Z & Prasanth SG, 2012). This 
restriction also ensures that DNA replication is completed only with minimal mistakes, 
with various damage and checkpoint controls having been evolved for the purpose of 
arresting or slowing down cell-cycle progression until the ‘problem’ encountered has been 
resolved by specific mechanisms (Kelly TJ & Spillman B, 2006; Bochman ML & Schwacha A, 
2009). 
 
1.3.2 Virus Replication                                                                                         
Viruses, as mentioned previously (See Section 1.1; Viruses), are considered to be obligate 
intracellular parasites that replicate by relying on their host to provide the majority of the 
material and machinery necessary for their reproduction. In other words, they manage in 
particular ways to force the infected host organism to produce more of the same viral 
components, hence more of the same viruses. [Cann AJ, 2001; Minor PD, 2007; Harper DR, 
2012]. Therefore, their replication cycle differs from that of other living organisms, as it 
basically relies on the accurate assembly of already pre-formed viral components, whereas 
in the case of archaea, bacteria and eukarya these replicate by duplicating their genetic 
material and then dividing it into equal and identical parts (Cann AJ, 2003). 
 
To do so, the viruses initially rely on their structural properties. The basic structure of a 
virus can be seen in Figure 1.1. In particular, during their replication cycle the viral 
component that plays the major role is the viral protein coat or envelope. The proteins of 
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the viral outer layer not only protect the viral genome from destruction, but they further 
enable the viruses to recognise, interact, and thus, infect the suitable host cells. Once this 
interaction has been established the viruses can then initiate a cycle that will eventually 
lead to the production of hundreds of identical viruses within a considerably short period of 
time. The steps that specifically follow after the viruses have identified, attached to and 
initiated infection of their hosts’ cells are: a) penetration into the host cells that 
immediately causes an alteration in the host cells’ cellular functions so as to support the 
time-dependent viral replication cycle; b) uncoating of the viral genetic material; c) 
replication and hence expression of the viral genome; d) assembly of the viral components 
produced and maturation of new generation virus particles; e) and finally, release of the 
mature virions from the parasitised host cell (Cann AJ, 2003; Minor PD, 2007; Harper DR, 
2011). A summarised diagram of the typical virus replication cycle is illustrated in Figure 
1.2.  
 
1.3.3 Giant Virus Replication 
The giant viruses under investigation all belong to the NCLDV group, as described 
previously (See Section 1.2; Giant Viruses). The NCLDV group of viruses is considered to 
be a monophyletic group, meaning that viruses belonging to this group are assumed to 
have emerged from a common ancestor (Filee J et al, 2008; Colson P and Raoult D, 2010). 
These viruses contain a linear, double-stranded DNA molecule and have a conserved core 
set of genes that are thought to play an important part in the viruses’ metabolism, 
replication and propagation (Filee J et al, 2006; Filee J & Chandler M, 2010). As a result, 
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these viruses may not be so dependent on the host cells’ material and machinery for their 
reproduction (Yutin N & Koonin EV, 2009; Koonin EV & Yutin N, 2010). 
 
The main difference between other viruses and giant viruses is that the latter are essentially 
capable of replicating their genomic material entirely within the cytoplasm of the 
parasitised cell (as described by the name given to the NCLDV group), instead of only 
being able to do so in the nucleus (Claverie JM et al, 2009-a/b). Subsequently, they have two 
replication phases from which they can choose (i.e. one exclusively in the cytoplasm and 
one that may initiate in the nucleus before finalising the process in the cytoplasm), 
compared to only having one replication phase like normal viruses do (i.e. in the nucleus) 
(Filee J et al, 2006; Yutin N & Koonin EV, 2009; Mutsafi Y et al, 2010). This fact is possibly 
sufficient to disengage the giant viruses’ replication and propagation activities from the 
hosts’ genome.  
 
In general terms, giant virus replication occurs in the following way (as has been already 
described for the Mimivirus): after endocytosis is initiated, the genomic material is 
released into the cytoplasm of the host cell causing an early initiation of transcription. This 
results in the production of mRNAs, which are transported to isolated sites within the 
cytoplasm. Next, DNA replication is commenced within specific replication factories 
generated for this particular purpose. These factories have been seen in areas of the host 
cytoplasm that are completely opposite to the areas where the mRNAs have accumulated, 
while the number of these factories generated depends on the starting number of infecting 
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virus particles. Therefore, when the individual replication factories expand due to 
extensive replication, they then fuse to form a single large factory taking up most of the 
hosts’ cytoplasm. Eventually, the huge single factory will burst and release the newly 
generated virus particles. [Katsafanas GC & Moss B, 2007; Suzan-Monti M et al, 2007; Mutsafi 
Y et al, 2010; Fischer MG, 2012]. 
 
Even though an entirely cytoplasmic replication cycle has been suggested for some giant 
viruses (i.e. Poxvirus, Mimivirus), this does not imply in any way an exclusively nucleus-
independent process.  The entirely cytoplasmic replication cycle does indeed provide proof 
of the fact that these giant viruses encode an important number of proteins essential for 
their own DNA replication and transcription mechanisms, as well as mRNA synthesis. 
Nevertheless, during these processes there will still be a participation of host-encoded 
protein factors. That being either due to the fact that, even though these viruses have a 
huge genome, they are still not capable of encoding all the necessary machinery for their 
complete replication, or due to some host nuclear factors being passively leaked out of the 
nucleus during viral replication. In the first case, the host proteins are actively exported 
from the nucleus and imported into the cytoplasm for association with the virus-encoded 
proteins and participation in the viral replication processes. This active transportation will 
take place as long as the host-encoded proteins found in the nucleus are not anchored to a 
nuclear structure (i.e. nuclear membrane), in which case they probably become resistant to 
cytoplasmic delivery. [Oh J & Broyles SS, 2005; Mutsafi Y et al, 2010]. However, the exact 
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requirements that are fundamental for this export-import process of host nuclear protein 
factors from the nucleus into the cytoplasm are not yet fully understood.  
 
1.4 Replication Components 
For efficient and complete DNA replication, taking place either in Archaea, Bacteria, 
Eukarya or viruses, specific DNA replication proteins are required. The eukaryotic 
replication proteins have already been discussed in detail in Section 1.3.1. In most cases, 
all organisms necessitate the presence of the same or equivalent proteins for their 
reproduction. [Leipe DD et al, 1999; Forterre P et al, 2000; Robinson NP & Bell SD, 2005; 
Barry ER & Bell SD, 2006; Aves SJ, 2009; Boyer M et al, 2010; Yutin N & Koonin EV, 2012]. 
There are a great number of such diverse DNA replication proteins, but for the purpose of 
this project we will specifically focus our interest on the PCNA and FEN1 proteins. 
 
1.4.1 Proliferating Cell Nuclear Antigen (PCNA), a sliding clamp protein                             
DNA replication is performed by a multicomponent complex of proteins known as DNA 
replicases. This complex typically contains a DNA sliding clamp, which is the central 
factor for DNA replication processes, the clamp loader, and of course, a DNA polymerase. 
The sliding clamp is a ring-shaped polymerase processivity factor, which is loaded onto the 
double-stranded DNA with the help of the clamp loader. The interaction between the 
sliding clamp (e.g. PCNA) and DNA is rendered stronger in the presence of positively 
charged residues located in the center of the circular PCNA molecule that create a suitable 
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DNA binding surface. [McNally R et al, 2010; Fig. 1.7]. By encircling the DNA molecule, 
the sliding clamp forms a platform and permits other replication factors, such as the DNA 
polymerases, to assemble and engage at the heart of the replication folk, hence allowing 
the initiation of the replication process (Kirchmaier AL, 2011). What is more, by tethering 
the various replication factors to the DNA molecule, it is able to augment their activity 
(Warbrick E, 1998; Maga G & Hubscher U, 2003; Kazlauskas D & Venclovas C, 2011).  
 
In addition, a vast array of other factors involved in DNA processing, such as DNA 
modulating and damage by-pass/repair enzymes, cell cycle regulators, as well as other 
enzymes that play an active part in chromatin assembly, cohesion and remodeling, bind to 
and interact with the sliding clamp in a highly dynamic and coordinated fashion. In the 
case of PCNA’s, such interactions usually involve the hydrophobic cleft of the PCNA 
interdomain connector loop and the PCNA-interacting peptide (PIP) box motif found on 
the interacting partner (De Biasio A et al, 2012; Ulrich HD & Takahashi T, 2013). This 
mechanism illustrates the crucial role of sliding clamps in controlling access to the DNA 
and to its machinery, by regulating and coordinating the function of a plethora of other 
enzymes (Winter JA & Bunting KA, 2012). This fine and complex interplay between sliding 
clamps and their effector proteins, at different stages of DNA replication and repair, has to 
be tightly controlled by a series of regulatory mechanisms; a) differential binding affinities 
of each protein to the sliding clamps leading to association or disassociation of one 
interacting partner by another, b) post-translational modifications [Ulrich HD & Takahashi 
T, 2013], c) accessory factors that modulate these interactions, d) appropriate destruction of 
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the complexes formed by recruiting other necessary proteins, when required. As such, 
sliding clamps play an essential role in maintaining the genome integrity and stability 
(Kirchmaier AL, 2011; Mailand N et al, 2013). 
 
A schematic representation of a characteristic PCNA/DNA binding interaction is depicted 
in Figure 1.9. 
 
Figure 1.9: Standard PCNA/DNA interaction model [McNally R et al, 2010]. 
 
In general, in the case of the PCNA sliding clamp; During DNA replication and repair, the 
PCNA protein is loaded onto the DNA template by the RFC clamp-loading complex. Once 
loaded, PCNA initially interacts and enhances the activity of the DNA polymerase Pol δ 
and Pol ε. In addition to these enzymes, however, PCNA acts as a platform for the direct 
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binding of other proteins involved in DNA synthesis and repair, ranging from the Flap 
Endonuclease I (FEN1) and DNA ligase I to other DNA polymerases or DNA damage 
repair proteins (e.g. DNA Pol η). Other DNA processes require the assembly of different 
protein that will bind to and interact with the PCNA protein (Majka J & Burgers PMJ, 2004; 
Kirchmaier AL, 2011; Mailand N et al, 2013). 
 
Computation analysis of the various components of the DNA replicase complex revealed 
that, in spite of DNA replication being a uniformal procedure between archaea, bacteria, 
eukarya and viruses, some of the components involved are not universally conserved. This 
was mostly the case for the DNA polymerase proteins, which were shown to have evolved 
independently from different ancestral proteins for bacteria and archaea/eukarya 
(Kazlauskas D & Venclovas C, 2011). In addition, the sliding clamp family is also extremely 
divergent in terms of their amino acid sequence, revealing no sequence homology between 
the diverse sliding clamps belong to the different organisms. The only fact that shows 
homology between all DNA processivity factors is their three dimensional ring-shaped 
structure (O’Reilly DR et al, 1989; Bruck I & O’Donnell M, 2001).   
 
Though the bacteria DNA sliding clamp was discovered to be a homodimer, the archaeal 
and eukaryotic sliding clamps, known as Proliferating Cell Nuclear Antigen (PCNA), were 
mostly observed as homotrimers (De Biasio A et al, 2012). Some archaea may also have a 
heterotrimeric PCNA. In the case of viruses, they all require the presence of processivity 
factors for successful viral DNA replication, however only a number of them encode for 
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PCNA-like proteins and this fact is basically dependent on their genome size. However, 
the different viruses, in which PCNA-like proteins have been studied, reveal different 
forms of this protein (Kazlauskas D & Venclovas C, 2011).  
 
Concerning the giant viruses; in the Mimivirus three varying PCNAs have been identified 
(these are referred to as MIMI_L108, MIMI_L823 and MIMI_R493; obtained from 
Uniprot, and in accordance with work conducted by Raoult D et al, 2004), but it is still not 
known if these altogether form a heterotrimer or if the individual proteins form 
homotrimers, homodimers, heterodimers or even monomers. In the case of the 
Marseillevirus the identified PCNA protein has been named MAR_ORF212, while for the 
CroV the identified PCNA protein is known as CroV_219 (information obtained from 
Uniprot). Unfortunately, not much more is known about these giant viruses and their DNA 
replicase complexes. Therefore, as this group of viruses appears to be of great significance 
due to their spectacular way of life, it is crucial to further investigate in depth exactly how 
they acquired such an enormity, and as such, precisely how they replicate their genomic 
material. 
 
As a final note; computation analysis studies surprisingly revealed that as the size of the 
organisms’ (including viruses) genome increases, then by rule they will encode for their 
own DNA replicase components (Kazlauskas D & Venclovas C, 2011). In the case of giant 
viruses this explains why most possibly they do not have to rely on the infected host to 
provide them with DNA replicase factors for their reproduction. 
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1.4.2 Flap Structure-specific Endonuclease 1 (FEN1) protein                           
All organisms, Archaea, Bacteria, Eukarya and viruses, require the action of a nuclease 
protein that will assist in DNA repair following DNA replication. Nucleases are key 
enzymes for controlling replication, taking part in repair processes, as well as multiple 
other metabolic pathways, and as such, maintaining the genome stability. One such 
enzyme is the FEN1 protein that plays a major role during DNA replication procedures, 
where it effectively remove the 5’ overhanging ends from the Okazaki fragments generated 
during double-stranded DNA synthesis by the DNA polymerase enzyme, hence forming a 
substrate for the DNA ligase enzyme to assist Okazaki fragment maturation (Warbrick E, 
1998; Gomes XV & Burgers PMJ, 2000; Sakurai S et al, 2005). Its activity in this type of 
process is based on the recognition of the bifurcated ends of the double-stranded DNA, and 
its specific action is to cut the phosphodiester bond at the 5’ prime end (firstly, 
exonucleolytically removes the ribonucleotide, and secondly, endonycleolytically removes 
the entire primer) leaving a 3’ hydroxyl end (Kaiser MW et al, 1999; Rumbaugh JA et al, 
1999). To complete accurately its action, FEN1 interacts with particular proteins. A 
schematic diagram of the representative FEN1 activity is illustrated in Figure 1.10. 
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In the case of Bacteria, their DNA polymerase protein itself contains a 5’ exonuclease 
domain. On the other hand, Archaea and Eukarya encode for a FEN1 protein. Both these 
nuclease enzymes are members of a family of ‘structure-specific 5’ exonucleases’, and 
even though they perform fairly similar functions, they have a very limited similarity 
between their sequences. Despite this fact, they all have the same substrate specificity. 
[Kaiser MW et al, 1999; Grabowski B & Kelman Z, 2003]. Moreover, viruses are believed to 
encode the FEN1 type nuclease protein (or a FEN1-like protein), but not much is known 
about this protein in the diverse virus families and groups, as minimum investigation has 
been carried out over the years. As a consequence, very little is mentioned in the literature 
Figure 1.10: Model for repair of DNA 
strands and completion of Okazaki 
fragment maturation. “First, the DNA 
polymerase complex makes a RNA primer 
(hatched line) and begins DNA synthesis, and 
then FEN1 removes the initiator RNA, 
perhaps including some DNA as well, with or 
without extension from an upstream fragment. 
Meanwhile, DNA polymerase continues DNA 
synthesis and inserts a mismatch that slightly 
disrupts the DNA helix. This disruption 
promotes the removal of the mismatch by 
FEN1 in one cut or a series of endonucleolytic 
cuts, depending on the location of the 
mismatch”. Eventually, ligation of the DNA 
fragments is completed [Rumbaugh JA et al, 
1999].  
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regarding the nuclease activity present in the various giant virus families [Da Silva M et al, 
2006; Iyer LM et al, 2006; Senkevich TG et al, 2009; Yoshida T et al, 2011]; so even though the 
Mimivirus, Marseillevirus and CroV have been determined to have a FEN1-like 
endonuclease protein (according to the UniProt database; MIMI_L386, MAR_ORF365, 
CroV_037, respectively), no more details have been acknowledged about this protein in the 
three viral organisms; the only slight exception being CroV for which the Flap (FEN1)-like 
endonuclease has been identified as a probable XPG nuclease (Fischer MG et al, 2010).  
 
1.4.3 Additional DNA replication proteins encoded by the three Giant viruses of 
interest, Mimivirus, Marseillevirus and CroV 
Most information available to date about the proteins encoded by giant viruses has been 
based on computational/bioinformatic studies and analysis of their viral genome 
sequences. In particular, various molecular sequence analyses of the Mimivirus, 
Marseillevirus and CroV genomes has revealed that these giant viruses encode 
homologous DNA replication proteins, a fact that appears to be dependent on their genome 
size. The key replication proteins found to be conserved in these viruses, actually form a 
core set of proteins found to be distributed in all giant NCLDVs (Kazlauskas D & Venclovas 
C, 2011). An early study performed by Iyer LM et al (2006) found a number of these 
conserved proteins involved in viral DNA replication. These include a shared Ser/Thr 
kinase, a D5R-like replicative primase/helicase, as well as other helicases, 
Topoisomerases, a DNA polymerase of the B family, a PCNA-like DNA clamp, RFC 
clamp loaders, ATP (Adenosine TriPhosphate)- and NAD (Nicotinamide Adenine 
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Dinucleotide)-dependent DNA ligases, Exonucleases, a Flap (FEN1)-like endonuclease, as 
well as additional endonucleases, and a RuvC-like Holiday junction resolvase (HJS).  
 
The initial studies performed for the purpose of deciphering the genetic content of these 
giant viruses, together with subsequent studies, were conclusive. In particular, concerning 
the three most vital DNA replication proteins (i.e. DNA polymerases, PCNA and RCF 
proteins), the outcomes from these studies were as follows: All three giant viruses, 
Mimivirus, Marseillevirus and CroV, were revealed to encode for a Family B DNA 
polymerase, while only Crov further encodes for a Family X DNA polymerase. In addition, 
they all encode for PCNA sliding clamps, with Mimivirus actually encoding for three 
separate PCNA proteins. With the exception of Marseillevirus, both Mimivirus and CroV 
were found to encode for all five RFC subunits, hence probably have a fully functional 
RFC protein. Studies performed by Kazlauskas D & Venclovas C (2011) showed that only 
three out of the five subunits (i.e. RFC1, RFC3, and RFC5) of the RFC protein complex, 
belonging to the Mimivirus and CroV, contain a PIP-box for interaction with the PCNA 
protein, and the affinities of each subunit for this particular interaction vary probably due 
to differential evolution. In Mimivirus, specifically, the PIP-boxes belonging to each of the 
RFC1, RFC3 and RFC5 subunits have progressively ‘weaker’ PCNA-binding strengths. 
However, the actual PIP-box in RFC5 is mostly similar to the one identified in RFC1. For 
a summary of the DNA replication proteins discussed and the organisms they are encoded 
by see Table 1.1. [Raoult D et al, 2004; Boyer M et al, 2009 & 2010; Colson P et al, 2010; 
Fischer MG et al, 2010; Kazlauskas D & Venclovas C, 2011]. 
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What is more, all viruses in question encode for various kinases. The most important ones 
were determined as being Thymidine and Serine/Threonine kinases. These, or equivalent 
enzymes, are encoded by all three giant viruses of interest; Marseillevirus and CroV 
encode for those exact enzymes, while in the case of Mimivirus the Thymidine kinase has 
been replaced by a Deoxynucleoside Kinase (DNK) and a Nucleoside Diphosphate Kinase 
(NDK). In regards to the central DNA primases, the Mimivirus, Marseillevirus and CroV 
primase proteins have been shown to be linked to and work in conjunction with the D5-like 
helicases. Interestingly, Marseillevirus additionally encodes for an AEP (Archaeo-
Eukaryotic Primase)-type primase. For a summary see Table 1.1. [Raoult D et al, 2004; 
Boyer M et al, 2009 & 2010; Colson P et al, 2010; Fischer MG et al, 2010; Kazlauskas D & 
Venclovas C, 2011]. 
 
Other essential DNA replication proteins, such as DNA helicases, topoisomerases, ligases 
and nucleases, are abundant in all three giant viruses of interest. Amongst others, SF 
(SuperFamily)-type helicases are very common and present in all three viruses [i.e. 
SW1/SNF2 (SWItch/Sucrose NonFermentable) ATPase helicase encoded by Mimivirus 
and Marseillevirus, Types I and II encoded by Marseillevirus, and only Type II encoded by 
CroV], while only Mimivirus and Marseillevirus moreover encode for a D6R-type 
helicase. In terms of the topoisomerase proteins present in these viruses, both Mimivirus 
and CroV encode for Types IA, IB and IIA, while Marseillevirus only encodes for Type II.  
(See Table 1.1) [Raoult D et al, 2004; Boyer M et al, 2009 & 2010; Colson P et al, 2010; Fischer 
MG et al, 2010; Kazlauskas D & Venclovas C, 2011]. 
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Regarding the repair of the DNA strands during replication, the most common types of 
DNA ligases present in giant viruses are the ATP-dependent DNA ligase and the NAD-
dependent DNA ligase. Both Mimivirus and Crov have the later type, while Marseillevirus 
encodes for the former type. Furthermore, all three encode for 5’-3’ exonucleases and 
RNases [i.e. Mimivirus and Marseillevirus were found to encode RNases Types III and HI, 
whereas CroV encodes for Types H and HI], while they have homologs of Flap (FEN1)-
like endonucleases. Finally, all three viruses encode for a RuvC-like HJS.  (See Table 1.1) 
[Raoult D et al, 2004; Boyer M et al, 2009 & 2010; Colson P et al, 2010; Fischer MG et al, 2010; 
Kazlauskas D & Venclovas C, 2011]. 
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Mimivirus Marseillevirus CroV 
Kinases 
- DNK,  
- NDK, 
- Ser/Thr  
- Thymidine, 
- Ser/Thr  
- Thymidine, 
- Ser/Thr 
Helicases 
- Type III (D5-
type ATPase),  
- D6R-type,  
-SW1/SNF2  
- SF-types I and II,  
- D6R-type,  
- SW1/SNF2  
- SF-type II 
Topoisomerases 
Types IA, IB and 
IIA 
Type II 
Types IA, IB and 
IIA 
Primases 
D5-like 
primase/helicase 
- D5-like 
primase/helicase, 
- AEP-type  
D5-like 
primase/helicase 
DNA 
Polymerases 
Family B Family B 
- Family B,  
- Family X 
RFC protein Five RFC subunits - 
Five RFC 
subunits 
PCNA protein Three PCNAs + + 
DNA ligases NAD-dependent  ATP-dependent  NAD-dependent  
RNases Types III and HI Types III and HI Types H and HI 
Exo-/ 
Endonucleases 
- 5’-3’ 
exonuclease,  
-Flap (FEN1)-like 
endonuclease 
- 5’-3’ 
exonuclease,  
- Flap (FEN1)-like 
endonuclease,  
- 5’-3’ 
exonuclease,  
- XPG (Flap-like) 
endonuclease, 
Resolvases RuvC-like HJS RuvC-like HJS RuvC-like HJS 
Table 1.1: Summary of the key DNA replication proteins encoded by Mimivirus, 
Marseillevirus and CroV. (The symbol ‘+’ indicates the presence of a protein, whereas ‘-’ 
indicates its absence). 
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A number of the key DNA replication proteins belonging to the giant viruses, Mimivirus, 
Marseillevirus and CroV, as discussed in this section, were subsequently compared, in 
terms of their sequence similarity, to the equivalent eukaryotic proteins. In particular, the 
proteins selected for this investigation were the PCNA, RFC and FEN1 proteins, while the 
equivalent proteins from two eukaryotic organisms were chosen for comparison reasons; 
these organisms were homo sapiens and the most extensively studied yeast, 
Saccharomyces cerevisiae.  
 
The three proteins of interest discovered in the various organisms selected for this study 
are demonstrated in Table 1.2. The details of each protein entry are in accordance with the 
information described on the Uniprot website (http://www.uniprot.org/), while at instances 
the NCBI protein database was also referred to (http://www.ncbi.nlm.nih.gov/protein).  
 
 PCNA RFC FEN1 
Homo sapiens PCNA_HUMAN, 
261aa, Accession 
No. P12004 
RFC subunit 1: 
RFC1_HUMAN, 1148aa, 
Accession No. P35251, 
RFC subunit 2: 
RFC2_HUMAN, 354aa, 
Accession No. P35250, 
RFC subunit 3: 
RFC3_HUMAN, 356aa, 
Accession No. P40938, 
RFC subunit 4: 
RFC4_HUMAN, 363aa, 
Accession No. P35249, 
RFC subunit 5: 
RFC5_HUMAN, 340aa, 
Accession No. P40937 
FEN1_ 
HUMAN, 
380aa, 
Accession 
No. P39748 
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S. cerevisiae PCNA_YEAST, 
258aa, Accession 
No. P15873 
RFC subunit 1: 
RFC1_YEAST, 861aa, 
Accession No. P38630, 
RFC subunit 2: 
RFC2_YEAST, 353aa, 
Accession No. P40348, 
RFC subunit 3: 
RFC3_YEAST, 340aa, 
Accession No. P38629, 
RFC subunit 4: 
RFC4_YEAST, 323aa, 
Accession No. P40339, 
RFC subunit 5: 
RFC5_YEAST, 354aa, 
Accession No. P38251 
FEN1_ 
YEAST, 
382aa, 
Accession  
No. P26793 
Mimivirus 1. PCNA_ 
MIMIV, 464aa, 
Accession No. 
Q7T6Y0 
2.YL108_ 
MIMIV, 273aa, 
Accession No. 
Q5UPJ0 (NCBI 
Reference: YP_ 
003986598.1), 
3. YL823_ 
MIMIV, 323aa, 
Accession No. 
Q5UQH4 (NCBI 
Reference: YP_ 
003987355.1) 
RFC large subunit: 
RFCL_MIMIV, 533aa, 
Accession No. Q5UQK9, 
RFC small subunit 1:  
RFCS1_MIMIV, 363aa, 
Accession No. Q5UQ72, 
RFC small subunit 2: 
RFCS2_MIMIV, 344aa, 
Accession No. Q5UP47, 
RFC small subunit 3: 
RFCS3_MIMIV, 319aa, 
Accession No. Q5UQ47, 
RFC small subunit 4: 
RFCS4_MIMIV, 370aa, 
Accession No. Q5UQE8. 
*According to Kazlauskas D & 
Venclovas C, 2011 paper, the entry 
names of the small RFC subunits on 
Uniprot for Mimivirus have been 
recorded incorrectly. Here are 
presented the corrected versions. 
Putative  
endonuclease 
YL386_ 
MIMIV,  
473aa, 
Accession  
No. Q5UQW7 
Marseillevirus D2XAL4_ 
9VIRU, 298aa, 
Accession No. 
D2XAL4 - 
Flap-specific 
endonuclease 
D2XB04_ 
9VIRU,  
362aa, 
Accession  
No. D2XB04 
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CroV E3T4Y9_9VIRU, 
278aa, Accession 
No. E3T4Y9 
1. E3T5A4_9VIRU, 
429aa, Accession No. 
E3T5A4 (not fully 
characterised protein), 
 
Putative RFCs (NCBI): 
2. Ref: YP_003970094.1, 
334aa 
3. Ref: YP_003969962.1, 
316aa 
Putative 
DNA endo-
nuclease 
E3T4F7_ 
9VIRU, 
321aa, 
Accession 
No. E3T4F7 
Table 1.2: The PCNA, RFC and FEN1 proteins as characterised in a selection of eukaryotic 
and viral organisms. Information acquired from the Uniprot database, as well as on some 
occasions from the NCBI website. 
 
The established protein sequences for each protein mentioned in Table 1.2 were obtained 
from Uniprot (or NCBI when required), and these were utilised in three individual protein 
sequence alignments. Multiple sequence alignments were specifically performed separately 
for the PCNA, RFC and FEN1 proteins, using either the Clustal Omega (for small scale 
alignments) or the MUSCLE (for big scale alignments, as it is pronounced to achieve 
‘better average accuracy’ compared to other tools) protein alignment software on the 
EMBL-EBI website (http://www.ebi.ac.uk/Tools/msa/clustalo/ and 
http://www.ebi.ac.uk/Tools/msa/muscle/, respectively). The corresponding results for the 
PCNA, RFC and FEN1 proteins were finally visualised using the Jalview 2.8 software 
program and are illustrated in Figures 1.11, 1.12 and 1.13, respectively. 
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Figure 1.11: Multiple sequence alignment of PCNA proteins belonging to two eukaryotic 
organisms, Homo sapiens and S. cerevisiae, and the three giant viruses of interest, Mimivirus, 
Marseillevirus and CroV. The protein alignments were performed using the ClustalO 1.1.0 
bioinformatics software program, while the results were visualised using Jalview 2.8. The ClustalX 
colour scheme was applied to conserved residues according to specific criteria set by the software 
(http://www.jalview.org/help/html/colourSchemes/clustal.html).  
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Figure 1.12: Multiple sequence alignment of RFC proteins belonging to two eukaryotic 
organisms, Homo sapiens and S. cerevisiae, and the Mimivirus. The location of the potential 
RFC PIP-box domains is highlighted, although only part of the protein alignment is shown. The red 
boxes demonstrate full or part PIP-box motifs belonging to the different organisms, further 
revealing conserved residues. The distribution of PIP-box motifs in the various RFC subunits, for 
all three organisms studied, is in agreement with preceding studies that discovered their presence 
only in the RFC1, RFC3 and RFC5 subunits (Kazlauskas D & Venclovas C, 2011). The protein 
alignments were performed using the MUSCLE bioinformatics software program, while the results 
were visualised using the same software program mentioned previously.  
 
Note: The Marseillevirus and CroV were not included in this protein alignment regarding 
the RFC protein. As previously discussed, none of the RFC protein subunits have been 
uncovered in the Marseillevirus genome. In the case of CroV, even though it has been 
established that it encodes for all five RFC subunits (Kazlauskas D & Venclovas C, 2011), 
these have not been fully characterised yet. Some CroV RFC proteins have been annotated, 
as can be seen in Table 1.2, but not much more has been acknowledged about them (i.e. 
what RFC subunits they actually demonstrate). Furthermore, only part of the protein 
alignment is depicted in Figure 1.12. The reason for this being the large sequence length of 
most proteins included in the alignment. However, the part of the alignment considered to 
be of most significance is illustrated. This specifically contains the majority of conserved 
residues between the different organisms, thus probably representing conserved protein 
sequence motifs such as PIP-box motifs, which are vital for interaction with the PCNA 
protein. The location of the potential RFC PIP-box domains highlighted in Figure 1.12 has 
been predicted due to knowledge surrounding this type of motifs (See Section 1.5), and is 
also in accordance with a similar study conducted by Kazlauskas D & Venclovas C, 2011 
(Refer to Figure 7 of their study). 
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Figure 1.13: Multiple sequence alignment of FEN1 proteins belonging to two eukaryotic 
organisms, Homo sapiens and S. cerevisiae, and the three giant viruses of interest, Mimivirus, 
Marseillevirus and CroV. The location of the potential FEN1 PIP-box domains is highlighted, 
although only part of the protein alignment is shown due to long unconserved protein sequences 
present in some of the organisms that were not aligned. The red boxes demonstrate the PIP-box 
motifs belonging to the different organisms. In the case of Mimivirus and Marseillevirus, however, 
their PIP-box domains are not apparent in this figure. The protein alignments were performed using 
the ClustalO 1.1.0 bioinformatics software program, while the visualisation of the results was 
performed in the same manner as before.  
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Some general conclusion can be drawn from these three protein alignment figures 
constructed for each of the PCNA, RFC and FEN1 proteins (Figures 1.11, 1.12 and 1.13, 
respectively). All figures show that a good proportion of all three proteins are well 
conserved amongst the different organisms, eukaryotic and viral, as can be observed from 
the multiple regions of conserved amino acid residues. However, apart for the PCNA 
protein, both the RFC and FEN1 protein alignments revealed long stretches of either not 
very well conserved or fairly unconcerned protein regions (these have been cut out from 
Figures 1.12 and 1.13).  
 
Regarding the PIP-box motif domains that were investigated in the RFC and FEN1 
proteins; these do not appear to be significantly conserved in either protein between the 
organisms examined, and this fact may further justify their fairly imprecise alignment. 
Nevertheless, for the RFC PIP-box domains, the protein alignments undertaken have 
confirmed that these motifs only exist in RFC subunits 1 (RFC1), 3 (RFC3) and 5 (RFC5), 
as can be seen in the three organisms studied (i.e. Homo sapiens, S. cerevisiae and 
Mimivirus). Interestingly, the protein sequence alignments for FEN1 demonstrated a 
completely aligned and fully conserved PIP-box motif between Homo sapiens and S. 
cerevisiae. On the contrary, an obvious FEN1 PIP-box motif could not be determined for 
either Mimivirus or Marseillevirus. The CroV, however, did reveal a distinct PIP-box 
motif at the far end of its FEN1 protein sequence, a discussion of which follows in Section 
1.5. 
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1.5 PCNA-Interacting Peptide (PIP) box 
A number of important studies have revealed that the PCNA is a target for the binding of 
several proteins, with the different proteins apparently competing between them for this 
binding. The explicit PCNA-binding domain has particularly been identified and 
characterised in a large number of assorted proteins, e.g. p21, Cdt1, Topo IIa, DNA 
polymerases and ligase I, RFC, XPG (including FEN1) etc., which are all involved in 
various cellular mechanisms, from DNA replication and DNA repair to DNA methylation 
and cell cycle control (Gomes XV & Burgers PMJ, 2000). The interesting fact about this 
discovery is that the interaction formed appears to take place through a conserved motif. 
This typical motif found within the sequence of the various proteins, either on the far end 
of their N- or most commonly C- terminus –depending on the protein, may possibly 
contact the same site on the PCNA, that possibly being the hydrophobic cleft of the PCNA 
buried under the interdomain connecting loop (Warbrick E, 1998). The proposed consensus 
PCNA-binding motif specifically is QXXΨXXA, where ‘X’ represents any amino acid, ‘Ψ’ 
stands for L/I etc. (i.e. residues with moderately hydrophobic aliphatic side chains) and ‘A’ 
refers to amino acids containing hydrophobic aromatic side chains (i.e. F/W/Y). The Q, 
‘Ψ’ and ‘A’ residues are all conserved, while the motif is usually followed by a non-
conserved sequence. [Maga G & Hubscher U, 2003; Vivona JB & Kelman Z, 2003; Scorah J et 
al, 2008]. The consensus PIP-box sequence has been found to be conserved in Archaea and 
Eukarya, as well as in some viruses. This fact indicates the importance of these conserved 
residues during evolution, when they most likely had a regulatory role in coordinating 
aspects of DNA metabolism. [Warbrick E, 2000; Bruning JB & Shamoo Y, 2004; Moldovan GL 
et al, 2007; Winter JA & Bunting KA, 2012; Mailand N et al, 2013]. 
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The specific effect of PCNA binding on various proteins, which takes place through their 
PIP-box motifs, still remains mostly unclear. Although, as these PCNA-protein partner 
interactions appear to be conserved through evolution, it is apparent that they must be 
highly essential for coordinated, probably enhanced, and therefore successful DNA 
synthesis and repair. For most proteins the only actual information available is whether or 
not they contain such a motif, and as such whether they are capable of binding to and 
interacting with the PCNA protein. For example, it has previously been discovered that in 
regards to DNA polymerases their PIP-box domains are located on the β-subunit of PolIII 
(Bacteria), and on the small (perhaps regulatory) subunits of Polδ [i.e. p12 and p66 in 
humans and p32 in yeast] and on two out of four subunits of Polε, including its catalytic 
Pol2 subunit (Eukarya). By forming an interaction with these replicative polymerases, 
PCNA presumably provides them with the high processivity required for replicating an 
entire genome. In the case of RFC, as discussed earlier, PIP-box motifs are specifically 
positioned on the RFC1 (also known as RFC-A), RFC3 (RFC-C) and RFC5 subunits (three 
out of five subunits). FEN1 and DNA ligase I both contain PIP-box domains, but while 
binding of FEN1 to PCNA has been shown to stimulate its activity (Hosfield DJ et al, 1998; 
Sakurai S et al, 2005), its precise effect on DNA ligase I is unknown. Nevertheless, PCNA 
should presumably coordinate the action of these proteins in a stepwise reaction during 
Okazaki fragment maturation. In general, it has been shown that Polδ, Polε, and RFC show 
strongest interactions compared to FEN1 and DNA ligase 1 that bind with somewhat lower 
affinity to PCNA. Regarding the XPG nuclease protein, which is a structure-specific repair 
endonuclease similar to FEN1, a PIP-box motif has been identified commonly on the C-
terminus of its protein sequence. The binding of XPG to PCNA is responsible for 
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nucleotide excision repair (NER) activity in cells; however, the exact way by which NER 
activity is promoted remains uncertain (Tsurimoto T, 1999; Maga G & Hubscher U, 2003; 
Moldovan GL et al, 2007). 
 
The binding sites of the protein factors mentioned above onto the PCNA protein structure 
have already been mapped (Figure 1.14). Most PCNA-protein interaction take place on 
two major sites of the PCNA protein; those being the interdomain connecting loop and its 
C-terminal tail. In particular, proteins such as Polδ, FEN1 and DNA ligase I recognise the 
PCNA loop, whereas other proteins such as Polε and RFC bind to the PCNAs’ C-terminus 
(Maga G & Hubscher U, 2003). 
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In terms of the FEN1 PCNA-binding peptide, which is of interest in this study; 
Characterisation studies of the PCNA-binding region of the FEN1 showed that the 
interaction between the two proteins took place in the presence of a specific 20aa sequence 
located at the C-terminus of the FEN1 protein, described as the FEN1 PIP-box motif 
(Warbrick E, 2000). The proposed sequence of the eukaryotic FEN1 PIP-box domain 
particularly is Q--L--FF (Warbrick E, 1998; Zheng L et al, 2007). The FEN1 PIP-box motif 
characteristics of giant viruses have not been studied yet, and generally not much is known 
about other proteins’ PIP-box domains belonging to this group of organisms (Note: The 
only study completed to date that mentions about a PIP-box sequence in giant viruses was 
conducted by Kazlauskas D & Venclovas C (2011) and particularly concerned the RFC 
PIP-box belonging to the Mimivirus and CroV; See Section 1.4.3). 
 
Consequently, during this project, an attempt was made to use a synthetic peptide 
containing a putative PIP-box domain as identified in the last 20aa of the CroV FEN1 
protein, on its C-terminus (CroV037; as obtained from UniProt and further highlighted in 
Figure 1.13). The sequence of the hypothetical PIP-box motif was N--I--LL. It can be 
argued that this domain is comparable to the proposed consensus PCNA-binding motif, 
and subsequently to the eukaryotic FEN1 PIP-box domain, due to the specific sequence of 
the different amino acid groups. In particular, the motif begins with a neutral polar amino 
acid (i.e. N, which has the same properties as Q), continues with a hydrophobic amino acid 
(i.e. I) and ends with two hydrophobic residues (i.e. LL), which even though non-aromatic, 
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are still hydrophobic and, as such, not atypical of such a motif. The resulting synthetic 
peptide was used as a PCNA purification tool. 
 
1.6 PCNA/FEN1 Protein Complex Interactions 
Previous experimental studies have revealed that the PCNA sliding clamp can actually 
stimulate the action of the FEN1 nuclease; PCNA specifically recruits FEN1 at the site of 
branched DNA substrates near the replication folk, where it enhances its nuclease activity 
by 10- to 50- fold (Hosfield DJ et al, 1998; Sakurai S et al, 2005). By forming a direct 
interaction, an increase of FEN1 binding stability to the dsDNA is achieved, further 
allowing for a far greater cleavage specificity and efficiency (Samson T et al, 2000). The 
interaction between the two proteins is particularly formed when FEN1 interact with the 
PCNA molecule through a hydrophobic cleft located at the front part of the latter. Notably, 
the interaction domains of the PCNA and FEN1 have been pinned down to two regions 
belonging to either protein; the hydrophobic cleft, formed by the interdomain connector 
loop of PCNA, and a small sequence of conserved residues on C-terminus of FEN1. In the 
initial stages of this interaction, the PCNA-binding motif (PIP-box) (Warbrick E, 1998 & 
2000) found on the C-terminus of FEN1 mediates the correct binding of the latter to the 
hydrophobic cleft of the former, but only in the absence of the double-stranded DNA. 
However, once the PCNA interacts and encircles the DNA molecule, FEN1 requires the 
formation of a C-terminus PCNA interaction so as to ensure its correct and accurate 
function. Furthermore, as PCNA interacts at the same time with DNA polymerases, it 
suggests that FEN1 is especially recruited to the DNA replicase complex bound to the 
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replication fork (Figure 1.15). [Hosfield DJ et al, 1998; Jonsson ZO et al, 1998; Gomes XV & 
Burgers PMJ, 2000; Maga G & Hubscher U, 2003; Chapados BR et al, 2004; Sakurai S et al, 
2005; De Biasio A et al, 2012]. 
 
 
It has been proved that mutations in the FEN1 protein disrupt its interaction capacities with 
the PCNA protein, therefore significantly decreasing FEN1 cleavage efficiency; at the 
same time they are accountable for a series of diseases seen to develop in mice (Zheng L et 
al, 2007; Zheng L et al, 2011). The latter outcome can be justified by the fact that correct 
FEN1/PCNA interaction is critical for faithful and efficient Okazaki fragment processing, 
hence for completing DNA replication and repair further supporting the stability of the 
genomic integrity in all organisms. 
Figure 1.15: PCNA and FEN1 interaction 
model. (A) A typical heterotrimeric PCNA 
molecule is displayed, containing its 
interdomain connector loop (IDCL). 
Attached to the PCNA is the one-subunit 
FEN1 molecule. Binding occurs between the 
hydrophobic cleft, formed under the IDCL of 
the PCNA, and the C-terminus of the FEN1. 
(B) PCNA shown to encircle the DNA 
strand, carrying with it the FEN1 enzyme.  
‘A model of the interaction on a FLAP 
structure is shown’. Figure obtained from 
Gomez XV & Burgers PMJ, 2000. 
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1.7 Project Aims                                                                                                          
In general terms; the aim of this project was to understand the molecular ‘make-ups’, as 
well as the properties and functions, of two viral proteins regarded as key components of 
the giant virus replication machinery; the PCNA sliding clamp and the FEN1 
endonuclease. Both these proteins have been shown to be conserved evolutionarily, and 
together they form a greater complex that is critical for DNA replication and repair. 
Therefore, the presence of both these proteins in whatever organism is absolutely 
necessary as it ensures the maintenance of the genomic integrity by passing safely the 
genetic information from generation to generation. 
 
To complete this project, an extensive biochemical analysis of the Mimivirus PCNA, the 
Marseillevirus PCNA, and the CroV PCNA and FEN1 was performed. At the same time, 
however, the probable PCNA/FEN1 interaction was also investigated. The general goal 
was to attempt to gain additional insights into the lifestyle and evolution of these unique 
viruses.  
 
On completion of this project, it was generally hoped that a better understanding would 
have been reached on how replication and genetic material propagation is accomplished in 
the giant viruses. Thus providing further knowledge as to how these giant viruses have 
expanded to such a great extent in genomic size, during the history of evolution; this fact 
has also made their visualisation under a microscope possible, as they are comparable in 
size to bacteria. 
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To conclude; the discovery of these extraordinary viruses has began to change the science 
community’s and probably the public’s view on evolution and the whole history of life. 
Debates regarding the nature of these viruses have been ongoing ever since they were first 
discovered, and still no one knows for certain how these discussions will end and what 
conclusions will be derived from them. For these reasons mentioned, it is imperative and of 
considerable value to continue this type of research. So far, however, the majority of 
research has mostly focused on the computation analysis ─both bioinformatic and 
phylogenetic studies─ of these types of viruses, struggling to decipher the entire history of 
their evolution, as well as whether or not they should be included in the ‘tree of life’. On 
the contrary, though, since the giant viruses’ discovery there has not been a great deal of 
research focusing on their actual biological nature. Scrutinising the actual molecular 
biology ‘make-up’ of these viruses may optimistically result in gaining a better 
understanding of their life cycle and a more intense insight into their own evolutionary 
hallmark. The outcome of this will hopefully be that one day in the near future the world 
will have a more conclusive and maybe definite answer regarding the nature of the giant 
viruses, and as such a better outlook of the evolution of this planet as we know it.  
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-CHAPTER TWO-  
 
Materials and Methods 
 
2.1 Materials 
2.1.1 Reagents 
The majority of reagents utilised for this study were purchased from Biogene (UK), 
Bioline (UK), BioRad (UK), Fermentas (UK), Fisher Scientific (UK), Formedium (UK), 
GE Healthcare (UK), IBA (Germany), Macherey-Nagel (UK), Melford (UK), New 
England Biolabs (NEB, UK), Novagen (UK), Promega (UK), Qiagen (UK), Sigma-Aldrich 
(UK) and ThermoScientific (UK), unless otherwise stated. 
 
2.1.2 Synthetic Genes 
The synthetic genes for the Mimivirus PCNA (APMV_L108; Appendix A.1.1), 
Marseillevirus PCNA (MAR_ORF212; Appendix A.1.2), CroV PCNA (CroV_219; 
Appendix A.1.3) and CroV FEN1 (CroV_037; Appendix A.1.4) were ordered from 
Genscript (UK). The maps of these constructs are attached in the Appendix (A.1, Construct 
Maps of the Synthetic Genes), as provided by the supplier.  
 
2.1.3 Vectors & Bacteria Cells 
The vectors used for cloning the Mimivirus (APMV_L108), Marseillevirus 
(MAR_ORF212), CroV (CroV_219) PCNA and CroV FEN1 (CroV_037) genes were 
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purchased from IBA (UK) and Novagen (UK), while some were designed ‘in-house’. In 
addition, the variety of bacteria cells used for the purpose of this study were obtained from 
Dr. MacNeills’ E.coli plasmid library. 
 
2.1.4 Primers 
The primers used for the amplification of the Mimivirus (APMV_L108), Marseillevirus 
(MAR_ORF212), CroV (CroV_219) PCNA and CroV FEN1 (CroV_037) genes were 
ordered from Eurofins MWG (UK) DNA Oligo Synthesis Company. 
 
2.1.5 Restriction Enzymes 
The enzymes utilised during the various cloning procedures were bought from NEB (UK), 
Fermentas (UK) or Promega (UK). 
 
 
2.1.6 Solutions and Buffers 
 
 
 Composition: 
Agarose Running Buffer; 
Tris-Acetate EDTA buffer 
(50x TAE) 
For 500ml: 
121g Tris-Hydrogen Chloride (HCl) 
28.6ml  glacial acetic acid 
50ml 0.5M Ethylene-Diamine-Tetra-Acetic 
acid (EDTA) (pH 8.0) 
Bacteria Freezing Medium 
(BFM) 
Luria-Bertani (LB) medium 
30% glycerol 
Blue Loading Dye; 
2x Sample Buffer (SB) 
(for SDS-PAGE) 
100mM Tris-HCl (pH 6.8)4% SDS 
20% Glycerol 
0.05% Bromophenol blue 
0.25% Dithiothreitol (DTT) 
H20 
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Lysis Buffer; 
Buffer A (pH 6.5 - 8.5) 
50mM Sodium Dihydrogen Phosphate 
(NaH2PO4)/ Sodium Phosphate Dibasic 
(Na2HPO4) 
150-600mM Sodium Chloride (NaCl) 
1mM β-mercaptoethanol 
10-40mM Imidazole 
Lysis Buffer; 
Buffer W 
100mM Tris-HCl (pH 8) 
150-500mM NaCl 
1mM EDTA  
[-/+] 0.5-2% Tween 
Lysis Buffer 
Phosphate-buffered Saline 
(PBS)-based 
PBS 
100mM Tris-HCl (pH 8)  
1mM EDTA 
1mM β-mercaptoethanol 
[-/+] 0.5% Tween 
[-/+] 0.5% Glycerol 
SDS-PAGE; Gels 
 
Resolving Gel 
Acrylamide (40%) 
1.5ml 1M Tris-HCl (pH 
8.8) 
20µl 20% SDS 
20µl 10% Ammonium 
Peroxodisulfate (APS) 
3.4µl 
Tetramethylethylenedia
mine (TEMED) 
H20 
4% Stacking 
Gel 
0.4ml 40% 
Acrylamide 
0.5ml 1M Tris-
HCl (pH 6.8)  
20µl 20% SDS 
20µl 10% APS 
5µl TEMED 
3.05ml H20 
SDS-PAGE; 5x Running 
Buffer 
For 1L: 
15g Tris-HCl 
72g Glycine 
5g SDS 
SDS-PAGE; Fix Solution 20% Ethanol (EtOH) 
7.5% Acetic Acid (HAc) 
SDS-PAGE; Staining 
Solution 
0.1% PAGE Blue G90 
4% Perchloric acid 
Transformation Buffer 
(TSB) 
LB 
5% Dimethyl Sulfoxide (DMSO) 
10% Polyethylene Glycol (PEG) 3350 
50mM Mg
2+
 (pH 6.5) 
Western Blot;  
10x Transfer Buffer 
For 1L: 
 
1x Transfer Buffer 
30g Tris-HCl 
144g Glycine 
 
 
+ 15% Methanol 
Table 2.1: Solutions and Buffers used during the experimental procedures. 
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2.1.7 Equipment 
 
AKTA Purification System ‘900 Series’, GE Healthcare, UK 
Cell Culture Incubators 1. Incubator Shaker Series, Innova
®
 44 
and I26, New Brunswick Scientific, 
UK  
2. Orbital Incubator SI50, Stuart 
Scientific, UK 
Centrifuges 1. Biofuge fresco, Heraeus, UK 
2. Centrifuge 5810, Eppendorf, UK 
3. Beckman Coulter, Optima™ L-90K 
Ultracentrifuge, UK 
4. Sorvall Evolution RC Centrifuge, 
ThermoScientific, UK 
Gel Imaging; Agarose and SDS-
PAGE 
U:Genius, Syngene, UK 
Heating Block Dri-Block
®
 DB-2D, Techne, UK 
Polymerase Chain Reaction 
(PCR) ThermalCycler 
PIKO, ThermalCycler, 
ThermoScientific, UK 
Shaker Model R100, Rotatest Shaker, 
Luckham, UK 
Sonicators 1. Soniprep 150, MSE, UK 
2. Ultrasound Processor UP2005, 
Hielscher Ultrasound Technology, UK 
Spectrophotometer SP-50 Spectrophotometer, Sanyo, UK 
UltraViolet (UV) 
Transilluminator 
 High Performance Ultraviolet 
Transilluminator, UVP, LLC, UK 
Western Blot Developer Kodak X-Omat 1000 Processor, UK 
Table 2.2: Equipment used during the experimental procedures. 
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2.2 Methods 
2.2.1 General Protocols 
2.2.1.1 Bacteria Transformation of PCNA/FEN1 constructs into E.coli cells 
Fresh competent E.coli cells were made each time they were required by inoculating 20ml 
of LB with 200µl of the appropriate E.coli bacteria culture. This was incubated at 37
o
C in a 
shaking incubator for approximately ~3 hours until the optical density (OD) of the bacteria 
culture reached 0.5-0.6. At that point, the bacteria culture was centrifuged at 3,000 rpm for 
10 minutes to collect the E.coli cells. The bacteria pellet was next resuspended in 1 ml of 
TSB buffer (See Table 2.1) and placed on ice for 30 minutes. E. coli competent cells were 
produced. 
 
To transform the PCNA and FEN1 constructs; 100µl of the competent cells were mixed 
with 10µl of the previously carried out ligation reaction. The bacteria transformation 
reaction was initially kept on ice for 30 minutes, while subsequently a further 200µl of 
TSB buffer were added to it and finally this was incubated at 37
o
C for an hour with 
shaking. 
 
The PCNA and/or FEN1 bacteria transformations were plated on appropriate antibiotic 
resistance agar plates and placed overnight in a 37
o
C incubator. 
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2.2.1.2 Bacteria Colony PCR for PCNA/FEN1 transformants 
This protocol involved standard PCR techniques. Specifically, after transforming the 
PCNA and/or FEN1 plasmids, a variety of bacteria colonies were selected and screened for 
correct transformants.  
 
The protocol undertaken was as follows: 
 
Bacteria Colony PCR Protocol 
Reagents Final Volumes 
Bacteria Colony 
(Diluted in 50-100µl H2O) 1.5µl 
Red PCR Master Mix (5x) 
(MyTaqRed, Bioline, UK) 
- dNTPs 
- MgCL2 
- MyTaqRed DNA Polymerase 
+ stabilizers/enhancers 
 
- Forward Primer (100µM) 
- Reverse Primer (100µM) 
 
Total Volume: 
 
 
5mM 
15mM 
1.25 units 
 
0.25µl 
0.25µl 
 
4.5µl  
Final Volume  6µl 
Table 2.3: Example of a typical 6µl volume Bacteria Colony PCR master mix. The red dye 
incorporated into this DNA polymerase mix allows for direct visualization of genomic bands 
produced during agarose gel electrophoresis. 
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The typical cycling conditions were as follows: 
 
Cycling Conditions for Bacteria Colony PCR 
Cycle Temperature Time 
Initial Denaturation 94
o
C 3’ 
30 cycles 
Denaturation 94
o
C 10’’ 
Annealing 55
 o
C 10’’ 
Polymerisation 72
o
C 10’’ 
Table 2.4: Example of the typical cycling conditions for a Bacteria Colony PCR reaction. 
 
The correct transformants were selected and grown on a small scale preparation. This was 
carried out by inoculating 10µl of the previously diluted bacteria colony, used for the PCR 
reaction, into 10ml of LB medium containing an appropriate antibiotic. This was then left 
to grow overnight by shaking in a 37
o
C incubator. Finally, the bacteria plasmids were 
purified using the QIAprep Spin Miniprep kit (NEB, UK) or the GeneJet Plasmid Miniprep 
kit (Fermentas, UK).  
 
2.2.1.3 Protein Expression Experiments for PCNA/FEN1 proteins 
Following the transformation of the Mimivirus PCNA (APMV_L108), Marseillevirus 
PCNA (MAR_ORF212), CroV PCNA (CroV_219) and CroV FEN1 (CroV_037) into the 
appropriate E.coli host strain(s), a single transformed colony was selected and grown 
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overnight on a small scale preparation in a 37
o
C incubator by shaking, as explained 
already.  
 
To test the protein expression efficiency of the PCNA and/or FEN1 proteins, initially a 
mini scale bacteria preparation was carried out; this was done by inoculating 500µl of the 
bacteria culture previously grown overnight in 50ml LB medium (+ appropriate antibiotic).  
[For a midi scale bacteria preparation, 2ml of the bacteria culture grown overnight were 
further inoculated in 250ml LB medium (+ appropriate antibiotic). Additionally, for a 
large scale bacteria preparation, 8ml of the bacteria culture grown overnight were further 
inoculated in 1L LB medium (+ appropriate antibiotic).] 
This was then left to shake in an incubator set at 37
o
C for ~3-4 hours until the OD of the 
bacteria culture reached ~0.5-0.6. At that stage, a small sample of the culture was taken 
before adding the appropriate amount (1,000 fold less than the actual bacteria culture) of 
anhydrotetracycline (AHT) or Isopropyl β-D-1-thiogalactopyranoside (IPTG) so as to 
induce PCNA and/or FEN1 protein expression. This sample was labeled ‘U’ for 
Uninduced because no protein expression would have taken place. After inducing protein 
expression, the bacteria culture was further incubated. However, at this point, the 
incubation time and temperature varied according to the particular experimental procedure 
being followed (i.e. overnight incubation was carried out for bacteria cultures growing at 
15-25
o
C, while a 4 hour incubation period was undertaken for cultures growing at 30-
35
o
C). At the end of the incubation period, another small sample of the culture was taken 
to represent the effect of the inducing reagents on protein expression levels. This sample 
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was labeled ‘I’ for Induced as protein expression should have occurred. Both the 
uninduced and induced samples were properly treated by taking a ~20µl sample of each 
and boiling it at 95
o
C for 4 min in 2xSB buffer (See Table 2.1). These samples were finally 
used for SDS-PAGE analysis; always following standard techniques. 
 
Finally, the PCNA/FEN1 bacteria cells were harvested by centrifugation. The cells would 
then be resuspended in a suitable lysis buffer and sonicated for the purpose of disrupting 
the cell membranes and hence releasing all the cellular contents (See below Section 2.2.1.4 
Preparing Soluble PCNA/FEN1 protein samples by Sonication procedures), further 
allowing for analysis of protein expression levels by SDS-PAGE or Western Blotting.  
 
As mentioned, SDS-PAGE and Western blot experiments were conducted following 
standard procedures. More specifically, for both types of experiments specific percentage 
resolving gels were prepared according to the size of the proteins to be detected (See Table 
2.1: Solutions and Buffers used during the experimental procedures); these most 
commonly were 10% or 12.5% resolving gels. The various protein samples of interest were 
then loaded onto the gel and run at a particular voltage (i.e. ~200V for 1 hour), alongside a 
suitable protein marker used as a size standard (PageRuler™ Plus, or non-Plus version, 
Prestained Protein Ladder (Fermentas, UK)). In the case of the SDS-PAGE experiments, 
once the gel had finished running it was fixed in a fix solution, made from ethanol and 
acetic acid, for 10 mins on a bench shaker, stained with a stain solution (i.e. PAGE Blue 
G90, also containing perchloric acid) for ~5 mins and finally destained in water for a 
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suitable amount of time until the protein bands became significantly visible for further 
analysis. The SDS-PAGE gel images were captured using the ImageLab Program (UK). In 
the case of the Western blot experiments, after running the SDS-PAGE, the proteins run on 
the gel were transferred onto a Westran PVDF membrane by running the prepared transfer 
gel/membrane ‘sandwich’ for 1 hour at ~100V. The resulting membrane was then blocked 
by a typical BSA-based solution, for the purpose of blocking non-specific binding sites. 
Detection of the target proteins was achieved by specific to the experiment antibodies. A 
chemiluminescent signal for the antibody-detected proteins present on the membrane was 
produced by soaking the Westran PVDF membrane in Pierce-ECL Western Blotting 
substrate (ThermoScientific, UK). The light corresponding to the proteins of interest was 
finally detected by photographic films that were developed using a Kodak X-Omat 1000 
processor (UK). 
 
Note: It is important to mention the predicted molecular masses (i.e. kDaltons) at which 
each PCNA and FEN1 protein, for the different viruses, was supposed to run on a SDS-
PAGE gel or Western blot; the Mimivirus PCNA (APMV_L108) protein has a 32 kDa 
molecular mass, the Marseillevirus PCNA (MAR_ORF212) protein has a molecular mass 
of 34 kDa, the CroV PCNA (CroV_219) protein has a 32 kDa molecular mass (same as the 
Mimivirus) and finally, the CroV FEN1 (CroV_037) protein has a molecular mass of 37 
kDa. Nevertheless, most proteins do not run at the exact same molecular masses as 
estimated and specifically PCNA proteins appear to have higher molecular weights than 
those predicted. 
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2.2.1.4 Preparing Soluble PCNA/FEN1 protein samples by Sonication procedures 
According to the specific mass/volume of PCNA and/or FEN1 bacteria cell pellet that was 
previously harvested; this was lysed in the appropriate amount of particular buffers (i.e. 
Buffer W; Tris-HCl base, or Buffer A; Phosphate-base, See Table 2.1). The residual 
suspension, representing the total protein sample, was then sonicated by performing 5x10 
sec bursts (<20-40% sonicator power) with 30 sec cooling intervals. The sonication 
protocol was always carried out under ice-cooling conditions (4
o
C). 
 
Following sonication, the suspension was centrifuged at high speed (i.e. 13,000rpm) for 15 
min again at low temperature conditions (4
o
C). This would allow for the membrane, and 
generally all the insoluble, contents of the cells to form a pellet, while all the soluble 
protein contents would remain in the supernatant. This sample that was labeled ‘S’ for 
Soluble, as it contained the solubilised protein of interest, would then be treated 
accordingly and used for SDS-PAGE or Western blot analysis; run alongside with the 
Uninduced and Induced samples, which were collected during the ‘Protein Expression 
Experiments’ (See Section 2.2.1.3; Protein Expression Experiments for PCNA/FEN1 
proteins). 
 
2.2.1.5 PCNA/FEN1 Protein Purification experiments using an AKTA system (GE 
Healthcare, UK)                     
The AKTA is a system for purifying proteins, fast and efficiently, for further use in 
biochemical analysis studies. It allows the user to easily develop specific and simple 
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protocols, while at the same time permitting the optimisation of the methods utilised for 
protein purification according to the experimental needs. Furthermore, it allows for small-
scale protein purification of either tagged or un-tagged proteins, making it extremely useful 
compared to other protein purification techniques. What is more, it simply works by 
loading the soluble protein sample of interest onto the system. During the protein 
purification, different protein fraction samples are collected and can be easily accessed by 
the UNICORN software program that, for this purpose, generates a graph illustrating 
where proteins are eluting off the particular column. 
 
2.2.1.6 Mass Spectrometry (MS) 
Mass spectrometry of the protein bands of interest was carried out by our in house mass 
spectrometry facilities (BSRC Mass Spectrometry and Proteomics Facility, University of 
St. Andrews, UK). More specifically, the protein band to be analysed was precisely 
excised from a SDS-PAGE gel, prepared carefully so as to minimise keratin 
contamination, and subjected to in-gel digestion by trypsin for peptide separation and 
extraction. Protein identification analysis was initially carried out on an AB Sciex 4800 
MALDI (Matrix-Assisted Laser Desorption/Ionisation) TOF/TOF™ Analyser (AB Sciex, 
UK) instrument; while samples were then processed using MASCOT and the data was 
compared against the NCBI (National Center for Biotechnology Information) and the in-
house BMS protein databases. In most instances, when no conclusive results could be 
produced by the MALDI analyser, then a higher sensitivity apparatus was used (i.e. ESI 
(ElectroSpray Ionisation) analyser). This particularly was the AB Sciex QStar XL 
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NanoLC-ESI qTOF™. All results were finally evaluated using the ProteinPilot™ software 
(version 4.0.8085, Applied Biosystems, UK) for protein identification and quantitation. 
 
2.2.2 Proliferating Cell Nuclear Antigen (PCNA) protein  
2.2.2.1 Cloning Techniques and Plasmid Construction for the Mimivirus, 
Marseillevirus and CroV PCNA proteins 
The original synthetic genes for the Mimivirus PCNA (APMV_L108), Marseillevirus 
PCNA (MAR_ORF212) and CroV PCNA (CroV_219) were cloned into a pUC57 
backbone by EcoRV restriction digest, as described by the provider company (Appendix 
A.1; Construct Maps of the Synthetic Genes_A.1.1-A.1.3, respectively). At the same time, 
unique BsaI restriction sites were intentionally introduced on either side of these PCNA 
genes to facilitate further digestion and hence cloning procedures.  
 
2.2.2.1.1 Cloning of the Mimivirus, Marseillevirus and CroV PCNA proteins into a 
pASK-IBA17plus vector backbone, containing a Strep-Tactin affinity tag (IBA, UK) 
for protein purification 
Note: The pASK-IBA17plus vector contains the Strep-Tactin affinity tag (= ~30 bp) 
attached to a TEV (Tobacco Etch Virus) protease cleavage site (= ~20 bp). So cloning the 
PCNA gene of interest, from the different viruses, into this vector would add an additional 
~50bp to the PCNA gene sequence or otherwise ~2 kDa to the PCNA protein sequence. 
This would increase the protein molecular masses of the three different viral PCNAs to: 34 
[96] 
 
kDa for the Mimivirus PCNA (APMV_L108) protein, 36 kDa for the Marseillevirus 
PCNA (MAR_ORF212) protein and 34 kDa for the CroV PCNA (CroV_219) protein 
(same as the Mimivirus). 
 
The Mimivirus PCNA (pUC57_APMV_L108), Marseillevirus PCNA 
(pUC57_MAR_ORF212) and CroV PCNA (pUC57_CroV_219) genes, as well as the 
empty pASK-IBA17plus vector, were digested with BsaI restriction enzyme. Restriction 
digests were carried out for 3 hours at 50
o
C; this temperature being specific to the BsaI 
restriction enzyme.  
 
At 2.5 hours of BsaI restriction digest, the 3’ and 5’ ends of the pASK-IBA17plus vector 
were cleaned from the phosphate (P)-groups using the Antarctic Phosphatase enzyme 
(NEB, UK) by placing the reaction for a final 30 minutes in a heating block set at 37
o
C. 
 
On the other hand, following the BsaI restriction digest of the three different PCNA 
constructs, the different sized fragments produced (i.e. PCNA genes at around ~900 bp and 
empty pUC57 vector backbone at around ~1800 bp), were separated on standard 1% (w/v) 
agarose electrophoresis gels and gel purified. This permitted correct restriction digest 
confirmation and accurate size validation of each PCNA product, when compared to a 
suitable DNA marker (GeneRuler™ 1kb DNA Ladder, Fermentas, UK).  
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Figure 2.1: Example of 1% Agarose Gel Photograph showing the products of a restriction 
digest; This 1% agarose gel shows the products generated after BsaI restriction enzyme digest of 
pASK-IBA7plus empty vector (3,220 bp), Mimivirus pUC57_APMV_L108 PCNA (840 bp), 
Marseillevirus pUC57_MAR_ORF212 PCNA (920 bp) and CroV pUC57_CroV_219 PCNA (860 
bp). All PCR amplification products were analysed against the GeneRuler™ 1kb DNA Ladder, and 
the images were captured using the ImageLab Program (UK). 
 
All restriction digest reactions were purified using the Qiagen MinElute Gel Extraction kit 
(Qiagen, UK). 
 
The three different ~900 bp BsaI digested PCNA fragments for the Mimivirus 
(APMV_L108), Marseillevirus (MAR_ORF212) and CroV (CroV-219) were ligated into 
the pASK-IBA17plus vector, using the Quick Ligation kit (NEB, UK). The ligation 
reactions were left for 20 minutes at room temperature (RT), after which they were 
transformed into DH5α E.coli cells on ampicillin resistance agar plates; [The pASK-
IBA17plus vector confers ampicillin resistance] (See Section 2.2.1.1; Bacteria 
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Transformation of PCNA/FEN1 constructs into E.coli cells). DH5α E.coli cells are the 
most common strain of choice for routine cloning as they increase the insert stability and 
improve the quality of plasmid DNA prepared from minipreps, as explained by the 
manufacturer. 
 
The selection of correct transformants containing the Mimivirus (APMV_L108), 
Marseillevirus (MAR_ORF212) and CroV (CroV_219) PCNA gene fragments ligated into 
the pASK-IBA17plus vector was performed by bacteria colony PCR reaction (See Section 
2.2.1.2; Bacteria Colony PCR for PCNA/FEN1 transformants). The primers used for this 
PCR reaction were specific to the pASK-IBA17plus vector (Table 2.5), so as to allow for 
specificity confirmation of the PCR amplification process and accurate size validation of 
each PCR product, when compared to a suitable DNA marker (Figure 2.2).  
 
Oligonucleotides  
(sequence 5’  3’) 
Ta
o
C 
PCR product size 
(bp) 
FW: GAGTTATTTTACCACTCCCT 
48 
1,150 
Rev: CGTTTACCGCTACTGCG 
49 
Table 2.5: Oligonucleotides specific to the pASK-IBA17plus vector; for amplification of the 
Mimivirus (APMV_L108), Marseillevirus (MAR_ORF212) and CroV (CroV_219) PCNA 
gene fragment. 
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Figure 2.2: Example of 1% Agarose Gel Photograph showing the amplification products of a 
bacteria colony PCR reaction; This 1% agarose gel shows the PCR products acquired when using 
as a DNA template bacteria colonies that grew after the ligation and transformation of Mimivirus 
(APMV_L108), Marseillevirus (MAR_ORF212) and CroV (CroV_219) PCNA gene fragments 
into the pASK-IBA17plus vector. The primers employed were specific for the pASK_IBA17plus 
vector. The correct transformants generate PCR products of 1,150 bp in size.  
  
However, to verify with certainty that the BsaI digested Mimivirus (APMV_L108), 
Marseillevirus (MAR_ORF212) and CroV (CroV_219) PCNA gene fragments had been 
inserted into the pASK-IBA17plus vector, another restriction digest was undertaken with 
the XbaI and HindIII enzymes, following standard procedures. The expected sizes for all 
three viruses were around ~1,000 bp. 
 
Once the correct pASK-IBA17plus Mimivirus (APMV_L108), Marseillevirus 
(MAR_ORF212) and CroV (CroV_219) PCNA constructs were confirmed (Appendix A.2; 
Construct Maps of the pASK-IBA17plus Mimivirus (APMV_L108), Marseillevirus 
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(MAR_ORF212) and CroV(CroV_219) PCNAs), these were further transformed into 
Rosetta2(DE3)(pLysS) E.coli cells on ampicillin/chloramphenicol resistance agar plates, 
following the same method as described previously. This Rosetta2(DE3)(pLysS) strain 
allows for a higher level of protein expression, as it is specifically “designed to enhance the 
expression of eukaryotic proteins that contain codons rarely used in E. coli”, as described 
by the supplier (Novagen, UK). 
 
The Rosetta2(DE3)(pLysS)_pASK-IBA17plus Mimivirus (APMV_L108), Marseillevirus 
(MAR_ORF212) and CroV (CroV_219) PCNA plasmids were used to perform protein 
expression studies. 
 
2.2.2.1.2 Cloning of the Mimivirus, Marseillevirus and CroV PCNA proteins into a 
pEHISTEV vector backbone, containing a PolyHistidine (or HexaHis/6xHis) affinity 
tag for protein purification 
Note: The pEHISTEV vector contains the 6xHis affinity tag (= ~20 bp) attached to a TEV 
protease cleavage site (= ~20 bp). So cloning the PCNA gene of interest, from the different 
viruses, into this vector would add an additional ~40bp to the PCNA gene sequence or 
otherwise ~2 kDa to the PCNA protein sequence. This would increase the protein 
molecular masses of the three different viral PCNAs, in the same manner as was the case 
for the pASK-IBA17plus vector (i.e. the Mimivirus PCNA (APMV_L108) protein 
molecular mass increases to 34 kDa, the Marseillevirus PCNA (MAR_ORF212) protein 
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molecular mass increases to 36 kDa and the CroV PCNA (CroV_219) protein molecular 
mass increases to 34 kDa (same as the Mimivirus). 
 
Similar procedures were followed as explained in Section 2.2.2.1.1; Cloning of the 
Mimivirus, Marseillevirus and CroV PCNA proteins into a pASK-IBA17plus vector 
backbone, containing a Strep-Tactin affinity tag (IBA, UK) for protein purification. 
 
More precisely, the CroV PCNA (pASK-IBA17plus _CroV_219; Appendix A.2.3) gene, as 
well as the empty pEHISTEV vector, were digested with NcoI and HindIII restriction 
enzymes for 3 hours at 37
o
C. The pEHISTEV vectors’ 3’ and 5’ ends were once again 
cleaned from the P-groups using the Antarctic Phosphatase enzyme, as previously 
described, while the digested CroV PCNA construct was run on an 1% agarose gel 
electrophoresis and the two bands of interest (= 460 + 400 = 860 bp; former band 
generated from single NcoI digest, while latter from double NcoI/HindIII, i.e. CroV PCNA 
contains two NcoI sites and one HindIII site resulting in the production of two different 
fragments) cut out and gel purified. The restriction digest reactions were specifically 
purified using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel, UK). Next, the 
total 860 bp NcoI/HindIII digested CroV PCNA fragment was ligated into the pEHISTEV 
vector, by a two-step ligation procedure (i.e. one fragment at a time), and transformed into 
DH5α E.coli cells on kanamycin resistance agar plates. [The pEHISTEV vector confers 
kanamycin resistance].  
 
[102] 
 
In the case of the Mimivirus PCNA (pASK-IBA17plus _APMV_L108; Appendix A.2.1) 
and the Marseillevirus PCNA (pASK-IBA17plus _MAR_ORF212; Appendix A.2.2); for 
the introduction of the particular PCNA gene fragments into the pEHISTEV vector, a 
novel NcoI site had to be generated to allow for NcoI/HindIII restriction digest. The 
Mimivirus and Marseillevirus PCNA gene sequence, in contrast to the CroV PCNA gene 
sequence, do not have a naturally occurring NcoI restriction site. Therefore, to create this 
novel NcoI site, specific primers had to be ordered containing a site-directed mutation 
forming the NcoI restriction site of interest. The new restriction site would purposely be 
introduced by a long-range PCR reaction, where the forward primers of the Mimivirus and 
Marseillevirus PCNA gene sequence, already containing the NcoI restriction site, together 
with the reverse primer of the pASK-IBA17plus vector would amplify the specific 
Mimivirus (APMV_L108) and Marseillevirus (MAR_ORF212) PCNA gene fragment 
introducing the new NcoI restriction site, which would then be utilised in a NcoI/HindIII 
restriction digest reaction. 
 
The sequence of the site-directed mutated primers containing the NcoI restriction site, were 
as follows: 
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Constructs 
Oligonucleotides  
(sequence 5’  3’) 
Ta
o
C 
PCR 
product 
size (bp) 
APMV 
FW: ATGCACTCA CCATGG CT 
ACGAGCTGTGCTGACAAC 
68 840 
MAR 
FW: ATGCACTCA CCATGG CT 
TCATTCGTGGGCTCACTG 
68 920 
pASK-
IBA17plus Rev: CGTTTACCGCTACTGCG 
49  
Table 2.6: Site-directed NcoI mutated oligonucleotides specific to Mimivirus PCNA (pASK-
IBA17plus _APMV_L108) and the Marseillevirus PCNA (pASK-IBA17plus 
_MAR_ORF212); these primers introduce a novel NcoI restriction site within the PCNA gene 
sequence. This will be exploited in a NcoI/HindIII restriction digest reaction. 
 
The PCR protocol undertaken was as follows: 
Long-Range PCR Protocol 
Reagents Final Volumes 
DNA Template  
(pASK-IBA17plus APMV/MAR 
PCNA constructs) 
~1µl 
10x Buffer (+MgCl) 5µl 
dNTPs mix 1µl 
DMSO 2.5µl 
APMV/MAR Fw Primers 0.5µl 
pASK-IBA17 plus Rev Primer 0.5µl 
Enzyme mix 
(Long-PCR enzyme, Fermentas, UK) 
0.25µl 
H2O 39.25µl 
Total Volume 50µl 
Table 2.7: Example of a Long-Range PCR Protocol. 
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The cycling conditions were as follows: 
Long-Range PCR Cycling Conditions 
Cycle Cycle Temperature Time 
 
Initial 
denaturation 
95
o
C 3’ 
35 
Denaturation 95
o
C 30’’ 
Annealing 58
o
C 30’’ 
Extension 72
o
C 2’ 30’’ 
 Extension 72
o
C 6’ 40’’ 
 Final Extension 72
o
C 10’’ 
Table 2.8: Example of Long-Range PCR cycling conditions. 
 
The Mimivirus PCNA (pASK-IBA17plus _APMV_L108) and the Marseillevirus PCNA 
(pASK-IBA17plus _MAR_ORF212) PCR products, after being successfully sequenced to 
guarantee no mutations had been introduced by the PCR reaction, were purified and 
digested with NcoI and HindIII restriction enzymes. The 840 bp and 920 bp generated 
from the NcoI/HindIII restriction digest for the Mimivirus PCNA (pASK-IBA17plus 
_APMV_L108) and the Marseillevirus PCNA (pASK-IBA17plus _MAR_ORF212), 
respectively, were also ligated into the pEHISTEV vector and transformed into DH5α 
E.coli cells on kanamycin resistance agar plates. 
 
The selection of correct transformants containing the Mimivirus (APMV_L108), 
Marseillevirus (MAR_ORF212) and CroV (CroV_219) PCNA gene fragments ligated into 
the pEHISTEV vector was performed by another NcoI/HindIII restriction digest. This 
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digest would allow the direct confirmation of the presence or absence of the Mimivirus, 
Marseillevirus and CroV PCNA fragments of interest cloned within the pEHISTEV vector. 
However, the transformants corresponding to the CroV PCNA (CroV_219) gene, ligated 
into the pEHISTEV vector, had to also be checked for their correct (i.e. sense) NcoI 
fragment orientation. This is due to the fact that the CroV PCNA (CroV_219) gene 
sequence contains two naturally occurring NcoI restriction sites, so when NcoI/HindIII 
digested it would have resulted in the appearance of two fragments instead of one, as is the 
case for Mimivirus (APMV_L108) and Marseillevirus (MAR_ORF212) PCNA. The 
confirmation that the NcoI/HindIII digested CroV PCNA fragments were cloned in a sense 
orientation in the pEHISTEV vector was achieved by another double SalI/PstI restriction 
digest, generating a fragment of 330 bp. [If the NcoI digested CroV PCNA fragment had 
been inserted in an anti-sense orientation then the SalI/PstI digest would have produced a 
fragment of 730 bp, as seen on a 1% agarose gel]. 
 
Once the correct pEHISTEV Mimivirus (APMV_L108), Marseillevirus (MAR_ORF212) 
and CroV (CroV_219) PCNA constructs were confirmed (Appendix A.3; Construct Maps 
of the pEHISTEV Mimivirus (APMV_L108), Marseillevirus (MAR_ORF212) and 
CroV(CroV_219) PCNAs), these were further transformed into Rosetta2(DE3)(pLysS) 
E.coli cells on kanamycin/chloramphenicol resistance agar plates. The resulting plasmids 
would then be used for various protein expression studies. 
 
[106] 
 
Note: In addition, only the CroV PCNA (pASK-IBA17plus _CroV_219) gene was also 
transformation into a variety of different other E.coli host strains (following a similar study 
as the one described by Busso D et al, 2011). So far all constructs created were only 
transformed into the Rosetta2(DE3)(pLysS) E.coli strain hoping for high efficiency of 
protein expression. The additional strains examined were: BL21(DE3), 
BL21(DE3)(pLysS), Rosetta2(DE3), Arctic Express(DE3)RP and C43(DE3). The BL21 
strains are “all-purpose strains for high-level protein expression and easy induction, while 
the pLysS one provides tighter control of protein expression for expression of toxic 
proteins”, as explained by the supplier (Stratagene, UK). The Arctic Express strain is 
usually used to overcome any protein insolubility and misfolding, while the C43 strain is 
effective for expressing toxic proteins. 
 
2.2.2.1.3 Cloning only of the CroV PCNA protein into pETDuet-1 & pCDFDuet-1 
vector backbones, containing NO affinity tags for protein purification 
Note: As the pETDuet-1 and pCDFDuet-1 vectors do not contain any sort of affinity tag, in 
this case the molecular masses of the PCNA proteins, for the three different viruses, remain 
intact. 
 
The CroV PCNA (pEHISTEV _CroV_219; Appendix A.3.3) gene, as well as the empty 
pETDuet-1 and pCDFDuet-1 vectors (not containing any affinity tags to aid in protein 
purification procedures), were digested with NcoI and HindIII restriction enzymes, treated 
suitably and purified for further use. Subsequently, the NcoI/HindIII fragments of interest 
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digested from the pEHISTEV _CroV_219_PCNA construct were ligated into the also 
digested pETDuet-1 and pCDFDuet-1 vectors and transformed into DH5α E.coli cells on 
ampicillin or streptomycin resistance agar plates; pETDuet-1 is ampicillin resistant, while 
pCDFDuet-1 is streptomycin resistant. The selection of correct transformants containing 
the CroV PCNA (CroV_219) gene fragment ligated into the pETDuet-1 and pCDFDuet-1 
vectors was conducted by another NcoI/HindIII restriction digest, but also by a SalI/NdeI 
double digest for reasons explained previously.  Once the correct pETDuet-1 (Appendix 
A.5.1) and pCDFDuet-1 (Appendix A.5.2) CroV PCNA (CroV_219) constructs were 
confirmed (Appendix A.5; Construct Maps of the pETDuet-1 and pCDFDuet-1 CroV 
PCNA (CroV_219) and CroV FEN1 (CroV_037)), these were further transformed into 
Rosetta2(DE3)(pLysS) E.coli cells on ampicillin or streptomycin/+chloramphenicol 
resistance agar plates.  
 
However, these CroV PCNA (CroV_219) constructs were additionally co-transformed 
with the equivalent CroV FEN1 (CroV_037) constructs in the same Rosetta2(DE3)(pLysS) 
E.coli cells, so as to examine if and how these two proteins interact when run on the AKTA 
system. More specifically, two co-transfections took place; these were: pETDuet-
1_CroV_219_PCNA + pCDFDuet-1_CroV_037_FEN1 and pCDFduet-
1_CroV_219_PCNA + pETDuet-1_CroV_037_FEN1 (See also Sections 2.2.1.5; 
PCNA/FEN1 Protein Purification experiments using an AKTA system, and  2.2.3.1.2; 
Cloning of the CroV FEN1 protein into pETDuet-1 & pCDFDuet-1 vector backbones, 
containing NO affinity tags for protein purification). The resulting plasmids would then be 
used for various protein expression studies. 
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2.2.2.2 Protein Expression Experiments for the Mimivirus, Marseillevirus and 
CroV PCNA proteins 
The exact method is described in Section 2.2.1.3; Protein Expression Experiments for 
PCNA/FEN1 proteins. Nevertheless, some adjustments were made; one of them being that 
protein expression for the pASK-IBA17plus Mimivirus (APMV_L108), Marseillevirus 
(MAR_ORF212) and CroV (CroV_219) PCNA constructs is only achieved by the addition 
of anhydrotetracycline (AHT) protein expression inducer.  
 
On the contrary, protein expression for the pEHISTEV Mimivirus (APMV_L108), 
Marseillevirus (MAR_ORF212) and CroV (CroV_219) PCNA constructs is only induced 
by Isopropyl β-D-1-thiogalactopyranoside (IPTG) reagent.  
 
2.2.2.3 Preparing Soluble PCNA protein samples from the Mimivirus, 
Marseillevirus and CroV by Sonication procedures 
The precise protocol is described in Section 2.2.1.4; Preparing Soluble PCNA/FEN1 
protein samples by Sonication procedures. However, for the different Mimivirus, 
Marseillevirus and CroV PCNA constructs produced different lysis buffers were tested, so 
as to evaluate the efficiency of PCNA protein expression. Below is a table with all the lysis 
buffers assayed (Table 2.9). 
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 Ingredient Concentration 
pASK-IBA17plus PCNA 
constructs 
1. 100mM Tris-HCl pH8, 150/250/500mM NaCl, 
1mM EDTA  
2. 100mM Tris-HCl pH8, 150/250/500mM NaCl, 
1mM EDTA + 1% Tween 
3. 100mM Tris-HCl pH8, 150/250/500mM NaCl, 
1mM EDTA + 2% Tween 
pEHISTEV & 
pEHISGFPTEV PCNA 
constructs 
1. 50mM Na2HPO4, 400mM NaCl, 1mM β-
mercaptoethanol, pH8 
2. 50mM Na2HPO4, 250/400/500/600mM NaCl, 
10/20/40/65mM Imidazole, 1mM β-
mercaptoethanol, pH8 
3. 50mM Na2HPO4, 250/400/500/600mM NaCl, 
10/20/40/65mM Imidazole, 1mM β-
mercaptoethanol, pH8 + 0.5% Tween 
4. PBS, + 0.5% Tween 
5. PBS, 100mM Tris-HCl pH8, 10mM Imidazole, 
0.5% Tween, 1mM EDTA and 1mM β-
mercaptoethanol 
pETDuet-1 & 
pCDFDuet-1 PCNA 
constructs 
1. 50mM NaH2PO4 (pH 6.5/ 7.5/ 8.5, with 
Na2HPO4), 0/ 150/ 300 mM NaCl, 1mM 
EDTA and 1mM β-mercaptoethanol (-/+ 0.5% 
Tween) 
2. 100mM Tris-HCl pH8,  150mM NaCl, 1mM 
EDTA (-/+ 0.5% Tween and/or 1mM β-
mercaptoethanol) 
3. PBS, 0.5% Tween, 1mM EDTA and 1mM β-
mercaptoethanol (-/+ 100mM Tris-HCl pH8) 
Table 2.9: The different Lysis Buffers tested for Mimivirus, Marseillevirus and CroV PCNA 
protein expression efficacy                                                  
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2.2.2.4 Protein Purification Experiments for the Mimivirus, Marseillevirus and 
CroV PCNA proteins 
2.2.2.4.1 Streptavidin pull-down of PCNA Solubilised protein samples for the 
Mimivirus, Marseillevirus and CroV, with the use of strept-tactin magnetic beads 
(only for the pASK-IBA17plus PCNA constructs) 
As already mentioned, the pASK-IBA17 plus vector has attached onto it a Strep-Tactin 
affinity tag to assist protein purification. In this case, to test the Mimivirus, Marseillevirus 
and CroV PCNA purification efficiency, ~20µl of the Strep-Tactin magnetic beads were 
added directly into each soluble PCNA protein sample, following the manufacturer’s 
instructions (IBA, Germany). The samples were mixed for an hour on a wheel at 4
o
C, 
followed by ~4-6 washes with the specific lysis buffer previously used for sonication. 
Finally, they were treated by boiling them at 95
o
C for 5 min in 2xSB buffer. These were 
then run on a SDS-PAGE gel for analysis of the effectiveness and purity of PCNA 
purification. In addition, these Strep-Tactin pulled-down PCNA protein samples were also 
run on a Western blot, for comparison reasons. The Western blot protocol carried out can 
be found in the ‘Expression and purification of proteins using Strep-tag and/or 
6xHistidine-tag’ manual from the IBA (UK) website. 
 
On another occasion, however, the Strep-Tactin beads were packed so as to create a Strep-
tag column. The column would always be equilibrated with the specific lysis buffer 
previously used for sonication. The soluble PCNA protein lysates prepared by the 
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sonication procedure would then travel through it and the different flow-through PCNA 
protein fractions would be collected for further analysis of protein purification. 
 
2.2.2.4.2 Pull-down of PCNA Solubilised protein samples for the Mimivirus, 
Marseillevirus and CroV, with the use of Nickel (Ni-NTA) affinity agarose beads 
(only for the pEHISTEV PCNA constructs) 
As mentioned earlier, the pEHISTEV vector has attached onto it a 6xHis affinity tag to 
assist protein purification. Therefore, to examine the Mimivirus, Marseillevirus and CroV 
PCNA purification efficiency, the exact same technique as described  in Section 2.2.2.4.1; 
Streptavidin pull-down of PCNA Solubilised protein samples for the Mimivirus, 
Marseillevirus and CroV, with the use of strept-tactin magnetic beads (only for the pASK-
IBA17plus PCNA constructs) was undertaken. The only difference in this case being that 
Ni-NTA agarose beads (Qiagen, UK) were used instead of Strep-Tactin magnetic beads. 
Furthermore, a Ni-NTA agarose bead packed column was also used for Mimivirus, 
Marseillevirus and CroV PCNA purification. The samples were collected, properly treated 
and run on a SDS-PAGE gel for analysis of the PCNA protein purity.  
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2.2.2.4.3 EZview™ Red Streptavidin pull-down of CroV PCNA Solubilised protein 
sample, with the use of EZview™ Red Streptavidin affinity agarose gel beads and the 
help of a Fen1 peptide (only for the pETDuet-1 PCNA construct) 
The pETDuet-1 vector differs from most vectors due to the fact that it contains no affinity 
tag for easy and straight-forward protein purification. Consequently, in the case of this 
experiment, an intermediate agent had to be utilised so as to assist purification of the 
PCNA protein. This was a biotinylated Fen1 designed oligopeptide, which would 
eventually be pulled-down with the help of the EZview™ Red Streptavidin affinity agarose 
gel beads (Sigma, UK). This type of beads strongly trap biotinylated target proteins on 
their N-terminus. 
 
The Fen1 peptide was produced by GenScript (UK). It was specifically 20aa in length and 
its exact sequence was “IKNKIYWKVNILNKHIKNLL”, while it contained the biotin tag 
on its N-terminus. The peptide was deliberately designed to correspond to the last 20aa of 
the CroV FEN1 (CroV_037) protein sequence, consequently also forming the specific PIP-
box motif domain (i.e. N--I--LL) for precise interaction with the PCNA protein. 
 
The protocol carried out was as mentioned in Section 2.2.2.4.1; Streptavidin pull-down of 
PCNA Solubilised protein samples for the Mimivirus, Marseillevirus and CroV, with the 
use of strept-tactin magnetic beads (only for the pASK-IBA17plus PCNA constructs), the 
only difference being that both the Fen1 peptide and the red beads were added 
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simultaneously to the soluble PCNA protein sample. The protein samples were collected, 
treated and run on a SDS-PAGE gel for analysis of the PCNA protein purity.  
 
2.2.2.4.4 Protein Purification Experiments for CroV PCNA using an AKTA system 
During the very first AKTA purification attempt for the CroV PCNA protein cloned into the 
pEHISTEV vector (i.e. pEHISTEV_CroV_219_PCNA construct), a simple one-step 
purification protocol was created. The column used for trapping the CroV PCNA protein of 
interest was a histidine binding His-Trap™ column containing Ni Sepharose™. During 
this procedure, two different salt (NaCl) concentrations were tested for the purpose of 
evaluating their effect on the PCNA protein purity.  The lysis buffers specifically chosen 
can be seen in Table 2.9 (pEHISTEV & pEHISGFPTEV PCNA constructs; Lysis Buffer 
No.3); both buffers contained 40mM Imidazole, while one contained 250mM NaCl and the 
other 500mM NaCl. The majority of the fractions collected were run on a SDS-PAGE gel. 
 
The CroV PCNA sample that had previously been resuspended in the 250mM NaCl lysis 
buffer was subsequently used in a gradient purification reaction. This time the variant 
being examined was the Imidazole concentration, which was varied between 40mM to 
500mM. These concentrations were assayed so as to evaluate how the gradual increase of 
Imidazole would affect the detachment of the PCNA protein from the His-Trap™ column 
used to originally trap it and finally to assess how pure the detached protein would be when 
collected. The fractions that produced a small peak, as seen on the graph generated by the 
UNICORN software, were run both on an SDS-PAGE gel and a Western blot. 
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The third attempt to purify the CroV PCNA protein, cloned this time into the pETDuet-1 
vector (i.e. pETDuet-1_CroV_219_PCNA), was another gradient purification protocol 
assaying different salt (NaCl) concentrations varying from 150mM to 1M (pETDuet-1 
PCNA construct Lysis Buffer No.2, Tables 2.9). A Hi-Trap™ Q (anion) HP column was 
used, as this column effectively binds negatively charged proteins, such as the PCNA 
protein. The most significant fractions collected (i.e. the ones that appeared as peaks on the 
UNICORN software graph) were run on a SDS-PAGE gel. 
 
2.2.3 Flap Structure-specific Endonuclease 1 (FEN1) protein 
2.2.3.1 Cloning Techniques and Plasmid Construction for the CroV FEN1 
protein 
The original synthetic gene for the CroV FEN1 (CroV_037) was cloned into a pUC57 
backbone by EcoRV restriction digest, as described by the provider company (Appendix 
A.1.4; Construct Maps of the Synthetic Genes_CroV (CroV_037) FEN1).  
 
2.2.3.1.1 Cloning of the CroV FEN1 protein into a pEHISTEV and 
pEHISGFPTEV vector backbone, both containing a 6xHis affinity tag for protein 
purification, while the latter also contains a GFP-tag 
Note: Both the pEHISTEV and pEHISGFPTEV vectors contains the 6xHis affinity tag (= 
~20 bp) attached to a TEV protease cleavage site (= ~20 bp). So cloning the FEN1 gene of 
interest, from CroV, into these vectors would add an additional ~40bp to the FEN1 gene 
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sequence or otherwise ~2 kDa to the FEN1 protein sequence. This would increase the 
CroV FEN1 (CroV_037) protein molecular mass to 39 kDa. Moreover, the 
pEHISGFPTEV vector also includes an eGFP-tag (= ~730 bp or 28 kDa). This would 
further increase the CroV FEN1 (CroV_037) protein molecular mass to 67 kDa. 
 
The precise same protocol, explained in Section 2.2.2.1.2; Cloning of the Mimivirus, 
Marseillevirus and CroV PCNA proteins into a pEHISTEV vector backbone, containing a 
PolyHistidine (or HexaHis/6xHis) affinity tag for protein purification, was undertaken. 
 
The CroV FEN1 (pUC57 _CroV_037_FEN1; Appendix A.1.4) gene, as well as the empty 
pEHISTEV and pEHISGFPTEV vectors, were digested with NcoI and HindIII restriction 
enzymes. The pEHISTEV and pEHISGFPTEV vectors’ 3’ and 5’ ends were treated with 
the Antarctic Phosphatase enzyme, while the digested CroV FEN1 (CroV_037) construct 
was directly purified. The pUC57 vector is ampicillin resistance, so it will not grow on 
kanamycin resistance plates that are required for pEHISTEV and pEHISGFPTEV plasmid 
growth. Subsequently, the 970 bp NcoI/HindIII digested CroV FEN1 (CroV_037) fragment 
was directly ligated into the pEHISTEV and pEHISGFPTEV vectors and transformed into 
DH5α E.coli cells on kanamycin resistance agar plates.  
 
The selection of correct transformants containing the CroV FEN1 (CroV_037) gene 
fragment ligated into the pEHISTEV and pEHISGFPTEV vectors was once again 
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performed by a NcoI/HindIII restriction digest, revealing either the presence or the absence 
of the FEN1 gene of interest. Moreover, a bacteria colony PCR reaction was also carried 
out to confirm that the transformants selected were indeed correct. The primers used for 
this PCR reaction were the T7 forward and reverse primers, while the products generated 
were a ~1,200bp fragment for the pEHISTEV_CroV_037_FEN1 construct and a ~2,200bp 
fragments for the pEHISGFPTEV_CroV_037_FEN1 construct.  
 
Once the correct pEHISTEV and pEHISGFPTEV CroV FEN1 (CroV_037) constructs 
were confirmed (Appendix A.4; Construct Map of the pEHISTEV and pEHISGFPTEV 
CroV FEN1 (CroV_037)), these were also transformed into Rosetta2(DE3)(pLysS) E.coli 
cells on kanamycin/chloramphenicol resistance agar plates. The resulting plasmids were 
used for different protein expression studies. 
 
Note: The CroV FEN1 (pEHISTEV _CroV_037_FEN1) construct was also transformed 
into various other E.coli host strains (based on a similar study performed by Busso D et al, 
2011); BL21(DE3), BL21(DE3)(pLysS), Rosetta2(DE3), Arctic Express(DE3)RP and 
C43(DE3).  
 
2.2.3.1.2 Cloning of the CroV FEN1 protein into pETDuet-1 & pCDFDuet-1 vector 
backbones, containing NO affinity tags for protein purification 
Note: As the pETDuet-1 and pCDFDuet-1 vectors do not contain any sort of affinity tag, in 
this case the molecular mass of the CroV FEN1 (CroV_037) protein remains unchanged. 
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The CroV FEN1 (pEHISTEV_CroV_037_FEN1; Appendix A.4) gene, as well as the empty 
pETDuet-1 and pCDFDuet-1 vectors, were digested with NcoI and HindIII restriction 
enzymes, treated suitably and purified for further use. Subsequently, the NcoI/HindIII 
fragments of interest digested from the pEHISTEV _CroV_037_Fen1 construct were 
ligated into the also digested pETDuet-1 and pCDFDuet-1 vectors and transformed into 
DH5α E.coli cells on ampicillin or streptomycin resistance agar plates; pETDuet-1 is 
ampicillin resistant, while pCDFDuet-1 is streptomycin resistant. This cloning technique 
resulted in the creation of un-tagged protein. The selection of correct transformants 
containing the CroV FEN1 (CroV_037) gene fragment ligated into the pETDuet-1 and 
pCDFDuet-1 vectors was conducted by another NcoI/HindIII restriction digest.  Once the 
correct pETDuet-1 (Appendix A.5.3) and pCDFDuet-1 (Appendix A.5.4) CroV FEN1 
(CroV_037) constructs were confirmed (Appendix A.5; Construct Maps of the pETDuet-1 
and pCDFDuet-1 CroV (CroV_219) PCNA and CroV FEN1 (CroV_037)), these were 
further transformed into Rosetta2(DE3)(pLysS) E.coli cells on ampicillin or 
streptomycin/+chloramphenicol resistance agar plates. The resulting plasmids would then 
be used for various protein expression studies. 
 
As described earlier, the pETDuet-1_CroV_037_FEN1 and pCDFDuet-
1_CroV_037_FEN1 constructs were also co-transformed with pCDFduet-
1_CroV_219_PCNA and pETDuet-1_CroV_219_PCNA, respectively, in the 
Rosetta2(DE3)(pLysS) E.coli strain. The reason for this being to check for any protein-
protein interactions between these two different proteins that are both involved in DNA 
replication. These experiments were conducted on the AKTA system. [See also Sections 
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2.2.1.5; PCNA/FEN1 Protein Purification experiments using an AKTA system, and 
2.2.2.1.3; Cloning of the CroV PCNA protein into pETDuet-1 & pCDFDuet-1 vector 
backbones, containing NO affinity tags for protein purification]. 
 
2.2.3.2 Protein Expression Experiments for the CroV FEN1 protein 
The same protocol described in Section 2.2.1.3; Protein Expression Experiments for 
PCNA/FEN1 proteins was followed. For both pEHISTEV and pEHISGFPTEV CroV 
FEN1 (CroV_037) constructs, protein expression was induced by the IPTG reagent. 
 
2.2.3.3 Preparing Soluble FEN1 protein samples from the CroV by Sonication 
procedures 
The protocol has already been described in Section 2.2.1.4; Preparing Soluble 
PCNA/FEN1 protein samples by Sonication procedures. For the pEHISTEV and 
pEHISGFPTEV CroV FEN1 (CroV_037) constructs produced, different lysis buffers were 
tested so as to evaluate the protein expression efficacy and levels of the FEN1 protein. 
Below is a table with the various lysis buffers assayed (Table 2.10). 
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 Ingredient Concentration 
pEHISTEV & 
pEHISGFPTEV FEN1 
constructs 
1. 50mM Na2HPO4, 300mM NaCl, 1mM β-
mercaptoethanol, 20mM Imidazole, pH8 
2. 50mM Na2HPO4, 500mM NaCl, 1mM β-
mercaptoethanol, 30mM Imidazole, pH8 
+0.5% Tween 
3. 100mM Tris-HCl pH8, 150/250mM NaCl, 
10/20mM Imidazole, 0.5% Tween, 1mM β-
mercaptoethanol 
4. PBS, +0.5% Tween or 0.5% glycerol 
5. PBS, 100mM Tris-HCl pH8, 10mM 
Imidazole, 0.5% Tween, 1mM EDTA and 
1mM β-mercaptoethanol 
Table 2.10: The different Lysis Buffers tested for CroV FEN1 protein expression efficacy                                                  
 
2.2.3.4 Protein Purification Experiments for the CroV FEN1 protein 
2.2.3.4.1 Pull-down of FEN1 Solubilised protein samples for the CroV, with the use 
of Nickel (Ni-NTA) affinity agarose beads (pEHISTEV & pEHISGFPTEV FEN1 
constructs) 
The same technique as explained  in Section 2.2.2.4.2; Pull-down of PCNA Solubilised 
protein samples for the Mimivirus, Marseillevirus and CroV, with the use of Nickel (Ni-
NTA) affinity agarose beads (only for the pEHISTEV PCNA constructs) was undertaken. 
The samples were collected, properly treated and run on both a SDS-PAGE gel and a 
Western blot for analysis of the FEN1 protein purity.  
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-CHAPTER THREE-  
 
Results 
 
3.1 Tagged Protein Expression of Giant Virus PCNA in E.coli 
In summary, the Mimivirus PCNA (APMV_L108_32 kDa; Appendix A.1.1), 
Marseillevirus PCNA (MAR_ORF212_34 kDa; Appendix A.1.2) and CroV PCNA 
(CroV_219_32 kDa; Appendix A.1.3) gene fragments of interest were cloned into two 
different expression vectors containing an affinity tag; the first such vector was the pASK-
IBA17plus vector containing a Strep-tag (~2 kDa), while the other one was a pEHISTEV 
vector containing a 6xHis-tag (~2 kDa). 
 
3.1.1 Mimivirus 
3.1.1.1 Cloning of the Mimivirus PCNA into the pASK_IBA17plus Strep-tag 
vector for Protein Expression Experiments 
Refer to Section 2.2.2.1.1; Cloning of the Mimivirus, Marseillevirus and CroV PCNA 
proteins into a pASK-IBA17plus vector backbone, containing a Strep-Tactin affinity tag for 
protein purification.  
The protocol resulted in the generation of construct pASK-IBA17plus_ 
Mimivirus(APMV_L108)_PCNA (Appendix A.2.1). 
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3.1.1.1.1 Protein Expression and Purification experiments for the Mimivirus 
PCNA, cloned into the pASK_IBA17plus Strep-tag vector and expressed in 
Rosetta2(DE3)(pLysS) E.coli cells 
Refer to Section 2.2.2.2; Protein Expression Experiments for the Mimivirus, Marseillevirus 
and CroV PCNA proteins, as well as Section 2.2.2.3 Preparing Soluble PCNA/FEN1 
protein samples from the Mimivirus, Marseillevirus and CroV by Sonication procedures. 
 
First Mimivirus PCNA protein expression study in the pASK_IBA17plus Strep-tag 
vector: 
For this first PCNA protein expression study, a mini-scale preparation of the Rosetta2 
(DE3) (pLysS)_pASK-IBA17plus_Mimivirus (APMV_L108)_PCNA plasmid was 
incubated for ~3 hours at 37
o
C, until the OD of the bacteria culture reached 0.5-0.6 
(represented by the ‘U’_APMV ‘uninduced’ sample on Figure 3.1). At that OD, PCNA 
protein expression was induced by the addition of AHT. The bacteria culture was left to 
incubate for a further 4 hours at 37
oC (represented by the ‘I’_APMV ‘induced’ sample on 
Figure 3.1). The cells were harvested by centrifugation and resuspended in ~2ml of Lysis 
Buffer W (Table 2.1 & 2.9; 100mM Tris-HCl pH8, 150mM NaCl, 1mM EDTA). The total 
cell extract was finally sonicated and the soluble cell extracts collected for protein 
expression analysis (represented by the ‘S’_APMV ‘soluble’ sample on Figure 3.1). The 
samples collected were run on a 12.5% SDS-PAGE gel (Figure 3.1).  
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In addition, the same exact procedure was undertaken for the 
Rosetta2(DE3)(pLysS)_pASK-IBA17plus empty vector, for use as a control (Figure 3.1). 
 
 
Figure 3.1: SDS-PAGE analysis of first Mimivirus, Marseillevirus and CroV PCNA protein 
expression study in the pASK_IBA17plus Strep-tag vector: 12.5% SDS-PAGE Gel Photograph 
showing PCNA protein expression efficiency and levels for the pASK-IBA17plus Mimivirus, 
Marseillevirus and the CroV PCNA constructs, respectively, after PCNA protein expression 
induction was carried out for 4 hours at 37
o
C; (S): soluble, (U): uninduced, (I): induced. The 
expected PCNA protein molecular masses were 34 kDa for the Mimivirus, 36 kDa for the 
Marseillevirus and 34 kDa for the CroV. An extra band is only slightly more apparent for the 
Marseillevirus PCNA protein at ~34 kDa. The PageRuler™ Plus Prestained Protein Ladder 
(Fermentas, UK) was used as a size standard for comparison, while the pASK-IBA17plus empty 
vector protein samples were used as a control. The image was captured using the ImageLab 
Program. 
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The same samples, for the pASK-IBA17plus_Mimivirus (MAR_ORF212) PCNA (Figure 
3.1), were used to perform a Western blot during which the Strep-tagged PCNA protein 
was directly detected using Strep-Tactin™ horse radish peroxidase (HRP) conjugate. The 
protocol conducted can be found in the “Expression and purification of proteins using 
Strep-tag and/or 6xHistidine-tag” manual (IBA, UK). However, no chemiluminescence 
signal was generated when developing the film. Therefore, the question that arose was 
whether or not the PCNA protein was actually being expressed. 
 
The soluble protein samples for the Mimivirus, as well as the Marseillevirus and CroV, 
PCNA were also used to perform an initial streptavidin pull-down, with the use of Strep-
Tactin magnetic beads (For protocol see Section 2.2.2.4.1; Streptavidin pull-down of 
PCNA Solubilised protein samples for the Mimivirus, Marseillevirus and CroV, with the 
use of strept-tactin magnetic beads (only for the pASK-IBA17plus PCNA constructs). No 
figure is attached because the streptavidin pull-down did not work. It could be questioned 
whether or not the Strep-tag that had been attached to these PCNA constructs was in some 
way obscured. 
 
3.1.1.1.2 Summary of Results 
As a general observation, the Mimivirus protein expression band patterns, as seen in 
Figure 3.1, are rather similar to the protein band patterns generated by the empty 
Rosetta2(DE3)(pLysS)_pASK-IBA17plus vector. Additionally, no distinct protein band 
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running at ~34 kDa (i.e. expected PCNA protein molecular mass) was produced by this 
organism. Therefore, the fact that no noticeable PCNA protein expression could be 
identified, not even when conducting a Western blot, led to the initial belief that most 
probably the protein expression conditions had to be optimised. However, instead of 
optimising the protein expression conditions, it was decided to clone the Mimivirus PCNA 
sequence into a different vector containing another protein tag hoping to obtain quicker 
better quality results. This decision would also save time in the case that the pASK-IBA17 
plus Mimivirus PCNA construct was for some reason non-functional. 
 
3.1.1.2 Cloning of the Mimivirus PCNA into the pEHISTEV 6xHis-tag vector for 
Protein Expression Experiments 
Refer to Section 2.2.2.1.2; Cloning of the Mimivirus, Marseillevirus and CroV PCNA 
proteins into a pEHISTEV vector backbone, containing a PolyHistidine (or 
HexaHis/6xHis) affinity tag for protein purification.  
The resulting construct was pEHISTEV_Mimivirus(APMV_L108)_PCNA (Appendix 
A.3.1).  
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3.1.1.2.1 Protein Expression and Purification experiments for the Mimivirus 
PCNA, cloned into the pEHISTEV 6xHis-tag vector and expressed in 
Rosetta2(DE3)(pLysS) E.coli cells 
(See Sections 2.2.2.2 & 2.2.2.3) 
 
First Mimivirus PCNA protein expression study in the pEHISTEV 6xHis-tag vector: 
For this second Mimivirus PCNA protein expression study, a midi-scale preparation of the 
Rosetta2 (DE3) (pLysS)_pEHISTEV_Mimivirus (APMV_L108)_PCNA plasmid was 
incubated and grown following standard protocols. When the bacteria culture reached the 
desirable OD, PCNA protein expression was induced by the addition of IPTG (not AHT). 
The bacteria culture was left to incubate at 25
o
C overnight. The cells were harvested by 
centrifugation and resuspended in ~2ml of the same Lysis Buffer W (Table 2.1 & 2.9; 
100mM Tris-HCl pH8, 150mM NaCl, 1mM EDTA). The total cell extract was finally 
sonicated and the soluble cell extracts collected for protein expression analysis. This time, 
however, the insoluble cell extracts were also used in the protein expression analysis, to 
allow the determination of whether or not the Mimivirus PCNA protein is soluble 
(represented by the ‘P’ellet samples in Figure 3.2). All the samples collected were run on a 
10% SDS-PAGE gel (Figure 3.2).  
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Figure 3.2: SDS-PAGE analysis of first Mimivirus PCNA protein expression study in the 
pEHISTEV 6xHis-tag vector: 10% SDS-PAGE Gel Photograph showing PCNA protein 
expression efficiency and levels for the pEHISTEV Mimivirus, Marseillevirus and the CroV 
PCNA constructs, respectively, after PCNA protein expression induction was carried out at 
25
o
C overnight; (U): uninduced, (I): induced, (S): soluble, (P): pellet. The hypothesised PCNA 
proteins for the Marseillevirus and CroV appeared to be insoluble (i.e. visible in the ‘P’ samples).  
 
The soluble PCNA protein samples for the Mimivirus, as well as the Marseillevirus and 
CroV (as seen in Figure 3.2), were also utilised in a pull-down procedure, with the use of 
Ni-NTA agarose beads (For protocol see Section 2.2.2.4.2; Pull-down of PCNA 
Solubilised protein samples for the Mimivirus, Marseillevirus and CroV, with the use of 
Nickel (Ni-NTA) affinity agarose beads (only for the pEHISTEV PCNA constructs). Pull-
down refers to a column purified protein sample. The results of this pull-down experiment 
can be seen in Figure 3.3. 
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Figure 3.3: SDS-PAGE analysis of first Mimivirus PCNA protein expression study in the 
pEHISTEV 6xHis-tag vector, gel No.2: 10% SDS-PAGE Gel Photograph showing soluble 
PCNA protein samples being pulled-down with Ni-NTA agarose beads for the pEHISTEV 
Mimivirus, Marseillevirus and the CroV PCNA constructs; (I): induced (as seen in Figure 3.2), 
(PD): pull-downs. A strong PCNA protein signal was produced for the CroV, as seen from the ‘PD’ 
sample, and was estimated to be running at ~35-36 kDa.  
 
3.1.1.2.2 Summary of Results 
During this experiment an additional step was carried out; the pellet sample was collected 
after sonication and used so as to determine whether the Mimivirus PCNA protein was 
actually insoluble. If this was the case, a fairly distinct band running at ~34 kDa should 
have been obvious for this sample. However, this was not the case and, same as what was 
seen in the previous experiment, no noticeable PCNA protein expression could be 
identified in any case, not even when conducting a Ni-NTA agarose bead pull-down 
experiment. At this point, it was assumed that something was wrong either with the 
purchased Mimivirus PCNA protein sequence or with both the pASK-IBA17 plus and 
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pEHISTEV Mimivirus PCNA constructs generated, while it was also possible that the 
protein tags found within the vectors chosen for these experiments may have had a 
negative effect on the particular proteins expression by probably skewing its structure. As a 
result, no further experiments were carried out with the PCNA protein sequence belonging 
to this organism. 
 
3.1.2 Marseillevirus  
3.1.2.1 Cloning of the Marseillevirus PCNA into the pASK_IBA17plus Strep-tag 
vector for Protein Expression Experiments 
(See Section 2.2.2.1.1.)  
The construct created was pASK-IBA17plus_Marseillevirus(MAR_ORF212)_PCNA 
(Appendix A.2.2) 
 
3.1.2.1.1 Protein Expression and Purification experiments for the Marseillevirus 
PCNA, cloned into the pASK_IBA17plus Strep-tag vector and expressed in 
Rosetta2(DE3)(pLysS) E.coli cells 
(See Sections 2.2.2.2 and 2.2.2.3) 
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First Marseillevirus PCNA protein expression study in the pASK_IBA17plus Strep-
tag vector: 
For the protein expression protocol of the Rosetta2 (DE3) (pLysS)_pASK-
IBA17plus_Marseillevirus (MAR_ORF212)_PCNA plasmid, refer to the corresponding 
‘Mimivirus PCNA protein expression’ section, while the results can be seen in Figure 3.1. 
 
In Figure 3.1, specifically for the pASK-IBA17plus_Marseillevirus (MAR_ORF212), the 
presence of an extra band in the induced and soluble protein sample at around ~35 kDa 
was quite noticeable, compared to the other viruses’ samples. Therefore, it was presumed 
that this extra band might indeed be the Marseillevirus PCNA protein being expressed. To 
verify this assumption, further protein expression studies were conducted for the 
Marseillevirus (MAR_ORF212) PCNA. 
 
Conclusions 
The Marseillevirus protein expression band patterns, as seen in Figure 3.1, are rather 
comparable to the protein band patterns generated by the empty 
Rosetta2(DE3)(pLysS)_pASK-IBA17plus vector, as well as with the protein band patterns 
produced by both the Mimivirus and CroV. In contrast, however, to the Mimivirus and 
CroV, the Marseillevirus produced a slightly more distinct protein band, running at what 
was estimated to be ~34-35 kDa. This band though was only present in the sample 
collected after protein expression had been induced. This outcome indicated that even if 
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this band did indeed represent the Marseillevirus PCNA, this protein was present in minute 
levels and was most possibly not greatly soluble. Nevertheless, the fact that a somewhat 
positive result was produced led to the decision to optimise the protein expression 
conditions for the Marseillevirus PCNA protein. 
 
Second Marseillevirus PCNA protein expression study in the pASK_IBA17plus 
Strep-tag vector: 
In this experiment, the same procedure as followed during the first Marseillevirus protein 
expression was undertaken, the only difference being that a midi-scale preparation of the 
Rosetta2 (DE3) (pLysS)_pASK-IBA17plus_Marseillevirus (MAR_ORF212)_PCNA 
plasmid was prepared. The aim was to separate the original bacteria culture into four equal 
amounts just after inducing protein expression. Each equally separated sample was grown 
under different temperature conditions, and hence different time periods. The temperatures 
chosen were 20
o
C (overnight protein expression), 25
o
C (overnight protein expression), 
30
o
C (4 hour protein expression) and 37
o
C (4 hour protein expression). 
 
Following Marseillevirus PCNA protein expression induction, the bacteria cells from each 
sample were harvested. Each sample was further divided into two additional samples; one 
that was then treated with 1% Tween, while the other one did not contain any detergent. 
Treatment with Tween was conducted by mixing on a rotating wheel for 30 minutes at 4
o
C. 
The results can be seen in Figure 3.4. 
[131] 
 
 
Figure 3.4: SDS-PAGE analysis of second Marseillevirus PCNA protein expression study in the 
pASK_IBA17plus Strep-tag vector: 12.5% SDS-PAGE Gel Photograph showing PCNA protein 
expression efficiency and levels for the cloned pASK-IBA17plus Marseillevirus PCNA 
construct, after inducing protein expression in the original culture at four different 
temperatures and lysing the total protein samples in two different buffers; Protein expression 
induction temperatures: 20
o
C, 25
o
C, 30
o
C and 37
o
C. Lysis buffers: 100mM Tris-HCl pH8, 150mM 
NaCl, 1mM EDTA, -/+ 1% Tween. The expected Marseillevirus PCNA protein molecular mass 
was 36 kDa.  Maybe a PCNA protein was slightly expressed at around that molecular mass.  
 
The samples depicted in Figure 3.4 were subsequently used to perform a Western blot. The 
antibody utilised was the Strep-Tactin™ HRP conjugate, making it a one-step 
probing/detection procedure. The outcome of the Western blot can be seen in Figure 3.5. 
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Figure 3.5: Western blot analysis of second Marseillevirus PCNA protein expression study in the 
pASK_IBA17plus Strep-tag vector: Western blot showing PCNA protein expression efficiency 
and levels for the cloned pASK-IBA17plus Marseillevirus PCNA construct, after inducing 
protein expression in the original culture at four different temperatures and lysing the total 
protein samples in two different buffers; The samples were run on a 12.5% resolving gel. The 
Western blot does indeed reveal the presence of the Marseillevirus PCNA protein being expressed 
and estimated to be running at approximately 36 kDa, while at the same time it can be pointed out 
that the protein appears to solubilise somewhat better when grown at 30-37
o
C. The image was 
captured using a Kodak processor (UK). 
 
Conclusions 
The initial results obtained after running the samples on a SDS-PAGE gel were 
uninterpretable, as all samples produced identical protein bands of the same intensity. 
Consequently, the same samples were used in a Western blot experiment were the 
differences between each sample were more noticeable, with the different growth 
conditions and lysis buffers having varying effects on the PCNA proteins’ expression and 
solubility. In conclusion; the Western blot revealed that the Marseillevirus PCNA was 
indeed expressed and running at the estimated size of ~36 kDa. As a result, it was decided 
to continue trying to optimise the protein expression and solubilisation conditions of the 
Marseillevirus PCNA. 
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Third Marseillevirus PCNA protein expression study in the pASK_IBA17plus Strep-
tag vector: 
Another midi-scale preparation of the Rosetta2 (DE3) (pLysS)_pASK-
IBA17plus_Marseillevirus (MAR_ORF212)_PCNA plasmid was prepared. The aim this 
time was to separate the final bacteria culture, which had already been induced for PCNA 
protein expression for 4 hours at 37
o
C, into a total of six equal volume samples. The cells 
harvested from each equally separated sample were resuspended in different lysis buffers 
(see also Table 2.9). All buffers set up had a Tris-base but contained varying amounts of 
salt (NaCl), from 150mM to 500mM (also testing an intermediate of 250mM), while the 
bacteria cell samples were also treated with 1% or 2% Tween detergent. The samples 
prepared were utilised in a Western blot experiment, and the proteins of interest were 
detected with the use of Strep-Tactin™ HRP conjugate (Figure 3.6).  
 
Figure 3.6: Western blot analysis of third Marseillevirus PCNA protein expression study in the 
pASK_IBA17plus Strep-tag vector: Western blot showing PCNA protein expression efficiency 
and levels for the cloned pASK-IBA17plus Marseillevirus PCNA construct, after inducing 
protein expression for 4 hours at 37
o
C and lysing the total protein samples in six different 
buffers; Lysis buffers: 100mM Tris-HCl pH8, 150/250/500mM NaCl, 1mM EDTA, 1% or 2% 
Tween. The samples were run on a 10% resolving gel. The Western blot under examination 
indicates that the Marseillevirus PCNA protein solubilises a bit better when lysed in a buffer 
containing 250mM NaCl and 2% Tween.  
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Conclusions 
The various samples produced during this experiment were once again utilised in a 
Western blot procedure were the results were rather positive, as it was revealed that 
different lysis buffers had a diverse effect on the PCNA proteins’ solubility, with some 
buffers being responsible for greatly improved protein solubility. However, the total levels 
of PCNA protein expression and solubility were not sufficient for use in further 
biochemical analysis of this protein, thus it was concluded to clone the Marseillevirus 
PCNA sequence in a different vector containing another protein tag anticipating to finally 
obtain greater levels of protein expression and solubility that could be applied in further 
experiments. 
 
3.1.2.1.2 Summary of Results 
The first Marseillevirus PCNA protein expression experiment revealed the presence of a 
protein band running at the estimated and anticipated size of ~35-36 kDa. This was a very 
positive result as it was expected that the specific band quite likely represented the 
Marseillevirus PCNA protein. However, even if that was indeed the case, it was obvious 
from the results obtained that the protein was only present in very low levels and probably 
not that soluble. As a consequence, during the second Marseillevirus PCNA protein 
expression experiment different growth conditions were tested so as to determine their 
effect on the protein expression of the Marseillevirus PCNA, while at the same time two 
different lysis buffers were used for protein solubilisation; one containing detergent and 
another one not containing any detergent. This method did not generate high-quality results 
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as all samples produced similar protein band patterns making the data uninterpretable. 
However, a Western blot did reveal the presence and expression of the Marseillevirus 
PCNA protein. Finally, the third Marseillevirus PCNA protein expression experiment, 
during which a greater variety of lysis buffers were tested for the purpose of once again 
increasing the proteins’ solubility, confirmed that even though different buffers had a 
varying effect on the PCNA proteins’ solubility, nevertheless they did not result in greatly 
improved protein solubilisation levels hence not allowing for further biochemical analysis 
of this protein. Consequently, the protein was cloned into a different vector hoping for 
more positive results. 
 
3.1.2.2 Cloning of the Marseillevirus PCNA into the pEHISTEV 6xHis-tag vector 
for Protein Expression Experiments                                
(See Section 2.2.2.1.2) 
The resulted construct was pEHISTEV_Marseillevirus(MAR_ORF212)_PCNA (Appendix 
A.3.2) 
 
3.1.2.2.1 Protein Expression and Purification experiments for the Marseillevirus 
PCNA, cloned into the pEHISTEV 6xHis-tag vector and expressed in 
Rosetta2(DE3)(pLysS) E.coli cells 
(See Sections 2.2.2.2 and 2.2.2.3) 
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First Marseillevirus PCNA protein expression study in the pEHISTEV 6xHis-tag 
vector: 
For the protein expression procedure of the Rosetta2 (DE3) 
(pLysS)_pEHISTEV_Marseillevirus (MAR_ORF212)_PCNA plasmid, refer to the 
equivalent ‘Mimivirus PCNA protein expression’ section, while the results can be seen in 
Figure 3.2. 
 
The soluble protein samples for the Marseillevirus PCNA protein (as seen in Figure 3.2), 
were also used to perform a pull-down, with the use of Ni-NTA agarose beads (See Figure 
3.3). 
 
3.1.2.2.2 Summary of Results 
The slightly distinct band running at ~35 kDa assumed to be the Marseillevirus PCNA, 
previously seen in the protein expression induced sample in Figure 3.1, was also visible in 
the same sample in Figure 3.2. In this experiment, however, a band of the same size and 
intensity was additionally visible in the insoluble ‘pellet’ sample. This outcome, as well as 
the fact that no band of interest was observed after performing a Ni-NTA agarose bead 
pull-down experiment (Figure 3.3), led to the conclusion that the Marseillevirus PCNA 
protein was in general insoluble. As a consequence, no further experiments were conducted 
for the PCNA protein belonging to this organism. 
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3.1.3 CroV  
3.1.3.1 Cloning of the CroV PCNA into the pASK_IBA17plus Strep-tag vector 
for Protein Expression Experiments 
(See Section 2.2.2.1.1.) 
The construct generated was pASK-IBA17plus_CroV(CroV_219)_PCNA (Appendix 
A.2.3). 
 
3.1.3.1.1 Protein Expression and Purification experiments for the CroV PCNA, 
cloned into the pASK_IBA17plus Strep-tag vector and expressed in 
Rosetta2(DE3)(pLysS) E.coli cells 
First CroV PCNA protein expression study in the pASK_IBA17plus Strep-tag vector: 
For the protein expression protocol of the Rosetta2 (DE3) (pLysS)_pASK-
IBA17plus_CroV (CroV_219)_PCNA plasmid, refer to the appropriate ‘Mimivirus PCNA 
protein expression’ section. The results can be seen in Figure 3.1. 
 
The samples depicted in Figure 3.1 for the pASK-IBA17plus_CroV (CroV_219) PCNA 
were additionally used in a Western blot experiment, during which the Strep-tagged PCNA 
protein was directly detected by Strep-Tactin™ HRP conjugate. The results of this 
experiment can be seen below (Figure 3.7). 
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Figure 3.7: Western blot analysis of first CroV PCNA protein expression study in the 
pASK_IBA17plus Strep-tag vector: Western blot showing PCNA protein expression efficiency 
and levels for the cloned pASK-IBA17plus CroV PCNA construct, after inducing protein 
expression for 4 hours at 37
o
C; The samples were run on a 10% resolving gel (as seen in Figure 
3.1). From the Western blot it can be concluded that even though the CroV PCNA protein seems to 
be expressed at a high level, nevertheless it is not significantly soluble (less than ¼ of the expressed 
PCNA protein has actually solubilised when sonicated in the particular lysis buffer).  
 
Conclusions 
As seen in Figure 3.1, the CroV protein expression band patterns are highly comparable to 
the protein band patterns generated by the empty Rosetta2(DE3)(pLysS)_pASK-
IBA17plus vector. Furthermore, as was the case for the Mimivirus, no intensively distinct 
protein band running at ~35 kDa (i.e. expected PCNA protein molecular mass) could be 
observed. However, when the exact same samples were used in a Western blot experiment, 
the results were clearer and fairly positive; the CroV PCNA was indeed being expressed 
and running at the anticipated size, but was not exceptionally soluble. Consequently, the 
next stages of the project involved trying to optimise the CroV PCNA proteins’ expression 
and solubilisation conditions by testing a range of different growth conditions and lysis 
buffers.  
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Second CroV PCNA protein expression study in the pASK_IBA17plus Strep-tag 
vector: 
This time, a midi-scale preparation of the Rosetta2 (DE3) (pLysS)_pASK-
IBA17plus_CroV (CroV_219)_PCNA plasmid was prepared. During this second CroV 
PCNA protein expression attempt, the main aim was to test a variety of different bacteria 
growth temperatures, as well as different lysis buffers for resuspension of the CroV 
bacteria plasmid cells.  
 
More specifically, the original bacteria culture was divided into four equal amounts just 
after inducing protein expression. Each equally separated sample was grown under 
different temperature conditions, and hence grown for different time periods. The 
temperatures chosen were once again 20
o
C (overnight protein expression), 25
o
C (overnight 
protein expression), 30
o
C (4 hour protein expression) and 37
o
C (4 hour protein expression). 
Following the completion of CroV PCNA protein expression induction, the bacteria cells 
from each sample were harvested. Each such sample was however further divided into nine 
samples, which were subsequently resuspended in various lysis buffers (see also Table 
2.9). The buffers had a Tris-base but all of them varied in the amount of salt (NaCl) they 
contained [NaCl concentrations ranged from 150mM to 500mM, testing also at 250mM]. 
In addition, the bacteria cell samples were or were not treated with 1% or 2% Tween 
detergent (i.e. a ‘No Tween’ lysis buffer was also prepared). The samples prepared were 
directly used in a Western blot experiment, where the target proteins were detected by 
using Strep-Tactin™ HRP conjugate. Even though prominent signals were produced in all 
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cases, even for the un-induced protein sample, no figure is shown as no definite 
conclusions could be drawn from this experiment, a reason being that the different 
temperatures and lysis buffers tested did not appear to have a distinguishable effect on the 
proteins’ expression and solubility, respectively. 
 
All the soluble protein samples resuspended in 250mM NaCl and treated with no, 1% or 
2% Tween were subsequently run on a 10% SDS-PAGE gel, for the purpose of checking if 
more obvious protein bands could be detected and the difference between them 
determined.  In the meantime, the differently lysed bacteria cultures, for which PCNA 
protein expression was induced at 25
o
C overnight and which were thought to have 
produced somewhat the best signals during the Western blot experiment, were repeated, 
exactly the same way as described above, and run on a 10% SDS-PAGE gel. However, no 
clear differences between the bands generated could once again be distinguished for either 
SDS-PAGE carried out (no figures included). 
 
Some of the soluble protein samples, which were previously used for the Western blot and 
SDS-PAGE analysis, were also used for a streptavidin pull-down (See Section 2.2.2.4.1). 
No figure is attached because the streptavidin pull-down did not work optimally. This was 
the second Strep-tag pull-down attempt for a specific pASK-IBA17plus PCNA construct. 
As a result, the question was still whether or not the Strep-tag attached to the CroV PCNA, 
and generally the Strep-tag found in all three pASK-IBA17plus PCNA constructs, was in 
some way obscured hence affecting PCNA protein expression and solubilisation. 
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Conclusions 
The results obtained after running the samples prepared on both SDS-PAGE gels and 
Western blots were unfortunately inconclusive, as all samples produced identical protein 
band patterns of the same intensity and hence no relative differences could be 
distinguished between them. Nevertheless, the Western blot experiments did provide some 
evidence of the presence and expression of the CroV PCNA protein. This outcome had as a 
result the cloning of the CroV PCNA protein sequence into a different vector containing 
another protein tag, thus expecting to achieve greater and more distinguishable levels of 
protein expression and solubility. 
 
3.1.3.1.2 Summary of Results 
The first CroV PCNA protein expression experiment, during which the samples prepared 
were run both on a SDS-PAGE gel and a Western blot, exposed the CroV PCNA protein 
being expressed and running at the anticipated size of ~34-35 kDa. However, the results 
also revealed that the protein was not exceptionally soluble. Therefore, for the second 
CroV PCNA protein expression experiment a variety of different growth conditions and 
lysis buffers were tested so as to determine their varying effect on the solubility of the 
CroV PCNA protein. The samples were once again run on both a SDS-PAGE gel and a 
Western blot; similar results were obtained. As a consequence, the protein was cloned into 
a different vector hoping for more positive results. 
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3.1.3.2 Cloning of the CroV PCNA into the pEHISTEV 6xHis-tag vector for 
Protein Expression Experiments                                
(See Section 2.2.2.1.2) 
The construct generated was pEHISTEV_CroV(CroV_219)_PCNA (Appendix A.3.3). 
 
3.1.3.2.1 Protein Expression and Purification experiments for the CroV PCNA, 
cloned into the pEHISTEV 6xHis-tag vector and expressed in Rosetta2(DE3)(pLysS) 
E.coli cells 
(See Sections 2.2.2.2 and 2.2.2.3) 
 
First CroV PCNA protein expression study in the pEHISTEV 6xHis-tag vector: 
For the protein expression procedure of the Rosetta2 (DE3) (pLysS)_pEHISTEV_CroV 
(CroV_219)_PCNA plasmid, again refer to the corresponding ‘Mimivirus PCNA protein 
expression’ protocol. The results can be seen in Figure 3.2. 
 
In Figure 3.2, specifically for the pEHISTEV_CroV (CroV_219), the presence of a 
pronounced band in the insoluble protein sample (i.e. ‘p’ellet sample) at around ~35-36 
kDa was evident. Therefore, it was presumed that this band was indeed the CroV PCNA 
protein being expressed but not being solubilised. To verify this assumption, further 
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protein expression studies were conducted, while at the same time different conditions 
were tested so as to try to improve the CroV PCNA protein solubility. 
 
The soluble protein samples for the CroV PCNA protein (as seen in Figure 3.2), were also 
used to perform a pull-down, with the use of Ni-NTA agarose beads (See Figure 3.3). 
 
Conclusions 
Similarly to the Marseillevirus; a previously undetectable band running at ~35 kDa was 
visible for the CroV in the insoluble ‘pellet’ sample, as seen in Figure 3.2, leading to the 
initial consideration that the CroV PCNA protein may also be insoluble. In contrast though 
to the Marseillevirus; the CroV Ni-NTA agarose bead pull-down experiment produced 
rather contradictory results to the previous ones discussed, specifically revealing a distinct 
and prominent band of the anticipated size also in the soluble sample purified by a ‘pull-
down’ technique. These results led to the assumption that the CroV PCNA protein could be 
significantly purifiable under the correct conditions and hence, following this outcome, 
numerous attempts were made to optimise the CroV PCNA protein expression and 
solubilisation conditions. 
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Second CroV PCNA protein expression study in the pEHISTEV 6xHis-tag vector 
(first Ni-NTA agarose bead column purification attempt): 
The same procedure as carried out during the ‘First CroV PCNA protein expression study 
in the pEHISTEV 6xHis-tag vector’ was performed, i.e. the IPTG protein induced bacteria 
culture was grown overnight at 25
o
C. The difference was that for this protein expression 
experiment, a different lysis buffer was used for the resuspension of the harvested CroV 
PCNA bacteria plasmid cells. This was conducted for the purpose of evaluating the effect 
of the new lysis buffer on CroV PCNA protein solubility. The buffer, which was 
Phosphate-based, was named Buffer A and can be seen in Tables 2.1 and 2.9 (i.e. 50mM 
Na2HPO4, 400mM NaCl, 10mM Imidazole, 1mM β-mercaptoethanol, pH8). 
 
Following the sonication of the total CroV PCNA protein extract, which had previously 
been resuspended in Lysis Buffer A, the soluble protein sample was collected by 
centrifugation and filtered through a column containing Ni-NTA agarose beads, attempting 
a small-scale PCNA protein purification (For protocol see Section 2.2.2.4.2). The column 
had been equilibrated with Buffer A prior to starting the experimental procedure. The flow-
through protein sample was collected for further analysis. 
 
Once the soluble CroV PCNA protein extract was filtered through the Ni-NTA agarose 
bead column, the column was washed with a second buffer (i.e. Buffer B: 50mM 
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Na2HPO4, 400mM NaCl, 30mM Imidazole, 1mM β-mercaptoethanol, pH8) and the 
resulting sample was collected for further analysis. 
 
Finally, the proteins bound to the Ni-NTA agarose beads were eluted with a third buffer 
(i.e. Buffer C: 50mM Na2HPO4, 400mM NaCl, 300mM Imidazole, 1mM β-
mercaptoethanol, pH8). Different fractions of this sample were collected and maintained 
for further analysis.  
 
All samples collected throughout this procedure were run on an SDS-PAGE gel (no figure 
displayed). Nevertheless, the attempted protein purification of the CroV PCNA protein was 
unsuccessfully and no conclusive outcome could be deduced, apart from the fact that the 
CroV PCNA protein did not preferentially bind to the column set up and, in addition, was 
not greatly soluble. 
 
Conclusions 
The samples prepared during this experiment, and which were directly utilised in a Ni-
NTA agarose bead packed column pull-down experiment, were run on a SDS-PAGE gel 
where it was apparent that the new phosphate-based lysis buffer had no improved effect on 
the proteins’ solubility, as no protein could be solubilised whatsoever. Specifically, it was 
determined that most proteins did not bind to the column as the majority of them were 
[146] 
 
eluted at once. One of the eluted proteins, which produced a prominent band on the gel, 
seemed to be running at the PCNA anticipated size of ~35 kDa. This fact led to the 
conclusion that even if that was the protein of interest, then it was significantly insoluble. 
However, even though this experiment did not generate encouraging results, the 
optimisation of the CroV PCNA protein expression conditions was continued as previous 
results were rather optimistic. 
 
Third CroV PCNA protein expression study in the pEHISTEV 6xHis-tag vector: 
Another midi-scale preparation of the Rosetta2 (DE3) (pLysS)_pEHISTEV_CroV 
(CroV_219)_PCNA plasmid was prepared. The aim this time though was to separate the 
final bacteria culture, which had similarly been induced for PCNA protein expression at 
25
o
C overnight, into a total of four equal volume samples. The bacteria cells harvested 
from each equally separated sample were resuspended in different lysis buffers (see also 
Table 2.9). This was once again the Phosphate-base buffer, but this time, containing 
varying concentrations of Imidazole, from 10mM to 40mM, while a ‘No Imidazole’ 
equivalent buffer was also prepared. The samples were sonicated and the soluble protein 
extracts were run on a 10% SDS-PAGE gel, which revealed fairly noticeable bands in all 
the soluble samples at around the predicted molecular weight for the CroV PCNA protein 
(no figure available). Furthermore, the soluble protein samples were used to perform a 
pull-down of the PCNA protein, hoping to achieve higher levels of protein solubility. The 
results of this Ni-NTA agarose bead pull-down, as well as the results from the whole 
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protein expression experiment, however were poor and no confident conclusions could be 
reached.  
 
Conclusions 
All samples obtained during this Ni-NTA agarose bead pull-down experiment were run on 
a SDS-PAGE gel. The results were rather inconclusive as all soluble protein samples 
produced identical protein band patterns of the same intensity, revealing no obvious 
difference between the lysis buffers employed. However, when observing the Ni-NTA 
agarose bead purified protein samples run on the gel it could be stated that the lysis buffer 
with the highest imidazole concentration produced slightly clearer and maybe more 
positive results (i.e. more soluble protein). Therefore, it was decided to continue with the 
phosphate-based lysis buffer containing a high amount of imidazole for any following 
experiments, while continuing to try and optimise the expression and solubilisation 
conditions of the CroV PCNA protein. 
 
Fourth CroV PCNA protein expression study in the pEHISTEV 6xHis-tag vector 
(plus pEHISTEV empty vector): 
After evaluating the results obtained from the previous experiment, another midi-scale 
preparation of the Rosetta2 (DE3) (pLysS)_pEHISTEV_CroV (CroV_219)_PCNA 
plasmid was prepared. This time, however, the same procedures were concurrently carried 
out for the Rosetta2(DE3)(pLysS)_ pEHISTEV empty vector, for the purpose of using this 
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as a control sample for comparison reasons. Protein expression induction was undertaken 
again at 25
o
C overnight, while the lysis buffer used for resuspension of the PCNA bacteria 
cells was: 50mM Na2HPO4, 400mM NaCl, 40mM Imidazole (considered to produce the 
best results compared to other amounts of Imidazole, according to the previous 
experiment), 1mM β-mercaptoethanol, pH8. A fraction of each soluble protein sample was 
used to carry out a pull-down experiment with Ni-NTA beads, which specifically bind to 
the 6xHis affinity tag found in the pEHISTEV vector. Specifically, 20µl of the beads were 
directly added into each sample, the samples were incubated at 4
o
C on a wheel for one 
hour, they were then washed 4-6 times with the lysis buffer previously used for sonication 
and finally were treated by boiling them at 95
o
C for 5 min in 2xSB buffer. A description of 
the exact pull-down procedure undertaken can be found in Section 2.2.2.4.2; Pull-down of 
PCNA Solubilised protein samples for the Mimivirus, Marseillevirus and CroV, with the 
use of Nickel (Ni-NTA) affinity agarose beads (only for the pEHISTEV PCNA constructs). 
The results of these experiments can be seen in Figure 3.8. 
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Figure 3.8: SDS-PAGE analysis of fourth CroV PCNA protein expression study in the pEHISTEV 
6xHis-tag vector (plus pEHISTEV empty vector): 10% SDS-PAGE Gel Photograph showing 
PCNA protein expression efficiency and levels for the cloned pEHISTEV CroV PCNA 
construct, compared to the empty pEHISTEV vector. Both bacteria plasmid samples were 
induced for protein expression at 25
o
C overnight and the bacteria cells lysed in four different 
buffers. The different soluble protein extracts were used to perform a pull-down; (U): 
uninduced, (I): induced, (S): soluble, (PD): pull-down. Once more, the anticipated CroV PCNA 
protein molecular mass was 34 kDa.  
Note: The band represented by the red arrow (*) was sent for Mass Spectrometry, to determine 
whether or not it is the CroV PCNA protein. 
 
Conclusions 
The results of this experiment were rather unexpected as no alterations to the previous 
protein expression and solubilisation conditions were undertaken. The only differing 
factors were that this Rosetta2 (DE3) (pLysS)_pEHISTEV_CroV (CroV_219)_PCNA 
plasmid preparartion was performed at a slightly larger-scale than the previous one, and 
also the use of the empty vector as a control sample throughout the method. In particular, 
* 
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the soluble PCNA protein samples were once again utilised in a Ni-NTA agarose bead 
pull-down procedure, which produced a very clear, distinct and prominent band running at 
the anticipated size for the CroV PCNA. This specific purified sample was subsequently 
sent for mass spectrometry analysis to verify its nature. The results were positive, but not 
significant; even though the PCNA protein of interest was the first hit identified by MS, the 
values corresponding to its score, specific peptides and sequence coverage were poor. 
Specifically, when using the ProteinPilot™ software system, the following data was 
retrieved for the protein band of interest analysed by ESI: ProteinPilot Score = 12 (at 
p≤0.05, based on the Paragon Algorithm™ used), Sequence Coverage (%) = 32, 
Significant Peptides (95%) = 6, Contribution of each Peptide = 2 at a 99% Confidence; the 
data was the same when compared against both the NCBI and BMS protein databases. As a 
consequence, the presence of the PCNA protein could not be identified with great 
confidence. Nevertheless, even though the PCNA protein was most likely present in the 
sample, the amount of protein was not sufficient for use in further biochemical analysis, 
and thus, the protein expression and solubilisation conditions had to be further optimised 
for the purpose of obtaining greater levels of clean and pure soluble protein. The exact 
reason as to why this experiment produced remarkably positive results still remains 
unknown, however the fact that it was a somewhat larger-scale plasmid preparation, 
compared to the previous experiment described, may have played a role.  
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Fifth CroV PCNA protein expression study in the pEHISTEV 6xHis-tag vector (plus 
pEHISTEV empty vector): 
The aim of this experiment was to test a variety of different bacteria growth temperatures, 
as well as different lysis buffers for resuspension of the CroV PCNA bacteria plasmid cells 
(similarly as was previously performed for the Rosetta2 (DE3) (pLysS)_pASK-IBA17plus_CroV 
(CroV_219)_PCNA plasmid). This experiments were particularly performed for the Rosetta2 
(DE3) (pLysS)_pEHISTEV_CroV (CroV_219)_PCNA plasmid, alongside with the 
Rosetta2(DE3)(pLysS)_ pEHISTEV empty vector plasmid. 
 
Therefore, as described elsewhere, four different temperature conditions, and hence four 
different time periods of bacteria culture growth, were examined. Following the 
completion of protein expression induction, the bacteria cells from each sample were 
harvested. This time, however, each individual sample was further divided into twelve 
samples, which were subsequently resuspended in various lysis buffers (see also Table 
2.9). All buffers had a Phosphate-base but contained varying concentrations of salt (NaCl) 
(i.e. from 250mM to 600mM, with a 400mM intermediate) and Imidazole (i.e. 40mM and 
65mM), while additionally the samples were either treated with 0.5% Tween or were not 
treated with any detergent whatsoever. All resulting samples were run on a 10% SDS-
PAGE gel. Nonetheless, as the different lysis buffers did not have any pronounced effect 
on the CroV PCNA protein expression efficacy, only a couple of the SDS-PAGE gels that 
were run will be demonstrated here (Figure 3.9). 
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Protein Expression Induction at 30
o
C for 4 hours; Soluble (S) Protein Extracts 
 
Figure 3.9: SDS-PAGE analysis of fifth CroV PCNA protein expression study in the pEHISTEV 
6xHis-tag vector (plus pEHISTEV empty vector): 10% SDS-PAGE Gel Photograph showing 
PCNA protein expression efficiency and levels for the cloned pEHISTEV CroV PCNA 
construct, compared to the empty pEHISTEV vector, after inducing protein expression in the 
original bacteria cultures at four different temperatures and lysing the total protein samples 
in twelve different buffers; Protein expression induction temperatures: 20
o
C, 25
o
C, 30
o
C and 
37
o
C; This gel however only demonstrates the soluble protein extracts representing protein 
expression induction at 30
o
C for 4 hours. Lysis buffers: 50mM Na2HPO4, 250/400/650mM NaCl, 
40/65mM Imidazole, 1mM β-mercaptoethanol, pH8, No or 0.5% Tween. Even though the 
anticipated molecular mass for the CroV PCNA protein was 34 kDa, in most gels run during this 
part of the experiment it appeared to have a somewhat higher molecular weight (i.e. around ~36 
kDa). A distinguishable band was observed in the ‘I’ protein samples, whereas the same band could 
not easily be distinguished in the ‘S’ protein samples.  
* 
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Conclusions 
The only conclusion that could be drawn from this experiment was that the various growth 
temperatures and lysis buffers tested had no distinct effect on the CroV PCNA proteins’ 
solubility. In general, all samples prepared and employed during this study produced 
exactly the same results (i.e. same pattern of protein bands), hence proving that the 
optimisation of the CroV PCNA protein expression and solubilisation conditions was more 
difficult than what expected. For this purpose, a different approach was taken whilst trying 
to further optimise the proteins’ expression conditions. This specifically was studying 
PCNA protein purification using an AKTA purifier and thus hoping for better quality 
results. 
 
Sixth CroV PCNA protein expression study in the pEHISTEV 6xHis-tag vector (for 
first AKTA purification attempt): 
A large-scale preparation of the Rosetta2 (DE3) (pLysS)_pEHISTEV_CroV 
(CroV_219)_PCNA plasmid was set up as usual. The bacteria culture was left to incubate 
at 27
o
C overnight, after protein expression induction by IPTG. The final bacteria culture 
was divided into two equal volume samples; for each, the cells were harvested by 
centrifugation and resuspended in two different Lysis Buffers A (Table 2.1 & 2.9; 50mM 
Na2HPO4, 250/500mM NaCl, 40mM Imidazole, 0.5% Tween, 1mM β-mercaptoethanol, 
pH 8). The total cell extracts were finally sonicated and the soluble cell extracts collected 
for a one-step PCNA protein purification analysis on the AKTA system allowing for further 
assessment of the CroV PCNA protein expression. The column utilised during this first 
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PCNA AKTA purification was a histidine binding His-Trap™ column (See Section 
2.2.2.4.4; Protein Purification Experiments for CroV PCNA using an AKTA system). The 
samples of interest were run on a 10% SDS-PAGE gel (no figure attached).  
 
Conclusions 
The conclusion from this AKTA purification experiment for the CroV PCNA was that, even 
though there clearly was a satisfactory level of induced protein expression, the purification 
of the protein was completely unsuccessfully. That was the case for both lysis buffers 
examined. As a result, more CroV PCNA protein expression conditions were investigated 
this time by performing a gradient AKTA purification experiment and testing an even 
greater range of lysis buffers containing increasing concentrations of Imidazole. 
 
Seventh CroV PCNA protein expression study in the pEHISTEV 6xHis-tag vector 
(for second AKTA purification attempt): 
Similarly to what was mentioned beforehand, a midi-scale preparation of the Rosetta2 
(DE3) (pLysS)_pEHISTEV_CroV (CroV_219)_PCNA plasmid was set up. The bacteria 
culture, however, was left to incubate at 25
o
C overnight (instead of 27
o
C) so as to induce 
PCNA protein expression. The bacteria cells were harvested and resuspended in Lysis 
Buffer A (Table 2.1 & 2.9; 50mM Na2HPO4, 250mM NaCl, 40mM Imidazole, 1mM β-
mercaptoethanol, pH 8). The lysis buffer containing 250mM NaCl, instead of 500mM 
NaCl, was selected for this experiment, after carefully evaluating the results observed in 
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the previous experiment. The total cell extracts were finally sonicated and the soluble cell 
extracts collected for PCNA protein purification analysis on the AKTA system allowing 
once again for further assessment of the CroV PCNA protein expression. The AKTA 
method set up was a gradient purification protocol, testing a range of Imidazole 
concentrations from 40mM to 500mM. The column utilised during this second PCNA 
AKTA purification attempt was the same His-Trap™ column (See Section 2.2.2.4.4). The 
samples considered to be of most importance were run on a 10% SDS-PAGE gel (no data 
shown). The purification of CroV PCNA protein was once again unsuccessful.  
 
The same samples run on the SDS-PAGE gel were subsequently used to perform a 
Western blot; the reason being to check if a stronger CroV PCNA protein signal could be 
detected. For this Western blot method, in particular, two antibodies were utilised making 
it a two-step probing/detection procedure; initially the blocked membrane was incubated 
with a primary anti-HIS mouse monoclonal antibody that recognised and bound to the 
6xHis-tag sequence, while the PCNA protein was further detected with the use of a 
secondary anti-mouse antibody specific to the primary antibody. However, no Western blot 
figure is attached as a strong chemiluminescence signal was only produced for the 
‘I’nduced CroV PCNA protein sample (i.e. total cell extract), while no other band(s) for 
any of the other samples were actually visible. The band generated was estimated to have a 
molecular mass of ~37 kDa (appeared between 35 kDa and 40 kDa, when compared to the 
protein ladder). 
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Conclusions 
The gradient AKTA purification method also proved unsuccessful, resulting in a similar 
outcome to the first AKTA purification experiment attempted. This result was also 
confirmed by performing a Western blot. Therefore, no further AKTA purifications were 
attempted for the CroV PCNA. Instead it was decided to attempt a final Ni-NTA agarose 
bead pull-down experiment under the same protein expression conditions. 
 
Eighth CroV PCNA protein expression study in the pEHISTEV 6xHis-tag vector 
(second Ni-NTA agarose bead column purification attempt): 
A Rosetta2 (DE3) (pLysS)_pEHISTEV_CroV (CroV_219)_PCNA plasmid bacteria 
culture was grown as usual. CroV PCNA protein expression induction was performed at 
30
o
C for 4 hours. The bacteria cells were harvested and resuspended in Lysis Buffer A 
(Table 2.1 & 2.9; 50mM Na2HPO4, 250mM NaCl, 40mM Imidazole, 1mM β-
mercaptoethanol, 0.5% Tween, pH 8). The total cell extracts were sonicated and the 
soluble cell extracts collected for PCNA protein purification on a Ni-NTA agarose bead 
column (See Section 2.2.2.4.2). The column had previously been equilibrated with the 
same Lysis Buffer A. The flow-through protein sample was collected. Next the column 
was washed with Lysis Buffer A that only contained 15mM Imidazole. The low Imidazole 
concentration buffer was used so as to prevent any CroV PCNA protein loss from the 
column. The wash-through protein sample was collected. Finally, the proteins bound to the 
Ni-NTA column were eluted with Lysis Buffer A that contained a much higher 
concentration of Imidazole (i.e. 300mM), to ensure all bound proteins would elute. 
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Different fractions of this elution process were collected and maintained for further 
analysis by SDS-PAGE. The outcome of this CroV PCNA protein purification method was 
not informative, as there was no obvious induction of protein expression. 
 
Conclusions 
This Ni-NTA agarose bead pull-down experiment generated contrasting results to the 
previous two AKTA purification attempts. More specifically, even though during the earlier 
AKTA purification studies PCNA protein expression induction was clearly noticeable, in 
the case of this experiment it was obvious that no protein expression was being induced. 
These results were rather confusing and contradictory to other positive results previously 
found, so as a consequence it was decided to change approach and instead express the 
specific CroV PCNA construct in a variety of different E.coli expression systems. By 
doing so it was anticipated that the different E.coli expression cells would have a varying 
effect on the expression and hopefully solubility of the CroV PCNA protein, thus allowing 
for more positive results and further biochemical analysis of the specific protein. 
 
3.1.3.2.2 Summary of Results 
The first CroV PCNA protein expression experiment revealed interestingly some positive 
results. Specifically, it was established that a good proportion of the PCNA protein being 
expressed could probably also be solubilised, even though a good majority of it still 
appeared to be insoluble. As a result, multiple attempts of optimising the proteins’ 
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expression and solubilisation conditions were carried out, primarily for the purpose of 
obtaining greater quantities of the solubilised CroV PCNA protein for use in further 
biochemical analysis. The first such attempt evaluated the effect of a new lysis buffer on 
the CroV PCNA proteins’ solubility; the new buffer was Phosphate-based, while all 
previous buffers utilised were Tris-based. The PCNA protein sample prepared was directly 
utilised in a Ni-NTA agarose bead packed column pull-down experiment, during which 
process a number of samples were collected for further analysis of the CroV PCNA protein 
solubility. The result of this study was that no protein actually bound to the column, 
suggesting either that the protein was obscured or that the column was problematic. 
However, in the eluted protein fraction collected, a protein running at the anticipated size 
was actually visible on the SDS-PAGE gel, suggesting that if it was the CroV PCNA 
protein then it was significantly insoluble. Following this, a variety of phosphate-based 
lysis buffers were tested so as to determine their probable varying effect on the solubility 
of the CroV PCNA protein; the differing factor between all buffers was the concentration 
of Imidazole reagent, while a buffer with no Imidazole was also prepared for use as a 
control. No great difference could be distinguished between the different samples, but it 
did appear that buffers with greater Imidazole concentrations may have produced slightly 
better results compared to the rest. The fourth CroV PCNA protein expression experiment 
generated the best results with a very prominent protein band being expressed at the 
anticipated PCNA size. This band was specifically seen in the purified protein sample. The 
mass spectrometry results showed that the PCNA protein was quite possibly present, but in 
very low levels within the sample. Therefore, the optimisation of the proteins’ expression 
and solubilisation conditions was continued. The first attempt was to examine a range of 
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growth conditions and lysis buffers. Nevertheless, all conditions chosen appeared to have 
the same effect on the CroV PCNA proteins’ expression and solubility. At this stage, it was 
decided to try and purify the protein with the use of an AKTA purifier. Nevertheless, both 
attempts failed, even though some of the protein was noticeably being expressed. The final 
attempt to purify the CroV PCNA protein was with the use of another Ni-NTA agarose 
bead column. This experiment did not produce any results. The optimisation of the CroV 
PCNA proteins’ expression and solubilisation proved very difficult and unsuccessful. In 
general, it can be stated that the CroV PCNA protein was mostly insoluble, with only a few 
lysis buffers slightly affecting and maybe increasing its solubilility. The amounts of 
soluble protein obtained, however, were considered insignificant for use in further 
experiments. 
 
3.1.3.2.3 Protein Expression and Purification experiments for the CroV PCNA, 
cloned into the pEHISTEV 6xHis-tag vector and expressed in a variety of E.coli cells 
First CroV PCNA protein expression study in a variety of E.coli cells: 
The E.coli cells selected for this part of the project were: BL21(DE3), BL21(DE3)(pLysS), 
Rosetta2(DE3), Arctic Express(DE3)RP and C43(DE3). More details of these protein 
expression strains can be found in Section 2.2.2.1.2. The main purpose of testing other 
E.coli host strains, apart from the usual Rosetta2(DE3)(pLysS), was to verify whether or 
not they would have a different effect on PCNA protein expression and solubility.  
 
[160] 
 
Small-scale bacteria cultures of the pEHISTEV_CroV (CroV_219)_PCNA plasmid, 
expressed in each of the BL21(DE3), BL21(DE3)(pLysS), Rosetta2(DE3), Arctic 
Express(DE3)RP and C43(DE3) E.coli host strains, were set up following standard 
techniques. CroV PCNA protein expression was induced at 37
o
C for 4 hours. The CroV 
PCNA bacteria cells were harvested and resuspended in a PBS-based buffer, additionally 
containing 100mM Tris-HCl pH8, 10mM Imidazole, 0.5% Tween, 1mM EDTA and 1mM β-
mercaptoethanol (See Table 2.1 and 2.9). No data is shown, as the different E.coli host 
strains did not seem to have any noticeable effect on the PCNA protein expression 
efficiency.  
 
Conclusions 
The general conclusion from this experiment was that the different E.coli expression 
systems used in the hope of increasing the CroV PCNA proteins’ expression and solubility, 
did not actually affect in any way those parameters; meaning that all the different bacteria 
expression cells utilised in fact produced comparable results none of which were 
significant. However, it should be noted that a distinct band of the anticipated size for the 
PCNA protein was evident on the gels, but this band was present in all the samples. Thus, 
this band was considered to be of no importance. Following this experiment, and as the 
outcome was not promising, a final attempt was made to try and optimise the conditions of 
the CroV PCNA proteins’ expression and solubility, while using the different E.coli 
expression strains. 
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Second CroV PCNA protein expression study in a variety of E.coli cells: 
The main scope of this second study was to investigate different protein expression 
induction temperatures for the CroV PCNA protein, previously expressed in a selection of 
E.coli host strains. The preferred expression constructs chosen for use in this experiment 
were the BL21(DE3)(pLysS), Arctic Express(DE3)RP and C43(DE3) pEHISTEV_CroV 
(CroV_219)_PCNA plasmids. 
 
Those three CroV PCNA plasmids, to begin with, were grown on a rather small-scale 
preparation, exactly as mentioned beforehand. The difference in this case being that the 
CroV PCNA protein expression was induced at two different temperatures (i.e. 16
o
C and 
25
o
C) overnight. In particular, the three different bacteria cultures after being induced for 
PCNA protein expression were divided into two equal volume samples; each sample was 
separately grown at the precise temperatures mentioned. After the CroV PCNA protein 
expression induction was finalised, the bacteria cells from each differently grown sample 
were harvested and resuspended in the same PBS-based buffer (See Table 2.1 and 2.9). 
The protein samples of interest were run on a SDS-PAGE gel, but once again the different 
E.coli host strains did not appear to have an evident effect on the PCNA protein expression 
efficiency (no figure included). 
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Conclusions 
Similarly to the experiment discussed above, the different E.coli expression strains created, 
containing the CroV PCNA protein, did not have any positive effect on the proteins’ 
expression and solubility, even when two different temperatures were tested for protein 
expression induction. All samples once again generated exactly the same results, which 
were uninterpretable and trivial. 
 
3.1.3.2.4 Summary of Results 
Both protein expression studies attempted with the various E.coli expression strains 
created, and containing the CroV PCNA protein, were uninformative. The different strains 
all produced exactly the same results; they specifically all generated the same protein band 
pattern and no difference could be distinguished between them. This was the case even 
during the second CroV PCNA protein expression experiment when two different protein 
expression induction temperatures were tested for the purpose of optimising the proteins’ 
expression and solubilisation conditions. Therefore, no further experiments were 
performed using these strains. At this point, it was decided to focus for a while on another 
protein, the FEN1, which interacts strongly with the PCNA protein under the right 
conditions. The purpose and hypothesis being that through the formation of an interaction 
between the two proteins of interest, maybe it would be plausible to isolate and solubilise 
our primary protein of interest, the PCNA. 
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3.2 Tagged Protein Expression of Giant Virus FEN1 in E.coli   
3.2.1 CroV 
The CroV FEN1 (CroV_037, Appendix A.1.4; 37 kDa) gene fragment of interest was 
cloned into two fairly similar expression vectors both containing a 6xHis affinity tag (2 
kDa); the first such vector was the typical pEHISTEV vector, while the other one was the 
equivalent pEHISGFPTEV vector that, in addition to the 6xHis-tag, also contained a GFP-
tag (~28 kDa). 
 
3.2.1.1 Cloning of the CroV FEN1 into the pEHISTEV 6xHis-tag and 
pEHISGFPTEV 6xHis-tag + GFP-tag vectors for Protein Expression Experiments                                
Refer to Section 2.2.3.1.1; Cloning of the CroV FEN1 protein into a pEHISTEV and 
pEHISGFPTEV vector backbone, both containing a 6xHis affinity tag for protein 
purification, while the latter also contains a GFP-tag. 
The protocol resulted in the generation of two different constructs: 
pEHISTEV_CroV_037_FEN1 and pEHISGFPTEV_CroV_037_FEN1 (Appendix A.4). 
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3.2.1.1.1 Protein Expression and Purification experiments for the CroV FEN1, 
cloned into the pEHISTEV 6xHis-tag and pEHISGFPTEV 6xHis-tag + GFP-tag 
vectors and expressed in Rosetta2(DE3)(pLysS) E.coli cells  
Refer to See Section 2.2.3.2; Protein Expression Experiments for CroV FEN1 protein, and 
Section 2.2.3.3; Preparing Soluble FEN1 protein samples from CroV by Sonication 
procedures. 
 
First CroV FEN1 protein expression study in the pEHISTEV 6xHis-tag and 
pEHISGFPTEV 6xHis-tag + GFP-tag vectors: 
Midi-scale preparations of the Rosetta2 (DE3) (pLysS)_pEHISTEV_CroV_037_FEN1 and 
Rosetta2 (DE3) (pLysS)_pEHISGFPTEV_CroV_037_FEN1 plasmids were incubated for 
~3 hours at 37
o
C, until the OD of the bacteria cultures reached the expected point. At that 
specific OD, FEN1 protein expression was induced in both plasmids by the addition of 
IPTG reagent. The bacteria cultures were left to incubate at 25
o
C overnight. The different 
plasmid bacteria cells were harvested by centrifugation and were resuspended in Lysis 
Buffer A (Table 2.1 & 2.10; 50mM Na2HPO4, 300mM NaCl, 20mM Imidazole, 1mM β-
mercaptoethanol, pH 8). The total cell extracts for both plasmid samples were sonicated 
and the soluble cell extracts collected for further FEN1 protein expression analysis. 
Moreover, the two different soluble protein samples, resulting from the two different 
expression vectors, were used to perform a pull-down of the FEN1 protein with Ni-NTA 
agarose beads (For protocol see Section 2.2.3.4.1; Pull-down of FEN1 Solubilised protein 
samples for the CroV, with the use of Nickel (Ni-NTA) affinity agarose beads (pEHISTEV 
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& pEHISGFPTEV FEN1 constructs).  All the protein expression samples of interest, as 
well as the ones resulting from the pull-down process, were run on a 10% SDS-PAGE gel 
(Figure 3.10).  
 
 
Figure 3.10: SDS-PAGE analysis of first CroV FEN1 protein expression study in the pEHISTEV 
6xHis-tag and pEHISGFPTEV 6xHis-tag + GFP-tag vectors: 10% SDS-PAGE Gel Photograph 
showing FEN1 protein expression efficiency and levels for the pEHISTEV and 
pEHISGFPTEV CroV FEN1 constructs, after FEN1 protein expression was inducted at 25
o
C 
overnight. The soluble FEN1 protein extracts were used to perform a Ni-NTA agarose bead 
pull-down; The expected FEN1 protein molecular masses were 39 kDa for the 
pEHISTEV_CroV_037_FEN1, and 67 kDa for the pEHISGFPTEV_CroV_037_FEN1. The 
molecular weight of the former FEN1 protein seemed to be somewhat lower (~37 kDa) than what 
predicted, while the latter was not particularly apparent on this gel. The plain (i.e. not the ‘Plus’ 
version) PageRuler™ Prestained Protein Ladder (Fermentas, UK) was used as a size standard for 
comparison.  
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The exact same FEN1 protein samples, as represented in Figure 3.10, were additionally 
used to conduct a Western blot experiment, for the reason of hopefully obtaining a stronger 
CroV FEN1 protein signal. During this method, the blocked membrane containing the 
FEN1 protein samples was initially incubated with an anti-HIS mouse monoclonal 
antibody, after which process the proteins were targeted and detected with a secondary 
anti-mouse antibody. The outcome of the Western blot can be seen below (Figure 3.11).  
 
 
Figure 3.11: Western blot analysis of first CroV FEN1 protein expression study in the pEHISTEV 
6xHis-tag and pEHISGFPTEV 6xHis-tag + GFP-tag vectors: Western blot showing FEN1 
protein expression efficiency and levels for the cloned pEHISTEV and pEHISGFPTEV CroV 
FEN1 constructs, after inducing protein expression at 25
o
C overnight. The soluble FEN1 
protein extracts were used to perform a Ni-NTA agarose bead pull-down; The samples were 
run on a 10% resolving gel (as seen in Figure 3.10). The pEHISGFPTEV_CroV_037_FEN1 
protein sample appeared to be running at approximately the same molecular mass as the 
pEHISTEV_CroV_037_FEN1 protein sample, with two distinct bands being produced. This might 
have been a strong indication of the fact that the eGFP-tag (~28 kDa) had probably been cleaved of 
the FEN1 protein, but was somehow still being detected by the antibodies used.  
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Conclusions 
When running the CroV FEN1 samples prepared on a SDS-PAGE gel, for both constructs 
generated, it was very difficult to distinguish any difference between the protein bands and 
hence interpret the results. Therefore, the same samples were subsequently run on a 
Western blot, so as to obtain a stronger protein signal. The outcome of this procedure was 
clearer, showing that in the case of the CroV FEN1 protein cloned into the pEHISTEV 
vector, containing no GFP tag, the protein was indeed being expressed at the correct size 
but was insoluble. On the other hand, in the case of the CroV FEN1 protein cloned into the 
pEHISGFPTEV vector, two protein bands were being expressed, one at the FEN1 
anticipated size and the other one running a bit lower, but both were also insoluble. The 
fact that two bands were observed in the latter case could possibly be due to the GFP tag 
being cleaved off from the protein sequence, but nevertheless still being detected by the 
antibodies used for Western blotting. These results led to the decision of trying to optimise 
the FEN1 proteins’ expression and solubilisation conditions. 
 
Second CroV FEN1 protein expression study in the pEHISTEV 6xHis-tag and 
pEHISGFPTEV 6xHis-tag + GFP-tag vectors: 
Midi-scale preparations of the Rosetta2 (DE3) (pLysS)_pEHISTEV_CroV_037_FEN1 and 
Rosetta2 (DE3) (pLysS)_pEHISGFPTEV_CroV_037_FEN1 plasmids were prepared, 
following the same protocol as above. The difference this time being the temperature/time 
period of CroV FEN1 protein expression induction, as well as the lysis buffer in which the 
bacteria cells were eventually resuspended in. 
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The CroV FEN1 bacteria cultures were induced for protein expression and left to incubate 
at 37
o
C for 4 hours. The plasmid bacteria cells were harvested for each culture and were 
resuspended in Lysis Buffer W (Table 2.1 & 2.10; 100mM Tris-HCl pH8, 250mM NaCl, 
20mM Imidazole, 0.5% Tween, 1mM β-mercaptoethanol). The lysis buffer chosen was a 
Tris-base one, instead of a Phosphate-base one. The samples collected throughout the 
procedure were run on a 10% SDS-PAGE gel. However, no figure is available as the 
resulting image was of very bad quality and none of the FEN1 proteins were particularly 
distinguishable.  
 
The same FEN1 protein samples, used during the SDS-PAGE, were furthermore used to 
carry out a Western blot experiment, for the purpose of not only obtaining a stronger CroV 
FEN1 protein signal but also pin-pointing the exact molecular mass of the protein as run on 
the gel. The FEN1 protein samples contained within the blocked membrane were incubated 
with an anti-HIS mouse monoclonal antibody and the proteins were then detected with a 
secondary anti-mouse antibody specific to the primary one. Nevertheless, no figure is 
attached due to its general poor quality. Particularly, the development of the film did not 
generate notable chemiluminescent signals, probably further suggesting that the expected 
FEN1 protein cloned into the pEHISTEV and pEHISGFPTEV vectors was not actually 
being expressed in any of the protein samples. 
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Conclusions 
For this experiment, two protein expression parameters were altered; the incubation 
temperature for protein expression and the lysis buffer for protein solubilisation. The 
protein samples prepared were utilised on a SDS-PAGE gel and subsequently on a Western 
blot. However, neither of the methods produced any results; in the case of the SDS-PAGE 
gel the protein bands were once again uninterpretable, while in the case of the Western blot 
no distinguishable chemiluminescent signal was generated. The latter results suggested that 
most likely the FEN1 protein, under the specific conditions chosen for protein expression, 
was in fact not being expressed. The optimisation of the CroV FEN1 proteins’ expression 
and solubilisation conditions was continued. 
 
Third CroV FEN1 protein expression study only in the pEHISTEV 6xHis-tag vector 
(plus pEHISTEV empty vector): 
A Rosetta2 (DE3) (pLysS)_pEHISTEV_CroV_037_FEN1 plasmid bacteria culture was 
prepared, as usual. This time, however, the same procedure was in parallel carried out for 
the Rosetta2(DE3)(pLysS)_ pEHISTEV empty vector, for the purpose of using this as a 
control. Protein expression induction was undertaken at 37
o
C for 4 hours, while a variety 
of lysis buffers were used for resuspension of the harvested bacteria cells (See Table 2.10). 
The selection of buffers tested specifically were: two PBS-based buffers (with either 0.5% 
Tween or 0.5% glycerol), a Phosphate-based buffer and a Tris-based buffer. The question 
being addressed was if completely different lysis buffers would have an effect on CroV 
FEN1 protein solubility. The results of this experiment can be observed in Figure 3.12. 
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Figure 3.12: SDS-PAGE analysis of third CroV FEN1 protein expression study only in the 
pEHISTEV 6xHis-tag vector (plus pEHISTEV empty vector): 10% SDS-PAGE Gel Photograph 
showing FEN1 protein expression efficiency and levels for the cloned pEHISTEV CroV FEN1 
construct, compared to the empty pEHISTEV vector. Both bacteria plasmid samples were 
induced for protein expression at 37
o
C for 4 hours and the bacteria cells lysed in four 
different buffers; Lysis Buffer 1: PBS, 0.5% Tween; Lysis Buffer 2: 50mM NaH2PO4, 500mM 
NaCl, 30mM Imidazole, 0.5% Tween, 1mM β-mercaptoethanol, pH 8; Lysis Buffer 3: 100mM 
Tris-HCl pH8, 150mM NaCl, 10mM Imidazole, 0.5% Tween, 1mM β-mercaptoethanol; Lysis 
Buffer 4: PBS, 0.5% glycerol. The anticipated CroV FEN1 protein molecular mass was 39 kDa, but 
no obvious band could be detected on the gel.  
 
Conclusions 
The purpose of this experiment was to evaluate a number of different lysis buffers and 
their effect on the FEN1 proteins’ solubility, while at the same time using the empty vector 
as a control sample for comparison. The results showed that the different buffers did not 
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have a varying effect on the proteins’ expression and solubility, while most importantly 
when observing the gel it became apparent that almost certainly no protein was being 
expressed. Therefore, the next stage of the project was to express the CroV FEN1 construct 
in a variety of E.coli cells. 
 
3.2.1.1.2 Summary of Results 
While the first CroV FEN1 protein expression study revealed the presence of the protein 
being expressed but not soluble, all further experiments failed to produce any protein 
expression. This was most likely due to the fact that the bacteria growth conditions had 
been altered. The different lysis buffers did not appear to have an effect on the proteins’ 
solubility either. The protein expressed in the primary experiment, however, was only 
present at a level detectable by blot. 
 
3.2.1.1.3 Protein Expression and Purification experiments for the CroV FEN1, 
cloned into the pEHISTEV 6xHis-tag vector and expressed in a variety of E.coli cells 
First CroV FEN1 protein expression study in a variety of E.coli cells: 
Similarly as for the CroV PCNA, the E.coli cells picked were: BL21(DE3), 
BL21(DE3)(pLysS), Rosetta2(DE3), Arctic Express(DE3)RP and C43(DE3) (See Section 
2.2.3.1.1). The main aim of testing other E.coli host strains, apart from the standard 
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Rosetta2(DE3)(pLysS), was to confirm whether or not they would have a different effect 
on FEN1 protein expression, solubility and purity.  
 
In particular, following the exact same procedure as was carried out for the 
pEHISTEV_CroV (CroV_219)_PCNA plasmid (See Section 3.1.3.2.2); small-scale 
bacteria cultures of the pEHISTEV_CroV_037_FEN1 plasmid, expressed in each of the 
BL21(DE3), BL21(DE3)(pLysS), Rosetta2(DE3), Arctic Express(DE3)RP and C43(DE3) 
E.coli host strains, were set up using standard techniques. CroV FEN1 protein expression 
was induced at 37
o
C for 4 hours. The CroV FEN1 bacteria cells were harvested and 
resuspended in the same PBS-based buffer, additionally containing 100mM Tris-HCl pH8, 
10mM Imidazole, 0.5% Tween, 1mM EDTA and 1mM β-mercaptoethanol (See Table 2.1 
and 2.10). Nevertheless, no apparent differences between the diverse E.coli protein 
expression strains could be distinguished. 
 
Conclusions 
In conclusion, as was the case for the CroV PCNA protein, the different E.coli expression 
strains prepared and employed for the purpose of increasing the CroV FEN1 proteins’ 
expression and solubility, did not in fact influence those parameters. Nevertheless, another 
attempt was made to try and optimise the conditions of the CroV FEN1 proteins’ 
expression and solubility, while using these different E.coli expression strains. 
 
[173] 
 
Second CroV FEN1 protein expression study in a variety of E.coli cells: 
The principle of this second study was to examine different protein expression induction 
temperatures for the CroV FEN1 protein, previously expressed in a range of E.coli host 
strains. The expression constructs selected for use in this experiment were the 
BL21(DE3)(pLysS), Arctic Express(DE3)RP and C43(DE3) pEHISTEV_CroV_FEN1 
plasmids. 
 
Once again, similarly to the pEHISTEV_CroV (CroV_219)_PCNA plasmid (See Section 
3.1.3.2.2); the three CroV FEN1 plasmids were grown on a small-scale preparation. 
However, the resulting bacteria cultures after being induced for FEN1 protein expression 
were divided into two equal volume samples; each sample was separately grown either at 
16
o
C or at 25
o
C overnight. Following CroV FEN1 protein expression induction at the 
chosen temperatures, the bacteria cells from each sample were harvested and resuspended 
in the same PBS-based buffer (See Table 2.1 and 2.10). Nonetheless, no visible differences 
could be determined between the E.coli protein expression plasmids or between the two 
protein expression induction temperatures (no figure available). 
 
Conclusions 
Similarly, the attempt to try and optimise the CroV FEN1 proteins’ expression and 
solubilisation conditions, while making use of the different E.coli expression strains 
containing the CroV FEN1 protein, was completely uninformative, even when two 
different temperatures were tested for protein expression induction.  
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3.2.1.1.4 Summary of Results 
As was the case for the CroV PCNA protein, the various E.coli expression strains 
generated to contain the CroV FEN1 protein, were not useful in that they did not allow for 
improved protein expression and solubilisation efficiency. Therefore, no further 
experiments were performed using these strains. At this point, it was decided to switch to 
another type of vector, one that did not contain any protein tags. The hypothesis being that 
maybe the presence of tags obscured the proteins’ natural structure and hence affected its 
expression and subsequently its solubilisation. The use of these particular vectors was 
advantageous as they permitted the concurrent protein expression of the CroV PCNA and 
the CroV FEN1, a fact that in theory should prove useful when trying to isolate and purify 
the PCNA protein.  
 
3.3 Un-Tagged Protein Expression and Co-Expression of Giant Virus PCNA and 
FEN1 in E.coli  
3.3.1 CroV 
The CroV PCNA (CroV_219; Appendix A.3.3; 32 kDa) and CroV FEN1 (CroV_037; 
Appendix A.4; 37 kDa) gene fragments of interest were cloned into two comparable 
expression vectors, none of which contained an affinity tag to assist in protein purification 
purposes. Namely these vectors were the pETDuet-1 and pCDFDuet-1. These vectors were 
selected as they facilitate co-expression (i.e. by containing two multiple cloning sites 
(MCS)) and co-transformation, in the same bacteria culture, of two target genes. As no 
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affinity tags were present within these vectors, thus no extra base pairs were added to the 
two gene sequences of interest and their protein molecular masses remained unaffected. 
 
3.3.1.1 Cloning of the CroV PCNA and CroV FEN1 into the pETDuet-1 and 
pCDFDuet-1 vectors for Protein Expression Experiments                                
Refer to Section 2.2.2.1.3; Cloning only of the CroV PCNA protein into pETDuet-1 & 
pCDFDuet-1 vector backbones, containing NO affinity tags for protein purification, and 
Section 2.2.3.1.2; Cloning of the CroV FEN1 protein into pETDuet-1 & pCDFDuet-1 
vector backbones, containing NO affinity tags for protein purification).  
 
The constructs created were: 
1. pETDuet-1_CroV(CroV_219)_PCNA (Appendix A.5.1) 
2. pCDFDuet-1_CroV(CroV_219)_PCNA (Appendix A.5.2) 
3. pETDuet-1_CroV(CroV_037)_FEN1 (Appendix A.5.3) 
4. pCDFDuet-1_CroV(CroV_037)_FEN1 (Appendix A.5.4) 
 
The resulting plasmids were: 
1. Rosetta2 (DE3) (pLysS)_pETDuet-1_CroV (CroV_219)_PCNA  
2. Rosetta2 (DE3) (pLysS)_pCDFDuet-1_CroV (CroV_219)_PCNA 
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3. Rosetta2 (DE3) (pLysS)_pETDuet-1_CroV(CroV_037)_FEN1 
4. Rosetta2 (DE3) (pLysS)_pCDFDuet-1_CroV(CroV_037)_FEN1 
 
Moreover, taking advantage of the fact that these two vectors that contain the target genes 
can actually be co-transformed in the same E.coli expression strain, the following plasmids 
were also set up: 
5. Rosetta2 (DE3) (pLysS)_pETDuet-1_CroV (CroV_219)_PCNA +  
Rosetta2 (DE3) (pLysS)_pCDFDuet-1_CroV(CroV_037)_FEN1 
 
6. Rosetta2 (DE3) (pLysS)_pCDFDuet-1_CroV (CroV_219)_PCNA + 
Rosetta2 (DE3) (pLysS)_pETDuet-1_CroV(CroV_037)_FEN1 
The reason for doing the latter co-transformations was to verify any protein-protein 
interactions between the PCNA and FEN1 CroV proteins, which, according to the 
literature, are both involved in DNA replication. Specifically, they have been discovered to 
closely cooperate during this procedure, hence aiding in keeping it under control. 
 
3.3.1.1.1 Protein Expression and Purification experiments for the CroV PCNA and 
CroV FEN1 (each protein separately), cloned into the pETDuet-1 and pCDFDuet-1 
vectors and expressed in Rosetta2(DE3)(pLysS) E.coli cells  
(See Sections 2.2.2.2 and 2.2.2.3 for CroV PCNA, and Sections 2.2.3.2 and 2.2.3.3 for 
CroV FEN1) 
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First CroV PCNA and CroV FEN1 protein expression study in the pETDuet-1 and 
pCDFDuet-1  vectors: 
For this first study, small-scale preparations of the CroV PCNA/FEN1 plasmids were set 
up following standard protocols. PCNA and FEN1 protein expression was simultaneously 
induced in all diverse plasmids by the addition of IPTG reagent. The bacteria cultures were 
left to incubate at 37
o
C for 4 hours. The different range of bacteria plasmid cells were 
harvested by centrifugation and were resuspended in a PBS-based lysis buffer (Table 2.1, 
2.9 & 2.10; PBS, 100mM Tris-HCl pH8, 0.5% Tween, 1mM EDTA and 1mM β-
mercaptoethanol). The total cell extract samples from each CroV plasmid were sonicated 
and the soluble cell extracts collected for further CroV PCNA and FEN1 protein 
expression analysis. All protein samples, collected throughout the process, were run on a 
10% SDS-PAGE gel (Figure 3.13).  
 
In addition, the same exact procedure was undertaken for the 
Rosetta2(DE3)(pLysS)_pETDuet-1 and Rosetta2(DE3)(pLysS)_pCDFDuet-1 empty 
vectors, for use as controls (Figure 3.13). 
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Figure 3.13: SDS-PAGE analysis of first CroV PCNA and CroV FEN1 protein expression study in 
the pETDuet-1 and pCDFDuet-1  vectors: 10% SDS-PAGE Gel Photograph showing PCNA 
and FEN1 protein expression efficiencies and levels, for the CroV PCNA and CroV FEN1 
proteins having been both cloned into the pETDuet-1 and pCDFDuet-1 vectors, compared to 
the empty pETDuet-1 and pCDFDuet-1 vectors. All the bacteria plasmid samples were 
induced for protein expression at 37
o
C for 4 hours; The samples indicated by the red asterisk (*) 
represent the PCNA and FEN1 constructs being co-transformed with each other in the same host 
strain.  The anticipated CroV PCNA protein molecular mass was 32 kDa, and the expected CroV 
FEN1 protein molecular mass was 37 kDa (no affinity tags present). Even though, no obvious band 
could be detected for the CroV FEN1 protein at that particular molecular mass on the gel, a very 
strong and distinguishable band was produced for the CroV PCNA at roughly ~36 kDa (shown by a 
red arrow).  
Note: The prominent band (red arrow), which was present both in the ‘I’ and the ‘S’ protein 
samples, was sent for Mass Spectrometry so as to determine whether or not it is indeed the CroV 
PCNA protein. 
 
Conclusions 
The results of this experiment, even though a bit divergent, were very positive and 
optimistic. In particular, strong protein bands of the anticipated sizes were evident for quite 
* * 
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a few of the PCNA and FEN1 protein constructs utilised during the experiment. 
Specifically, strong bands were obvious for all PCNA constructs and for all the constructs 
co-expressing the PCNA and FEN1 proteins, whereas no strong protein bands could be 
detected for the FEN1 constructs. Moreover, the protein bands that were being strongly 
expressed were also present in the soluble protein samples and were of the same intensity, 
revealing that probably all the protein being expressed could be solubilised. One of these 
strong protein bands was sent for mass spectrometry to determine its true nature. The 
results of this procedure were clear and most importantly showed that the PCNA protein 
was indeed present. Specifically, when using the ProteinPilot™ software system, the 
following data was retrieved for the protein band of interest sent for MS and analysed by 
ESI: ProteinPilot Score = 96.19, when using the BMS database, and 88.04, when using the 
NCBI database, (p≤0.05), Sequence Coverage (%) = 98.9, Significant Peptides (95%) = 96 
(BMS database) and 101 (NCBI database). The results when analysing the same protein 
sample by MALDI were extremely poor. Even though these results were encouraging, the 
problem of producing high quantities of soluble and especially pure PCNA protein for use 
in additional biochemical analysis still remained, and thus the conditions of the proteins’ 
expression and solubilisation had to be further optimised. 
 
Second protein expression study only for CroV PCNA in the pETDuet-1 vector: 
A pETDuet-1_CroV(CroV_219)_PCNA plasmid was set up, following the usual protocol. 
The aim of this experiment was to test the effect various lysis buffers had on the PCNA 
protein solubility. The variety of lysis buffers used for the resuspension and sonication of 
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the harvested bacteria plasmid cells can be seen in Table 2.10. The results of the 
experiment are shown in Figure 3.14. 
 
 
 
 
Figure 3.14: SDS-PAGE analysis of second protein expression study only of CroV PCNA in the 
pETDuet-1 vector: 10% SDS-PAGE Gel Photograph showing PCNA protein expression 
efficiency and levels for the cloned pETDuet-1 CroV PCNA construct, after inducing protein 
expression at 37
o
C for 4 hours. The bacteria plasmid cells were lysed in six different buffers; 
(LB): Lysis buffer. LB 1: PBS, 0.5% Tween, 1mM EDTA and 1mM β-mercaptoethanol; LB 2: 
PBS, 0.5% Tween, 1mM EDTA and 1mM β-mercaptoethanol, 100mM Tris-HCl pH8; LB 3: 
50mM NaH2PO4 (pH 6.5, with Na2HPO4), 150 mM NaCl, 1mM EDTA and 1mM β-
mercaptoethanol; LB 4: 50mM NaH2PO4 (pH 6.5, with Na2HPO4), 150 mM NaCl, 1mM EDTA 
and 1mM β-mercaptoethanol, 0.5% Tween; LB 5: 100mM Tris-HCl pH8,  150mM NaCl, 1mM 
EDTA; LB 6: 100mM Tris-HCl pH8,  150mM NaCl, 1mM EDTA, 0.5% Tween and 1mM β-
mercaptoethanol. The anticipated CroV PCNA protein molecular mass was 32 kDa. A more 
obvious band was noticed at approximately ~36 kDa, in both the ‘I’ and ‘S’ protein samples, but no 
obvious difference was visible between the various lysis buffers used for resuspension of the 
bacteria cells.  
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Conclusions 
The aim of this experiment was to examine a number of different lysis buffers and evaluate 
their effect on the CroV PCNA proteins’ solubility efficiency. All the different lysis 
buffers chosen had the same effect on the proteins’ solubility, producing the same intensity 
protein bands. It appeared though that quite a significant amount of protein was still being 
solubilised, but this was still not adequate. The next stage of the project was to try and 
purify as much of the soluble CroV PCNA protein as possible with the use of the AKTA 
protein purifier. 
 
Third protein expression and purification study only for CroV PCNA in the 
pETDuet-1 vector (AKTA purification with HiTrap™ Q HP column): 
A pETDuet-1_CroV(CroV_219)_PCNA plasmid was set up, following the typical 
protocol. The soluble cell extract prepared from this plasmid was employed in a protein 
purification analysis using the AKTA system. The soluble cell extract had previously been 
resuspended in Lysis Buffer W (Table 2.1 & 2.9; 100mM Tris-HCl pH7.5, 150mM NaCl, 
0.5% Tween, 1mM EDTA and 1mM β-mercaptoethanol). This was directly loaded onto a 
Hi-Trap™ Q HP column, which interacts and binds negatively charged proteins. Protein 
elutions were assessed by performing a gradient purification of salt (NaCl) concentrations, 
ranging from 150mM to 1M. For the exact protocol see Section 2.2.2.4.4; Protein 
Purification Experiments for CroV PCNA using an AKTA system. The samples collected 
were run on a 10% SDS-PAGE gel, but only the important SDS-PAGE gel photographs 
are shown here (Figure 3.15).  
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Figure 3.15: SDS-PAGE analysis of third protein expression and purification study only of CroV 
PCNA in the pETDuet-1 vector (AKTA purification with HiTrap™ Q HP column): 10% SDS-
PAGE Gel Photograph showing PCNA protein purification efficacy for the cloned pETDuet-
1 CroV PCNA construct, after inducing protein expression at 37
o
C for 4 hours. The soluble 
protein extract was filtered through a Hi-Trap™ Q HP column on the AKTA system; (I): 
induced. Lysis Buffers: 100mM Tris-HCl pH7.5, 150mM  1M NaCl, 0.5% Tween, 1mM EDTA 
and 1mM β-mercaptoethanol. Two separate buffers were made up so as to conduct a gradient 
purification; one buffer contained 150mM NaCl, while the second one contained 1M NaCl. An 
incredibly prominent band was visible at roughly ~36 kDa in some of the eluted protein samples 
(illustrated by the red arrow).  
Note: One of the bands represented by the red arrows was sent for Mass Spectrometry, to 
determine whether or not it is the CroV PCNA protein. 
 
Conclusions 
The result of this experiment was in general very positive, even though the CroV PCNA 
protein could not be greatly purified. More specifically, the PCNA protein was still being 
expressed and somewhat soluble, but when attempting to purify it did not emerge in a very 
pure form, i.e. it was eluted from the column together with a variety of other proteins, thus 
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making it difficult to isolate. In addition, this experiment verified that under certain 
conditions, and when employing certain elution buffers, greater amounts of PCNA protein 
were eluted. Additional attempts to purify the protein would have resulted in losing a 
significant amount of protein. One of the distinct protein bands was once again sent for 
mass spectrometry analysis. The results however were not as good a quality as anticipated. 
Specifically, when using the ProteinPilot™ software system, the following data was 
retrieved for the protein band of interest analysed by ESI: ProteinPilot Score = 6 (p≤0.05), 
Sequence Coverage (%) = 21.2, Significant Peptides (95%) = 5; the data was the same 
when compared against both the NCBI and BMS protein databases. These results were 
unexpected due to the original protein band size and intensity produced on the SDS-PAGE 
gel, a fact which meant that the PCNA protein could not be easily purified and isolated 
from other proteins. Following this experiment, all efforts were focused on trying to isolate 
the PCNA protein with the help of its FEN1 protein partner. 
 
3.3.1.1.2 Summary of Results 
In general, this set of experiments produced the most positive and optimistic results found 
during the course of this project. Initially, it was established that the new vectors, which 
lacked protein tags and were used to clone both the CroV PCNA and FEN1 proteins, 
produced higher-quality results in comparison to all previous vectors used. Therefore, the 
hypothesis that the presence of protein tags may in fact obscure the proteins structure may 
be to some extent correct. Additionally, from the first protein expression experiment it was 
apparent that most of the anticipated PCNA protein being expressed may also have been 
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soluble. The second protein expression experiment confirmed that the use of different lysis 
buffers for protein resuspension did not affect the proteins’ solubility, as all samples 
produced the same protein band pattern of the same intensity. Finally, the protein 
purification study demonstrated that even though a good amount of the CroV PCNA 
protein could be eluted from the column under certain conditions, this was not pure and 
hence could not be easily isolated for use in additional biochemical analysis. For two of the 
experiments mentioned, the presence of the expected CroV PCNA protein was verified by 
mass spectrometry analysis, however only for the first experiment can we be 100% 
confident for the proteins’ presence. 
 
3.3.1.1.3 Protein Expression and Purification experiments for the CroV PCNA and 
FEN1 (both proteins together), cloned into the pETDuet-1 and pCDFDuet-1 vectors 
and expressed in Rosetta2(DE3)(pLysS) E.coli cells  
Refer to Section 2.2.1.5;PCNA/FEN1 Protein Purification experiments using an AKTA 
system. 
 
First simultaneous CroV PCNA and FEN1 protein purification study in the 
pETDuet-1 and pCDFDuet-1  vectors (AKTA purification with Heparin HP Trap™ 
column): 
In this part of the study, one of the co-transformed CroV PCNA and FEN1 plasmid 
samples, that produced the extra protein band at ~36 kDa  (as seen in Figure 3.13), was 
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obtained for the purpose of conducting the very first simultaneous PCNA and FEN1 
protein purification experiment. In particular, the plasmid chosen was the “Rosetta2 (DE3) 
(pLysS)_pETDuet-1_CroV (CroV_219)_PCNA + Rosetta2 (DE3) (pLysS)_pCDFDuet-
1_CroV (CroV_037)_FEN1”.  
 
Purification methodologies for this sample on the AKTA system, would allow the 
determination of any protein-protein interactions. By using particular protein trapping 
columns, a two-way interaction could possibly form, with the one protein binding onto the 
actual column while the second protein interacting and binding to the already bound first 
protein (if a protein-protein interaction does actually occur). Then the two proteins would 
detach from the column and elute together. At the same time, it could be hypothesised that 
by co-transfecting the two different proteins, each one might have an effect on the protein 
expression efficiency and levels, but also on the purification purity, of the other. 
 
The soluble cell extract prepared from the plasmid mentioned above, expressing both CroV 
PCNA and FEN1 proteins, was thus employed in a protein purification analysis using the 
AKTA system. The soluble cell extract had previously been resuspended in the PBS-based 
lysis buffer (Table 2.1, 2.9 & 2.10; PBS (usually contains 150mM NaCl), 100mM Tris-HCl 
pH8, 0.5% Tween, 1mM EDTA and 1mM β-mercaptoethanol). This was loaded directly 
onto a Heparin HP Trap™ column, as this type of column is effective in binding proteins 
that interact with DNA. Therefore, the general hypothesis was that this column would 
allow the PCNA to bind to it through a FEN1 intermediate interaction (presuming that the 
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PCNA protein interacts with the FEN1 protein). More precisely, the FEN1 protein would 
presumably bind directly to the column, while the PCNA protein would also bind by 
forming a secondary interaction with the FEN1 protein, or vice versa. Eventually the two 
proteins would detach from the column and elute in the same fraction(s). Protein elutions 
were assessed by performing a gradient purification of salt (NaCl) concentrations, ranging 
from 150mM to 2M. The samples of interest were run on a 10% SDS-PAGE gel (Figure 
3.16).  
 
 
Figure 3.16: SDS-PAGE analysis of first simultaneous CroV PCNA and FEN1 protein purification 
study in the pETDuet-1 and pCDFDuet-1 vectors (AKTA purification with Heparin HP Trap™ 
column): 10% SDS-PAGE Gel Photograph showing PCNA and FEN1 protein purification 
efficacy for the co-transformed pETDuet-1 CroV PCNA and pCDFDuet-1 CroV FEN1 
constructs. The soluble protein extract was filtered through a Heparin HP Trap™ column on 
the AKTA system for simultaneous PCNA/FEN1 protein purification; Lysis Buffers: PBS 
(150mM NaCl  2M NaCl), 100mM Tris-HCl pH8, 0.5% Tween, 1mM EDTA and 1mM β-
mercaptoethanol. Two separate buffers were made up so as to conduct a gradient purification; one 
buffer already containing 150mM NaCl (amount present in all PBS-based buffers) and a second 
one containing a further ~2M NaCl. The soluble protein sample (red asterisk) utilised, as well as 
the (U): uninduced and (I): induced, can be seen in Figure 3.13.  
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3.3.1.1.4 Summary of Results 
For the purpose of this experiment, a strain co-expressing the PCNA and FEN1 proteins was 
used. Protein expression was induced and the resulting sample was directly utilised in an 
AKTA purification experiment. However, the assumption that the two proteins would bond by 
forming an interaction between them and also with the particular column, and hence elute 
together under certain conditions did not take place. No noticeable bands could be detected 
for either the PCNA or the FEN1 CroV protein, throughout the gradient AKTA purification. 
Some further CroV PCNA protein purification experiments were attempted next. 
 
3.4 Additional Trials of Protein Purification Experiments 
3.4.1  Protein Purification experiments for the CroV PCNA, cloned into the 
pETDuet-1 vector and expressed in Rosetta2(DE3)(pLysS) E.coli cells  
Refer to Section 2.2.2.4.3; EZview™ Red Streptavidin pull-down of CroV PCNA 
Solubilised protein sample, with the use of EZview™ Red Streptavidin affinity agarose gel 
beads and the help of a Fen1 peptide (only for the pETDuet-1 PCNA construct). 
 
First CroV PCNA protein purification study in the pETDuet-1 vector (first EZview™ 
red streptavidin affinity agarose gel bead purification attempt): 
A small-scale preparation of the pETDuet-1_CroV (CroV_219)_PCNA plasmid was set 
up, following standard techniques. The bacteria culture was induced for PCNA protein 
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expression at 37
o
C for 4 hours. The bacteria plasmid cells were harvested and were 
resuspended in the usual PBS-based lysis buffer (Table 2.1, 2.9 & 2.10; PBS, 100mM Tris-
HCl pH8, 0.5% Tween, 1mM EDTA and 1mM β-mercaptoethanol). The total cell extract 
sample was sonicated and the soluble cell extract sample collected for further CroV PCNA 
protein purification analysis. In addition, the exact same procedure was undertaken for the 
pETDuet-1 empty vector, for use as a control sample.   
 
In this part of the project, CroV PCNA protein purification was attempted by a slightly 
different streptavidin pull-down protocol. The completion of this technique required the 
use of a biotinylated Fen1 peptide, as well as EZview™ red streptavidin affinity agarose 
gel beads. The Fen1 peptide specifically included a putative PCNA-interacting peptide 
(PIP) box motif sequence (i.e. N--I--LL). The hypothesis was that the Fen1 peptide could 
possibly bind to and interact with the PCNA protein through the specific PIP-box 
recognition sequence. Once an interaction between the peptide and the protein was formed, 
then the Fen1-PCNA complex could be pulled-down from the soluble E.coli cell extract by 
the EZview™ Red Streptavidin affinity agarose gel beads, which attract and attach to 
biotinylated targets.  
 
For this purpose, the soluble cell extract, corresponding to either the control pETDuet-1 or 
the pETDuet-1_CroV (CroV_219)_PCNA plasmid, was further divided into two soluble 
cell extract samples of equal volumes; one sample was incubated with the Fen1 peptide to 
allow potential interaction with the PCNA protein, while the other one was once again 
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used as a control (no Fen1 peptide added). All samples, even the controls, were incubated 
with the EZview™ red streptavidin affinity agarose gel beads and washed a few times with 
the PBS-based buffer used for lysing the bacteria cells. The pull-down protein samples 
were checked for successful CroV PCNA protein purification by being run on a 10% SDS-
PAGE gel (Figure 3.17). 
 
.  
Figure 3.17: SDS-PAGE analysis of first CroV PCNA protein purification study in the pETDuet-1 
vector (first EZview™ red streptavidin affinity agarose gel bead purification attempt): 10% SDS-
PAGE Gel Photograph showing PCNA protein purification efficacy for the cloned pETDuet-
1 CroV PCNA construct, compared to the empty pETDuet-1 vector. The soluble protein 
extracts were used to perform a EZview™ red streptavidin affinity agarose gel bead pull-
down, with the intermediate assistance of a Fen1 peptide. Both bacteria plasmid samples 
were induced for protein expression at 37
o
C for 4 hours; An extra band was indeed noticeable 
in the ‘I’ sample of the pETDuet-1_CroV_PCNA construct but it appeared to have a molecular 
weight higher (~36 kDa) than what anticipated (~32 kDa). Nevertheless, the PCNA streptavidin 
purification with the Fen1 peptide did not appear to have worked.   
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Conclusions 
This experiment unfortunately did not produce significant results, apart from the fact that a 
protein band of the anticipated size, for the PCNA protein, was slightly being expressed 
but could not be purified. Therefore, the hypothesis that the PCNA protein can be purified 
and isolated with the help of a Fen1 intermediate peptide may not be plausible, specifically 
under the conditions chosen. Nevertheless, an additional attempt was made to isolate the 
PCNA protein in this manner.  
 
Second CroV PCNA protein purification study in the pETDuet-1 vector (second 
EZview™ red streptavidin affinity agarose gel bead purification attempt): 
A pETDuet-1_CroV(CroV_219)_PCNA plasmid was set up as usual. However, the 
bacteria cells once harvested were resuspended in different lysis buffers, instead of the 
typical PBS-based buffer. The lysis buffers chosen for this procedure were all Phosphate-
based, but each one was made up to a different salt NaCl concentration (ranging from no to 
300mM NaCl; x3 salt concentrations) and was also measured to a different pH (ranging 
from pH 6.5 to pH 8.5; x3 pHs) [See table 2.1 & 2.9; 50mM NaH2PO4 (pH 6.5/ 7.5/ 8.5, 
calibrated with Na2HPO4), 0/ 150/ 300 mM NaCl, 1mM EDTA and 1mM β-
mercaptoethanol]. This resulted in an overall of nine different total cell extract samples, 
due to the diverse combination of lysis buffers prepared. The soluble cell extracts collected 
were used in an EZview™ red streptavidin affinity agarose gel bead pull-down PCNA 
purification experiment, assisted by the intermediate biotinylated Fen1 peptide (as 
described beforehand).  
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No SDS-PAGE gel photograph has been attached as the streptavidin pull-down of the 
PCNA soluble cell extract samples once more did not work. Only unspecific proteins were 
purified. However, the extra band running at ~36 kDa, presumed to be the PCNA protein, 
was still present in the ‘I’nduced protein samples (same as previously seen in Figure 3.15). 
It should be noted though that the different lysis buffers applied had no distinguishable 
variation in their effect on the PCNA protein solubility. 
 
Conclusions 
During this experiment a variety of different lysis buffers were tested and their effect on 
the CroV PCNA proteins’ solubility evaluated. The outcome was the same as previously, 
even though a protein band was being expressed at the anticipated size, no protein of 
interest could be purified. Moreover, the different buffers did not have a noticeable 
difference on the PCNA proteins’ solubility. 
 
3.4.2 Summary of Results 
In this part of the project, purification of the CroV PCNA protein was attempted with the 
use of a Fen1 peptide, hypothesised to interact through a PIP-box domain with the PCNA 
protein. This assumption, however, could not be proven as no PCNA protein could actually 
be purified and isolated, not even when employing a number of different lysis buffers for 
protein solubilisation. In conclusion, PCNA protein purification and isolation with the help 
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of intermediate proteins and peptides has proven to be very difficult, if not impossible, 
under the conditions employed during the course of this project. 
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-CHAPTER FOUR-  
 
Discussion 
 
4.1 Results of this study  
The aim of this study was to perform a thorough biomolecular and biochemical 
investigation on the DNA replication machinery of the giant viruses Mimivirus, 
Marseillevirus and CroV. In particular, two key viral proteins involved in this fundamental 
procedure were taken into consideration; the PCNA sliding clamp and the FEN1 
endonuclease. The main purpose of this project was to examine the properties and 
functions of these two vital DNA replicatory components. Upon completion of this study, 
it was anticipated that it would have generally been possible to gain a better understanding 
on the life-cycle of these viruses, which, during the course of history, have somehow 
acquired an enormous amount of genetic information granting them such a huge size that 
they cannot actually pass unnoticed. Therefore, to achieve the original goal set, a series of 
different protein expression protocols were undertaken; initially by cloning the synthetic 
PCNA genes encoded by the Mimivirus, Marseillevirus and CroV, and the synthetic FEN1 
gene encoded only by the CroV, into a collection of suitable expression vectors and then 
expressing these into a range of E.coli host expression strains. In the final stages of the 
project, a few trial protein purification methods were attempted.  
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For the first part of this study; the synthetic PCNA genes encoded by the Mimivirus, 
Marseillevirus and CroV, and the synthetic FEN1 gene encoded only by the CroV, were 
cloned into a variety of expression vectors containing a specific tag. Cloning the gene of 
interest into a tagged-vector is usually extremely helpful, as it allows for easy and simple 
protein purification, while sometimes the presence of a tag may also increase the efficiency 
of the protein expression conferring larger amounts of the particular protein.  
 
First of all, the Mimivirus, Marseillevirus and CroV PCNA synthetic genes were cloned 
into a pASK-IBA17plus vector backbone. This vector had been supplied by its 
manufacturer with a Strep-tag, which permits protein purification with the use of 
streptavidin beads. When a correct clone had been established for all three organisms, 
these were next expressed in a Rosetta2(DE3)(pLysS) E.coli host strain; a strain that offers 
enhanced protein expression levels, as stated by the producer.  
 
The samples collected from an initial protein expression experiment were run on a simple 
SDS-PAGE gel (Figure 3.1); the results did not reveal a great difference between the 
protein expression patterns for the Mimivirus, Marseillevirus and CroV, while additionally 
a very distinct band running at ~ 35 kDa (i.e. expected PCNA protein molecular mass) 
could not be observed for either of the organisms. However, a slightly more noticeable 
band was seen for the Marseillevirus and this was estimated to be running at approximately 
34 kDa. This suggested that the specific band may have possibly represented the PCNA 
protein; but this information was not convincingly positive. This band, nonetheless, was 
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only present in the protein induced sample and not in the soluble fraction, indicating that 
the protein if present might have been completely insoluble. The best way to increase a 
proteins’ solubility, apart from changing the conditions under which protein expression is 
performed, is by modifying the lysis buffers in which it is resuspended for protein 
extraction. Different amounts or concentrations of reagents within a lysis buffer can have 
varying results on a proteins’ expression and solubility. Therefore, a next step in the 
experimental plan could have been to try out different lysis buffers containing varying 
amounts of the appropriate reagents. 
 
The fact that no expression was obtained for the Mimivirus and CroV PCNA protein, while 
only a small (if any) was obtained for the Marseillevirus, primarily hinted towards the fact 
that maybe the protein expression conditions (i.e. growth temperatures and time periods) 
were not optimised. It is a well known fact that different proteins require different 
conditions for their proper growth and competent expression; even the precise same protein 
found in diverse organisms will require different growth and expression conditions. 
Therefore, a next step during the experimental plan would have been to test other protein 
expression conditions, hoping to determine the right conditions that would allow for more 
efficient and greater PCNA protein expression, separately for the Mimivirus, 
Marseillevirus and CroV. 
 
Before proceeding to test other protein expression conditions, however, a Western blot was 
performed for the Mimivirus, Marseillevirus and CroV PCNA protein using the same 
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samples previously run on the SDS-PAGE gel. The viral PCNA proteins were detected by 
incubating the samples of interest with Strep-Tactin™ horse radish peroxidase (HRP) 
conjugate, in a one-step protein detection process. The outcome of this procedure would 
determine whether or not PCNA protein expression was indeed present or absent; this 
process failed to expose the presence of any PCNA protein expression for the Mimivirus 
and the Marseillevirus, although for the latter it was hypothesised that PCNA expression 
had been produced to an extremely low level during the protein expression experimental 
procedure. This led to the belief that maybe, to some extent, it was quite possible that there 
was either something wrong with the vector used or, even if the vector was not 
problematic, then maybe there was a problem with the Strep-tag. It has previously been 
reported that the presence of a tag may have a bad effect on the protein of interest basically 
by obscuring its confirmation and folding. Additionally, the Strep-tag may itself have an 
altered confirmation thus somehow being concealed within the PCNA protein structure; 
this would mean that it would remain undetectable from any antibodies or beads. 
Nonetheless, a chumiluminescence signal was generated for the CroV PCNA protein, 
demonstrating a particularly high level of protein expression (molecular mass ~ 34 kDa), 
but unfortunately the protein was not greatly soluble (Figure 3.7). 
 
Consequently, after taking into serious considerations the results obtained from the 
Western blot, it was decided: A) First of all, not to continue with the pASK-IBA17plus 
Mimivirus PCNA construct. B) Secondly, to continue with the pASK-IBA17plus 
Marseillevirus PCNA construct, as on the SDS-PAGE gel performed a tiny amount of what 
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was thought to be the PCNA protein was noticeable, and therefore the plan was to test a 
range of protein expression conditions so as to hopefully increase PCNA protein 
expression efficacy (Figure 3.4). However, the diverse growth conditions chosen did not 
appear to have any noticeable effect on the PCNA protein expression, as seen when the 
protein samples were run on an SDS-PAGE gel, where no difference could basically be 
identified between them. These samples were also run on a Western blot hoping to acquire 
more distinguishable results (Figure 3.5); this method demonstrated that the Marseillevirus 
PCNA protein was indeed being expressed (molecular mass of ~ 34 kDa) in all conditions 
selected, but some of the conditions (i.e. higher temperatures) did certainly seem to have a 
greater effect on its expression than others. The best experimental conditions were selected 
so as to perform another protein expression experiment this time attempting to increase the 
Marseillevirus PCNA proteins’ solubility, thus miscellaneous lysis buffers were tested. The 
resulting protein samples were once again run on a Western blot (Figure 3.6). The various 
buffers were shown to have a diverse effect on the PCNA expression; some being 
responsible for improved and generally a greater level of protein expression (i.e. buffers 
containing double the amount of salt than usual, as well as considerably more detergent), 
while others were rather insufficient. C) Finally, it was decided to continue experiments 
with the pASK-IBA17plus CroV PCNA construct, as PCNA protein expression was 
confirmed but the proteins’ solubility had to be largely improved. For this purpose, a wide 
variety of growth conditions and lysis buffers were checked. The resulting protein samples 
were run on a Western blot, where CroV PCNA expression appeared to be prominent with 
an obvious band running at ~34 kDa (no data shown). In general terms, it can be stated that 
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lower temperatures gave more satisfactory results, while the various lysis buffers did not 
seem to greatly affect the protein expression levels. 
 
After extensively trying to gain good quality PCNA expression from the pASK-IBA17plus 
Mimivirus, Marseillevirus and CroV constructs, eventually the Mimivirus, Marseillevirus 
and CroV PCNA synthetic genes were cloned into another vector containing a different 
tag. By performing this procedure it was anticipated that more efficient PCNA protein 
expression would be achieved, mainly due to the different tag that would be present. The 
vector chosen specifically was the pEHISTEV, which contains a 6xHis-tag. The 6xHis-tag 
allows for protein purification with the use of Ni-NTA agarose beads. The approved 
Mimivirus, Marseillevirus and CroV clones were expressed once again in the 
Rosetta2(DE3)(pLysS) host strain. 
 
The samples collected from this experimental protocol were run on a SDS-PAGE gel for 
PCNA protein expression confirmation (Figures 3.2 & 3.3). This time both the soluble and 
insoluble protein samples were examined, revealing that the Marseillevirus and CroV 
PCNA proteins, even though expressed at around ~ 35 kDa, were not exceptionally 
soluble. Nevertheless, a one-step Ni-NTA bead pull-down was performed for all the 
soluble Mimivirus, Marseillevirus and CroV PCNA fractions displaying that only for the 
CroV quite a large amount of what was considered to be the PCNA protein could be 
isolated but not in an incredibly pure form. This meant that, even though some CroV 
PCNA protein was found in the insoluble samples, still quite a significant amount of the 
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protein seemed to be purifiable. To increase the proteins purity a solution would have been 
to carry out multiple steps of the Ni-NTA pull-down, but unfortunately this solution would 
also have a negative effect, considering that after every purification step a significant 
amount of the desirable protein would have been lost. Concerning the Marseillevirus 
PCNA protein, no protein was actually pulled-down with the use of the Ni-NTA beads, 
meaning that the protein was probably all in the insoluble fraction.  
 
After these results, two decisions were reached; a) As no results whatsoever could be 
produced for the Mimivirus PCNA protein, and the low level of PCNA protein that was 
expressed for the Marseillevirus was apparently insoluble in every condition tested, thus 
research on the PCNA protein in these two virus would be aborted; and b) The PCNA 
protein expression trials for the CroV would be continued, because for this virus PCNA 
expression was the most efficient of all. 
 
As a consequence, following this, an even greater assortment of growth conditions and 
lysis buffers were investigated and analysed for the CroV PCNA (Figures 3.9). The 
general results were similar to those established for the pASK-IBA17plus CroV PCNA 
construct; even though some protein expression conditions had a somewhat notable effect 
on the PCNA protein expression, others had an insignificant effect on it. Moreover, not a 
huge difference could be detected between the data obtained from all the varying 
conditions, while in all cases the levels of protein expression were still considerably low. 
So it had become fairly obvious that no matter what protein expression conditions were 
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chosen, the PCNA expression was still not optimal. By this point, the solutions and options 
for optimising the CroV PCNA protein expression were becoming quite scarce; different 
vectors containing diverse tags were tested, a large variety of protein expression conditions 
had been examined and an even greater range of lysis buffers had been checked. The 
question needing to be answered was ‘what was the real problem causing the PCNA 
protein to be expressing so poorly?’. 
 
Some PCNA protein purification trials were also performed, mainly to check two things: a) 
if the PCNA could actually be purified (i.e. if the 6xHis-tag was not hidden within the 
PCNA protein structure and hence undetectable by the Ni-NTA agarose beads), and b) if 
the PCNA could indeed be purified, how pure was it and how much of it was actually 
being generated that could eventually be used in further biomolecular and biochemical 
analysis.  
 
For the first protein purification trial a soluble fraction of the CroV PCNA was manually 
filtered through a column packed with Ni-NTA beads; different buffers were utilised for 
lysing and eluting the protein sample. The result of this trial was run on a SDS-PAGE gel 
(no data shown), which illustrated that although the PCNA protein was being expressed it 
was directly coming off the column in the ‘flow-through’ sample. A very similar outcome 
was also verified when another soluble CroV PCNA protein sample was automatically 
filtered through a His-trap column on an AKTA system (no data shown). This principally 
meant that the protein was not binding to the Ni-NTA beads, further suggesting that the 
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6xHis-tag was either problematic or concealed within the PCNA protein structure. In 
addition, it could also imply that the tag had been cleaved off the actual protein structure. 
The 6xHis-tag is quite small so it could not easily be identified if cleaved off the protein 
structure. 
 
A second purification trial, however, did produce an evident band at around ~ 35 kDa that 
was believed to be the PCNA protein (Figure 3.8). In addition, this procedure seemed to 
accomplish a rather high degree of protein purity. This band was sent for mass 
spectrometry to confirm its nature. As a result, the presence of the CroV PCNA was 
confirmed, but only at a low level hence not permitting further biochemical analysis. As 
such, even though this purification experiment was considered successful in that it finally 
allowed us to identify the presence of the CroV PCNA, the fact, however, that the actual 
protein could only be purified and isolated in very low levels meant that the procedure 
required again further optimisation steps. Therefore, as time was running short, it was 
decided against trying to optimise the conditions of this protocol, but rather move on to 
new protein expression optimisation experiments hoping to get better quality results much 
faster, i.e. higher levels of purified CroV PCNA protein enough to perform a number of 
further biochemical analysis.  
 
The bacteria colonies and cultures grown and used throughout this project were in all 
circumstances considered fresh, as they were not more than five days to a week old. 
However, in regards to the experiment just discussed, fresh bacteria transformations into 
[202] 
 
E.coli cells for both the CroV PCNA construct and the empty vector, used as a negative 
control, were performed on the day the specific experiment was initiated. Thus, the fresh 
bacteria cultures that were grown, which were only a day old, could have had a more 
efficient and enhanced protein expression level, justifying the positive results of this 
experiment. In addition, all reagents and solutions prepared and applied throughout this 
experiment were also fresh, having been prepared on the day. This could also be a possible 
explanation as to why this experiment worked more optimally compared to previous ones. 
 
Following these protein purification trials, it was thought that maybe expressing the PCNA 
protein in various other E.coli host expression strains would possibly help to improve the 
effectiveness of the CroV PCNAs’ expression levels. Therefore, once the CroV PCNA was 
expressed in a careful choice of E.coli host expression strains (each one of these strains 
being able to enhance protein expression efficiencies in a different way to the other), the 
plasmids generated were used in a number of protein expression trials. Once more, 
different protein expression conditions were studied.  
 
The results acquired from the first such protein expression experiment demonstrated that 
the previous assumption made was in fact wrong; specifically, expressing the CroV PCNA 
in the different E.coli host strains had no effect whatsoever on the PCNA protein 
expression levels or efficiency. At the same time, it was fairly difficult to detect any kind 
of expression for the PCNA protein, as the band pattern of expressed proteins generated 
was similar for all plasmids (no data shown). However, when the same CroV PCNA 
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plasmids were grown at much lower temperatures, a somewhat greater effect on their 
PCNA protein expression levels could be detected, but still this was not considered to be of 
major significance. 
 
At this point in the project, a second key protein involved in DNA replication was 
introduced into the study. This was FEN1 and it was only studied in CroV. The CroV 
FEN1 synthetic gene was initially cloned into the pEHISTEV vector, while the equivalent 
pEHISGFPTEV vector was also selected so as to check its efficacy and compare it to the 
previous one. The pEHISGFPTEV vector, apart from containing the 6xHis-tag, it 
additionally contains a GFP-tag. It was assumed that by increasing the overall molecular 
mass of the protein under investigation, maybe it would either prevent it from misfolding 
(if that was a cause for the poor protein expressions achieved so far), or due to the presence 
of two tags, one of which was quite considerable in size, maybe it would have been 
impossible for them to become concealed within the protein structure hence allowing them 
to be detectable by the binding substrate. The correctly checked CroV FEN1 clones were 
expressed in the Rosetta2(DE3)(pLysS) host expression strain.  
 
The FEN1 protein samples collected from some of the earlier protein expression trials were 
run on a SDS-PAGE gel (Figure 3.10). As usual, exceptionally distinguishable bands were 
not observed either for the pEHISTEV CroV FEN1 construct or for the pEHISGFPTEV 
CroV FEN1 construct. Nevertheless, a slightly more visible band was seen for the 
pEHISTEV CroV FEN1 construct running approximately at the expected molecular mass 
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(~ 37 kDa), but it was not certain whether or not it did represent the FEN1 protein. The 
band was only noticeably present in the expression induced protein sample, while it was 
not obviously present either in the soluble or in the insoluble fractions. To obtain a clearer 
picture of these results the exact same samples were run on a Western blot (Figure 3.11), 
during which the target proteins were detected by incubating the blocked membrane with 
an initial anti-HIS mouse monoclonal antibody further targeted by a secondary anti-mouse 
antibody. In the case of the pEHISTEV CroV FEN1 construct the outcome was as 
expected; some FEN1 protein was being expressed but it could not be identified in either 
the soluble or the insoluble sample, which further suggested that it was somehow lost from 
the total protein sample or it may have degraded drastically over time. On the other hand, 
in the case of the pEHISGFPTEV CroV FEN1 construct the results were rather 
unexpected; it appeared as if the HIS-GFP-tag (~28 kDa) had been completely cleaved off 
the FEN1 protein structure, as two different protein fragments of an approximate ~ 35-40 
kDa molecular mass were running one right below the other, and were only seen in the 
original protein sample were expression had been induced. Maybe the presence of protease 
enzymes could have been the reason for this outcome, as during all protein expression 
procedures no protease inhibitors were dialysed in the lysis buffers used. 
 
Following these results, it was decided that: a) the research on the CroV FEN1 protein 
cloned into the pEHISGFPTEV vector would be terminated, as it became obvious that no 
correct results could be generated, while b) the FEN1 protein expression trials for the CroV 
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cloned into the pEHISTEV vector would be continued, this time analysing various protein 
expression conditions. 
 
For the first such trial, a number of different lysis buffers were examined. However, when 
the protein samples were run on a SDS-PAGE gel (Figure 3.12), no noticeable difference 
could be seen in the protein expression patterns created between the control and the 
plasmid of interest, around the region on the gel corresponding to 37 kDa. Therefore, so as 
not to waste any time, it was concluded that the FEN1 protein would be expressed in a 
range of E.coli host strains (similarly to the CroV PCNA protein), hoping once again to 
elevate the CroV FEN1 protein expression efficiency and levels. When the FEN1 protein 
expressions were completed and the various plasmids created, additional protein 
expression trials were commenced. These resulted in the knowledge that expressing the 
CroV FEN1 in the different E.coli host strains has no effect whatsoever on the FEN1 
protein expression efficiency or levels, while at the same time no FEN1 protein expression 
could be detected altogether (likewise to the CroV PCNA protein expression process). On 
growing similar CroV FEN1 plasmid samples but at much lower temperatures than the 
ones usually chosen, a somewhat greater effect on the FEN1 protein expression levels 
could be seen (no data shown). This, however, was not considered to be of major 
importance. 
 
For the second part of this study; both the synthetic PCNA and FEN1 genes encoded by the 
CroV were cloned into two specific expression vectors. These vectors differed from the 
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previous ones used in that they did not contain any sort of tag. This protocol was carried 
out so as to validate whether or not the presence of the tag in all the formerly described 
experiments was the reason for the extremely poor PCNA and FEN1 protein expression 
levels and efficiency. Furthermore, these vectors are a good choice for studying protein-
protein interactions, for two basic reasons: a) Firstly, they permit cloning of two different 
proteins in the same vector backbone, and b) Secondly, they allow co-expression of two 
different proteins in the same host expression strain, even if the two proteins have not been 
cloned in exactly the same but equivalent vectors. 
 
In particular, the vectors mentioned were the pETDuet-1 and the pCDFDuet-1. Once the 
PCNA and FEN1 synthetic genes were cloned into these vectors, they were then expressed 
once more into the Rosetta2(DE3)(pLysS) E.coli host expression strain. This was the very 
first experimental procedure that unexpectedly provided the most distinctive and best 
quality results, proving the hypothesis already stated. 
 
The protein samples collected during this method were all run on a SDS-PAGE gel (Figure 
3.13). Surprisingly, exceptionally clear protein bands were visible for both the CroV 
PCNA and FEN1 proteins. These bands could easily be detected in both the total protein 
samples, as well as the soluble samples. Thus, it could positively be stated that the CroV 
PCNA and FEN1 proteins were being favourably expressed and in fact they were also 
highly soluble. Mass spectrometry also confirmed the presence of the CroV PCNA protein 
(FEN1 was not sent for mass spectrometry), in an incredibly high level. This information, 
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however, confirmed that the previous presence of an affinity tag somehow modified the 
proteins of interest resulting in the production of reduced expression levels and poor 
expression efficiencies. 
 
Subsequent to these results and as there was little experimental time available, it was 
considered best to focus all the experimental efforts only on the CroV PCNA protein, 
expressed in the ‘no-tag’ vectors, as it was also the original protein of interest. The 
following protein expression trial aimed to examine whether or not the PCNA protein 
expression level and efficiency could be improved when lysing the cells in a mixture of 
buffers. The resulting CroV PCNA protein samples were run on a SDS-PAGE gel (Figure 
3.14), where the PCNA and FEN1 protein bands of interest were still present. 
Nevertheless, the outcome depicted, not only that there was no difference in protein 
expression between the diverse lysis buffers utilised, but on the contrary it was determined 
that the lysis buffers used, in reality, slightly decreased the CroV PCNA protein 
expression, for yet unknown reasons. So for follow-up procedures the original buffer was 
used. 
 
In the next part of the project, a CroV PCNA protein purification trial was undertaken, for 
similar reasons as stated above. The soluble fraction of the CroV PCNA was automatically 
filtered through a HiTrap Q (anion) column on the AKTA system; different buffers were 
utilised for lysing and eluting the protein samples. The protocol specifically carried out 
was a gradient of salt concentrations trying to determine exactly at what salt concentration 
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the CroV PCNA protein elutes from the column. The choice of the column itself was due 
to the fact that, first of all, there was no tag present so a column with an affinity towards a 
specific binding substrate would have been utterly useless, and secondly, the PCNA 
protein is by nature negatively charged so it should supposedly bind to such an anion 
column. The results of this purification trial were run on a SDS-PAGE gel (Figure 3.15); 
they illustrated that an apparently significant amount of CroV PCNA protein was 
expressed and this was clearly eluting from the column at approximately ~ 350mM of salt. 
Therefore, the HiTrap Q column seemed to have a high affinity for the protein. However, it 
was also thought that maybe much smaller amounts corresponding to the PCNA protein 
were in fact eluting throughout the elution protocol hence causing what could be 
considered as a significant loss of protein. The presence of the CroV PCNA protein was 
validated by mass spectrometry. 
 
Subsequently, a relatively unusual CroV PCNA protein purification procedure was 
performed (Section 3.4.1); a soluble CroV PCNA protein fraction was attempted to be 
purified by another streptavidin pull-down protocol. For this particular purification 
procedure the most important component utilised was an intermediate biotinylated Fen1 
peptide containing a specific PIP-box motif (i.e. N--I--LL). This Fen1 peptide sequence 
was particularly designed to match the last 20 aa of the CroV FEN1 protein, hence also 
containing the corresponding PIP-box domain. It was presumed that the presence of this 
oligopeptide would assist interaction and hence form a complex with the PCNA protein; 
this would supposedly be achieved by the PCNA protein through specific recognition of 
[209] 
 
and binding to the PIP-box motif of the Fen1 peptide. If such an interaction between the 
Fen1 peptide and the PCNA protein was accomplished, then hypothetically the PCNA 
protein could be pulled-down and purified from the soluble cell extract by specific 
streptavidin gel beads (i.e. EZview™ Red Streptavidin affinity gel beads), which are very 
competent in recognising and binding to biotinylated proteins (in this case the Fen1 
oligopeptide, which will expectantly be carrying along with it the PCNA protein). The 
resulting samples from this Fen1/PCNA co-purification trial were run on an SDS-PAGE 
gel (Figure 3.17). The outcome, however, was not as positive as expected; although a 
rather distinguishable band presumably representing the CroV PCNA protein was observed 
(this band could not be noticed in the equivalent control sample, thus the assumption that it 
must be the CroV PCNA protein), this was only present in fairly low amounts in the total 
protein extract (no protein of the anticipated molecular mass was visible in the soluble 
protein extract). Generally, very few protein bands were illustrated on the SDS-PAGE gel 
for the soluble protein extract, suggesting that the streptavidin beads characteristically had 
an unusually low affinity for biotinylated proteins. This overall outcome could have 
resulted because of the following reasons: a) The particular Fen1 peptide did not have the 
capacity of interacting and forming a complex with the CroV PCNA protein, thus in this 
case, the PCNA protein would not have been pulled-down or purified. This fact could not 
be verified owing to the small molecular mass of the Fen1 peptide; although it would have 
supposedly been pulled-down and purified by the technique performed, it would have 
remained undetected on the SDS-PAGE gel. b) Even if an extremely strong interaction 
between the two factors had indeed formed maybe it lacked the ability and affinity to bind 
tightly to the streptavidin beads. This would have essentially indicated that the biotin-tag of 
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the Fen1 peptide, or even of the streptavidin beads, was problematic and did not have such 
a great affinity towards biotin; in this case, the Fen1/PCNA complex interaction if formed 
would have probably been present in the flow-through protein extract (not run on the gel) 
and hence it would have been lost. c) Finally, perhaps the whole Fen1/PCNA complex 
could not be properly solubilised in the lysis buffer used.  
 
Taking into further consideration the third reason mentioned, the above procedure was 
repeated. The purpose this time was to test a variety of diverse lysis buffers, so as to 
evaluate if different buffers would have a varying effect on the formation of a Fen1/PCNA 
peptide-protein interaction complex; also to check whether they would enhance its affinity 
towards and allow its accurate binding to the streptavidin beads, as well as whether the 
various buffers could improve the general proteins’ purification and solubility. 
Unfortunately, the results obtained were identical to the previous experiment; even though 
there was an extra band visible in the total protein extract, the equivalent band could not be 
observed in the soluble protein extract. Moreover, during this second CroV PCNA protein 
purification attempt numerous unspecific proteins seemed to have been pulled-down by the 
streptavidin beads, suggesting that for some reason (probably caused by the different lysis 
buffers used) the streptavidin beads had gained a greater, or most likely unspecific, affinity 
for biotinylated proteins. Whatever the actually cause, it was evident that the protocol 
required further optimisation. 
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Towards the end of the project, as there was some time left, a PCNA and FEN1 co-
expression experiment was attempted taking advantage of the untagged ‘Duet-1’ vectors’ 
properties. The soluble fraction containing both the expressed PCNA and FEN1 CroV 
proteins was automatically filtered through a Heparin-Trap column on the AKTA system; 
once again different buffers were utilised for lysing and eluting the protein samples. The 
protocol created was a gradient of salt concentrations, testing at what salt concentration the 
PCNA/FEN1 protein-protein complex would elute at. The choice of the column itself was 
theoretically due to the fact that heparin is supposed to effectively bind any protein that has 
the capacity of interacting with DNA; therefore, it was assumed that the FEN1 protein, due 
to its direct action on the DNA template during replication, would consequently bind 
directly to the column. At the same time though, FEN1 can also form a strong interaction 
with PCNA itself, leading to a final two-way binding interaction (i.e. PCNA binds to FEN1 
that binds to the column). So the overall hypothesis when planning this experiment was, 
that if the two proteins interact with each other then they could be purified and isolated by 
filtering them through such a column; eventually they would elute in the same fraction. 
This type of interaction is of major importance during DNA replication, as through it the 
PCNA can considerably enhance the activity of the FEN1. Therefore, technically purifying 
the two proteins together would further allow additional studies on the properties and 
nature of the original PCNA/FEN1 protein-protein interaction. The results of this 
PCNA/FEN1 co-expression purification trial were run on a SDS-PAGE gel (Figure 3.16); 
unfortunately, no PCNA or FEN1 protein expression could be visualised, probably 
suggesting one of three things: either that both proteins are gradually eluting at very low 
levels throughout the elution protocol, or that the PCNA/FEN1 complex is so tightly bound 
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to the heparin column that it does not elute with the specific buffer employed or that no 
PCNA/FEN1 interaction is taking place whatsoever. The second hypothesis could be re-
tested. 
 
To summarise, this study led to the following main conclusions: A) In the case of all 
Mimivirus, Marseillevirus and CroV PCNA proteins, as well as the CroV FEN1 protein, 
the presence of a tag in the selected expression vectors had an exceptionally negative effect 
on the proteins’ expression levels and efficiencies, no matter how many different protein 
expression conditions were tested; thus protein purification techniques in this case were not 
possible and the biochemical analysis of the proteins could not be continued.  B) On the 
contrary, the absence of any tag from other expression vectors used to clone both the CroV 
PCNA and FEN1 proteins had a surprisingly positive effect on the proteins’ expression 
levels and efficiencies, hence allowing a certain amount of protein purification trials. It is 
assumed that the latter point should have also been the case for the Mimivirus and 
Marseillevirus PCNA proteins; it would have been of value proving this if more time had 
been available. As a final point, the experimental techniques performed during this study 
failed to provide evidence for a PCNA/FEN1 protein-protein interaction. However, this 
detail should not be considered of major significance, as it was possibly a result of the 
actual protocols not being fully optimised. 
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4.2 Technical and Experimental problems  
The technical and experimental problems faced during this project have analytically been 
discussed throughout Section 4.1. In particular, these were: A) No protein being expressed; 
this problem was dealt with by altering the protein growth and expression conditions. B) 
Protein solubility problems; determined efforts to solve this problem were made by 
changing the protein expression conditions, as well as the lysis buffers used for 
resuspension of protein cells. C) Problems with the expression vectors of choice, and 
especially with the tags they had attached to them; the solution was to exchange them for 
vectors not contain any kind of tag. When this technical problem was encountered it was 
assumed that perhaps the tag was either being cleaved off from the protein structure, e.g. 
by proteases, or that it was being concealed within it, e.g. due to altered protein 
confirmation. In the former case, the tag would have been expressed normally, but because 
of its minute molecular mass it would have remained undetectable on the gel, while in 
accordance to the results obtained, the protein would not have been expressed at all. In the 
latter case, an atypical protein structure confirmation would have been caused by the tag 
folding into the PCNA structure, and therefore the protein would not have been able to 
express itself correctly. Nevertheless, the second case scenario appears more plausible; 
going by the protein expression experiments performed with the use of the un-tagged 
protein constructs, if the tag had supposedly been cleaved off from the protein structure 
then that should have resulted in a high degree of protein expression instead of no or little 
expression whatsoever. D) No protein being purified, when using the tagged protein 
constructs. The main reason behind this fact was thought to be that the protein of interest 
was actually not binding to the column, and as such, was directly flowing through. This 
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could be explained if the tag was cleaved off or concealed. So protein purification was 
quite impossible. E) Low levels of protein purity during the purification trials, when using 
the untagged protein constructs. This was a result of not being able to use purification 
columns that had a high specificity and affinity towards one particular substrate, meaning 
that more general columns had to be used due to the absence of a tagged-protein and these 
may have attracted a number of proteins with similar properties. F) No PCNA/FEN1 
protein-protein interaction could be detected. This outcome could be due to a number of 
reasons: maybe the conditions chosen during the experimental procedure were not optimal 
for such an interaction to be accomplished; if the complex was formed then maybe it was 
not binding correctly to the purification column and thus, was directly filtering through; if 
the complex was binding optimally to the column then maybe it was not eluting. 
 
During protein expression experiments there are generally many different obstacles 
causing difficulties which have to be solved. Proteins can unexpectedly be lost during the 
experimental studies performed or they can even degrade fairly dramatically over time, 
hence rendering them unusable. Another significant setback is whether the protein being 
produced is indeed stable or not; this could have as a consequence both structure 
confirmation and degradation problems. In addition, proteins may express rather poorly for 
reasons already described, while they may also do so due to host strain toxicity (maybe the 
protein is inconsistent with the expression strain of choice) or even due to the formation of 
secondary structures that influence and negatively affect the proteins interaction with other 
important components. Most importantly, uncontrolled protein expression can actually 
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affect the host cells’ growth and therefore result in a decreased protein yield. At the same 
time, it has been reported that forceful protein induction can result in the formation of 
inclusion bodies. Finally, during this experimental study it was even considered that maybe 
the synthetic genes purchased were not as optimal as contemplated or maybe they were not 
the most satisfactory choice for these types of procedures. However, they were the easiest 
option as they are simple to use and manipulate, and most importantly lack any unsafe 
properties that the living viruses may have (i.e. the Mimivirus may be a causative agent of 
pneumonia). 
 
4.3 Future work  
In the near future, it would be extremely productive if some of the experimental plans 
discussed in this project were repeated just to confirm whether similar results would be 
achieved.  
 
Concerning protein expression; a huge variety of other experimental processes could have 
been investigated and evaluated during the course of the project if there had been more 
time available. These would have been based on the procedures already performed, but 
always altering one or more of the parameters entailed. Some of these could have 
specifically been: A) Cloning the synthetic genes in such a way that the tag would be 
attached to their C-terminus, instead of their N-terminus as was employed during this 
study. This technique would validate whether or not attaching the tag on the opposite end 
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of the protein could solve any structural confirmation problems that may have been faced 
during this project. B) Cloning the synthetic genes in a selection of other tagged expression 
vectors, so as to examine if different tags would have the same effects as the ones utilised 
in this case. Moreover, it would have also been valuable if the Mimivirus and 
Marseillevirus PCNA proteins had been cloned into the pEHISGFPTEV, pETDuet-1 and 
pCDFDuet-1 vectors, as well as if the CroV PCNA protein had been cloned into the 
pEHISGFPTEV, for comparison reasons. D) The immense diversity of constructs 
generated could have been expressed in further host strains. Even though quite a significant 
number of E.coli host expression strains were assessed during this study and were 
determined not to have any sort of effect on the protein expression efficiencies, maybe 
other strains exist that would be more functional. Another proposal would have been to 
express the proteins of interest in other organisms, apart from bacteria, such as yeast or 
even native viruses. The results may have been of outstanding interesting. E) A final idea 
would have been to check a wide range of protein expression conditions, as well as lysis 
buffers. Generally, it is of utmost importance to optimise to the highest degree possible all 
the conditions employed during an experiment. 
 
Concerning protein purification; towards the end of the project, and after having 
accomplished good-quality protein expression of the CroV PCNA protein cloned into the 
Duet-1 vectors, a fairly successful and hopeful protein purification trial was also 
completed. This purification, which was carried out with the use of Hi-Trap Q (anion) 
column, however did not permit a high protein purity yield due to the nature of the column 
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used. Therefore, as a follow up experiment, it would be a key idea to use the samples 
obtained from the preceding experiment and perform a Hydrophobic Interaction 
Chromatography (HIC) purification technique, specifically using two types of columns the 
phenyl sepharose and the butyl sepharose. Both purification columns allow for the highest 
protein purity yield. HIC takes advantage of the presence of hydrophobic areas on the 
surface of proteins, which when filtered through such a HiTrap column will be attracted 
and bound to the hydrophobic areas of the solid support. Nonetheless, HIC is unique in that 
proteins bind to it at high salt concentrations and elute at low salt concentrations, in 
contrast to other columns (e.g. the HiTrap Q) for which the opposite method has to be 
applied. As a result, the protein of interest could be filtered through various HiTrap HIC 
columns following a reverse salt gradient protocol and this could be carried out multiple 
times until improved protein purity has been accomplished. At the same time, a simple gel 
filtration procedure could be undertaken. Gel filtration relies on the size and molecular 
weight of the proteins of interest and separates them on that basis. In a similar manner, 
concerning the FEN1 protein, equivalent experiments could be executed. As a general rule, 
in order to increase a proteins’ purity it is always worth re-filtering the protein a number of 
times through a particular column. However, it is noteworthy that this routine would as a 
result cause a significant loss of protein levels.  
 
Subsequent to successfully completing PCNA and/or FEN1 protein expression and 
purification, it would then be possible to continue and perform other biomolecular and 
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biochemical analysis on these proteins, so as to determine their molecular make-ups and 
evaluate their exact action during DNA replication. 
 
In the broader context, further research is necessary in order to elucidate the functions and 
properties of the PCNA and FEN1 proteins in the Mimivirus, Marseillevirus and CroV, as 
well as other giant viruses. So far the majority of studies completed are based on 
computation analysis, mainly including bioinformatics and phylogenetic studies. Research 
focusing on the nature of these two proteins through a molecular and chemical perspective 
is very limited, if any at all. More virologists need to participate and get involved, directing 
and maybe focusing their attention towards in vitro, or even in vivo, experiments involving 
these key DNA replicatory proteins. In this way, it will become more likely to establish the 
actual role they play within these viruses, while at the same time it will be possible to 
evaluate precisely how they interact with each other in order to complete their action. By 
gaining more knowledge in the way these proteins function during DNA replication, will 
probably further allow the determination of the nature of giant virus’ DNA replication; 
how they replicated inside their host and thus how do they propagate their genetic material 
through generations causing such a huge genomic expansion. As such, it will also be 
potential to determine whether or not these proteins have been evolutionary conserved in 
these organisms and hence specify their origin in terms of evolutionary history. This fact 
may further shed some light on information regarding the origins of the giant viruses 
themselves, and therefore, maybe it will become more evident whether or not they could be 
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considered as living organisms, based on current definition found in the literature, and 
included in a separate fourth domain of life. 
 
4.4 Conclusions  
In conclusion; in this study, even though initially it was in no way feasible to express the 
two proteins of interest, PCNA and FEN1, in the Mimivirus, Marseillevirus and CroV, 
eventually protein expression of these two proteins was accomplished only for the CroV. 
The detail that finally allowed protein expression to be achieved was the absence of a tag 
in the expression vectors used. This in itself was a very valuable and significant outcome, 
noteworthy for future references. Following this achievement, it was possible to attempt 
some protein purification trials but only for the CroV PCNA protein. However, with little 
experimental time remaining, the protein purification trials could not be fully finalised or 
properly evaluated; in general, it was possible to demonstrate a low level of PCNA protein 
purification, with the protein yield not being especially high and many unspecific proteins 
being pulled-down in the same fractions as the protein of interest. To improve these results 
it would have been essential to perform multiple other protein purification trials, during 
which the yield of the CroV PCNA protein would have had to be greatly increased and its 
purity significantly enhanced. As a consequence, by the end of the study it was not 
possible to obtain a high yield of pure CroV PCNA protein for use in further biomolecular 
and biochemical analysis, hence not contributing to our further understanding of the role of 
this specific gene in DNA replication of the CroV giant virus. There is still a great deal of 
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knowledge to be gained concerning these giant viruses, as well as their cellular and genetic 
components, and therefore further research is compulsory. 
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APPENDIX 
 
A.1 Construct Maps of the Synthetic Genes (as provided by GenScript, UK) 
A.1.1 Mimivirus (APMV_L108) PCNA  
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A.1.2 Marseillevirus (MAR_ORF212) PCNA 
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A.1.3 CroV (CroV_219) PCNA 
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A.1.4 CroV (CroV_037) FEN1 
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A.2 Maps of the pASK-IBA17plus PCNA constructs  
(Modified from the original ‘pASK-IBA17plus’ construct map, IBA, UK) 
A.2.1 pASK-IBA17plus_Mimivirus (APMV_L108)_PCNA 
Plasmid Name: pASK-IBA17plus_APMV_L108_PCNA_SENSE 
Plasmid size: 4062 bp 
Cloning Info: Digested BsaI 843 bp fragment from PCNA plasmid construct APMV_L108 
(Mimivirus) into digested BsaI pASK-IBA17plus vector. Sense orientation. 
Map: 
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A.2.2 pASK-IBA17plus_Marseillevirus (MAR_ORF212)_PCNA 
Plasmid Name: pASK-IBA17plus_ MAR_ORF212_PCNA_SENSE 
Plasmid size: 4137 bp 
Cloning Info: Digested BsaI 918 bp fragment from PCNA plasmid construct 
MAR_ORF212 (Marseillevirus) into digested BsaI pASK-IBA17plus vector. Sense 
orientation. 
Map: 
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A.2.3 pASK-IBA17plus_CroV (CroV_219)_PCNA 
Plasmid Name: pASK-IBA17plus_ CroV (CroV_219)_PCNA_SENSE 
Plasmid size: 4077 bp 
Cloning Info: Digested BsaI 858 bp fragment from PCNA plasmid construct CroV (CroV 
virus) into digested BsaI pASK-IBA17plus vector. Sense orientation. 
Map: 
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A.3 Maps of the pEHISTEV PCNA constructs 
(Modified from Fig. 1: Multiple cloning sites of pEHISTEV/pEHISGFPTEV; Liu H and 
Naismith JH, 2009) 
A.3.1 pEHISTEV_Mimivirus (APMV_L108)_PCNA 
Plasmid Name: pEHISTEV_APMV_L108_SENSE 
Cloning Info: Digested NcoI/HindIII 840 bp fragment from PCNA plasmid construct 
pASK-IBA17plus_APMV_L108 (Mimivirus) into digested NcoI/HindIII pEHISTEV 
vector. Sense orientation. 
Map: 
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A.3.2 pEHISTEV _Marseillevirus (MAR_ORF212)_PCNA 
Plasmid Name: pEHISTEV_MAR_ORF212_SENSE 
Cloning Info: Digested NcoI/HindIII 920 bp fragment from PCNA plasmid construct 
pASK-IBA17plus_MAR_ORF212 (Marseillevirus) into digested NcoI/HindIII pEHISTEV 
vector. Sense orientation. 
Map: 
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A.3.3 pEHISTEV _CroV(CroV_219)_PCNA 
Plasmid Name: pEHISTEV_CroV_219_SENSE 
Cloning Info: Digested NcoI/HindIII 860 bp fragment from PCNA plasmid construct 
pASK-IBA17plus_CroV (Cafeteria roenbergensis) into digested NcoI/HindIII pEHISTEV 
vector. Sense orientation. 
Map: 
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A.4 Construct Map of the pEHISTEV and pEHISGFPTEV CroV (CroV_037)_FEN1 
(Modified from Fig. 1: Multiple cloning sites of pEHISTEV/pEHISGFPTEV; Liu H and 
Naismith JH, 2009) 
 
Plasmid Name: pEHISTEV_CroV_037_SENSE & pEHISGFPTEV_CroV_037_SENSE 
Cloning Info: Digested NcoI/HindIII 970 bp fragment from FEN1 plasmid construct 
pUC57_CroV (Cafeteria roenbergensis) into digested NcoI/HindIII pEHISTEV and 
pEHISGFPTEV vectors. Sense orientation. 
Map: 
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A.5 Maps of the pETDuet-1 and pCDFDuet-1 constructs 
(Modified from the original ‘pETDuet-1’ and ‘pCDFDuet-1’ construct map, Novagen, UK) 
 A.5.1 pETDuet-1_CroV_219_PCNA 
Plasmid Name: pETDuet-1_ CroV (CroV_219)_PCNA_SENSE 
Plasmid size: 6,200 bp 
Cloning Info: Digested NcoI/HindIII 860 bp fragment from CroV PCNA construct 
(pEHISTEV_CroV_219_PCNA) into digested NcoI/HindIII pETDuet-1 vector. Sense 
orientation. 
Map: 
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 A.5.2 pCDFDuet-1_CroV_219_PCNA 
Plasmid Name: pCDFDuet-1_ CroV (CroV_219)_PCNA_SENSE 
Plasmid size: 4,567 bp 
Cloning Info: Digested NcoI/HindIII 860 bp fragment from CroV PCNA construct 
(pEHISTEV_CroV_219_PCNA) into digested NcoI/HindIII pCDFDuet-1 vector. Sense 
orientation. 
Map: 
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A.5.3  pETDuet-1_CroV_037_FEN1 
Plasmid Name: pETDuet-1_ CroV_037_FEN1_SENSE 
Plasmid size: 6,320 bp 
Cloning Info: Digested NcoI/HindIII 970 bp fragment from CroV FEN1 construct 
(pEHISTEV_CroV_037_FEN1) into digested NcoI/HindIII pETDuet-1 vector. Sense 
orientation. 
Map: 
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 A.5.4 pCDFDuet-1_CroV_037_FEN1 
Plasmid Name: pCDFDuet-1_ CroV_037_FEN1_SENSE 
Plasmid size: 4,677 bp 
Cloning Info: Digested NcoI/HindIII 970 bp fragment from CroV FEN1 construct 
(pEHISTEV_CroV_037_FEN1) into digested NcoI/HindIII pCDFDuet-1 vector. Sense 
orientation. 
Map: 
 
